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Tauopathies are a group of neurodegenerative diseases characterised by cognitive and 
motor dysfunction, and pathological aggregates of abnormally phosphorylated and 
cleaved tau, a microtubule associated protein. Whilst the cause of these pathological 
changes is unknown, it is likely to be a combination of toxic gain-of-function acquired by 
aggregated tau, along with a loss of normal function of tau. This laboratory previously 
identified a form of cleaved tau (Tau35) in post-mortem human tauopathy brain and has 
developed animal and cell models expressing Tau35 to investigate molecular mechanism 
underlying tauopathy. These models include a transgenic mouse expressing Tau35 in low 
amounts, and Chinese hamster ovary (CHO) cells stably expressing Tau35 (CHO-Tau35) or 
full-length human tau (CHO-FL). This thesis aims to determine how Tau35 affects 
molecular mechanisms involved in tau metabolism, including the unfolded protein 
response (UPR) and autophagic/lysosomal degradation. 
 
In aged Tau35 mice, there was evidence of a toxic gain of function, including increased tau 
phosphorylation at disease-relevant epitopes in multiple brain regions. In addition, Tau35 
mice exhibit activation of the UPR in specific brain regions. In CHO-Tau35 cells, a significant 
reduction in basal autophagy was identified, which was not apparent in either 
untransfected CHO cells or in CHO-FL cells expressing full-length tau, suggesting that 
Tau35 expression results in defective autophagy. Under conditions that stimulate 
autophagy, CHO-Tau35 cells exhibited a reduced capacity to activate mTOR-mediated 
autophagy and reduced autophagic flux. Conversely, expression of Tau35 promoted 
activation of autophagy through an mTOR-independent mechanism. Furthermore, 
inhibition of glycogen synthase kinase-3 rescued the defective autophagy in CHO-Tau35 
cells. Notably, CHO-Tau35 cells exhibited a reduction in the number of lysosomes, as well 
as defective lysosomal functionality and a deficit in lysosome biogenesis compared to 
CHO-FL and untransfected CHO cells.  
 
Taken together, these findings suggest novel mechanisms through which the presence of 
Tau35, a tau fragment associated with the development of human tauopathy, exerts a 
detrimental effect on cells and provides insights into the significance of protein 
degradation systems in the development of tauopathy. 
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Chapter 1 Introduction 
1.1 Tau gene and protein 
Human tau is a microtubule-associated protein encoded by the MAPT gene located on 
chromosome 17 (17q21). MAPT consists of 16 exons, although exons 0 and 14 are 
transcribed but not translated. MAPT pre-RNA is differentially spliced in a manner 
correlating with stages of neuronal maturation and neuronal types (see below) (Wang et 
al., 2007). 
 
Tau has an N-terminal acidic projection domain that, when is bound to microtubules, 
extends from the surface of the microtubule and a C-terminal domain encoded by exons 9 
to 13, which contains the microtubule-binding region of tau (Goedert and Jakes, 1990).  In 
human brain, alternative splicing of tau mRNA at exons 2 and 3 (in the N-terminal region) 
and exon 10 (in the C-terminal half of tau) gives rise to six different tau isoforms. 
Differential splicing of exons 2 and 3 leads to 2N tau isoforms being under-represented 
(9% of total human CNS tau), unlike 0N and 1N tau (comprising 37% and 54% of human 
CNS tau, respectively). (Goedert and Jakes, 1990). These tau isoforms differ from one 
another by the presence or absence of a 29- or 58-amino acid insert at the N-terminus of 
the protein. Isoforms containing 0, 1 (encoded by exon 2) or 2 (encoded by exons 2 and 3) 
inserts are termed 0N, 1N and 2N, respectively. Another difference between the tau 
isoforms is the inclusion or exclusion of a 31-amino acid microtubule-binding repeat 
sequence encoded by exon 10. Exclusion of the sequence encoded by exon 10 gives rise to 
tau isoforms (3R) bearing three microtubule binding repeats (MTBs), whereas the inclusion 
of the sequence leads to the expression of isoforms with four MTBs (4R) (Panda et al., 
2003; Wray et al., 2008) (Figure 1-1). In healthy individuals, 3R and 4R tau isoforms are 
present in an approximately equal ratio. Tau is predominantly found in neurons. It is 
present at much lower levels in glia and in interstitial fluid, and barely detectable amounts 
in astrocytes and oligodendrocytes (Goedert, 2004; Wang and Mandelkow, 2016). 
 
Tau expression is developmentally regulated. The shortest tau isoform (0N3R) comprising 
352 amino acids, is expressed early in development and also in adult human brain. 
However, 4R tau isoforms are expressed solely in adult brain. The 0N3R tau isoform has a 
21 
molecular weight of 48 kDa on SDS-PAGE while the longest tau isoform, 2N4R, comprising 
441 amino acids runs at 67 kDa (Crowther et al., 1989; Lee, 2001). 2N4R tau contains 80 
Ser or Thr residues, 56 negatively charged acidic (Asp or Glu) residues, 58 positively 
charged basic  (Lys or Arg) residues and 8 aromatic (5 Tyr and 3 Phe) residues (Wang and 
Mandelkow, 2016). 
 
Within adult neurons, tau is found primarily in axons, with barely detectable amounts 
present in dendrites and nuclei (Forman et al., 2004; Wray et al., 2008). However, in young 
neurons, tau is found to be more evenly distributed between the neurites and cell body 
(Papasozomenos and Binder, 1987; Sultan et al., 2011). The relative proportions of tau 
isoforms present in different brain regions differs between animal species. For instance, in 
humans the amount of 0N3R tau is lower in the cerebellum than it is in other brain regions 
(Boutajangout et al., 2004; Trabzuni et al., 2012). In addition, murine 3R tau isoforms are 
only transiently expressed in the neurons of foetal and new-born mice. On the other hand, 
in adult mouse brain, the three isoforms of 4R tau are almost exclusively expressed (Kosik 





Figure 1-1 Domains of tau protein and alternative splicing in the human CNS: The six 
human brain tau isoforms are generated through alternative splicing of exons 2, 3 and 10. 
These tau isoforms differ according to the presence of 0, 1 or 2 amino-terminal inserts (0N, 
1N or 2N, respectively) and the presence of microtubule-binding repeat R2, encoded by 
exon 10, yielding 3 or 4 carboxy-terminal repeat domain (3R or 4R, respectively) tau 
species (adapted from (Guo et al., 2017)). 
 
1.1.1 Relating tau structure to its functions 
Tau is hydrophilic and is found as an unfolded protein in its native state and is stable under 
acidic conditions and at high temperatures. However in solution, tau shows a preference 
to adopt a paperclip-like conformation, in which the N-terminal, C-terminal and the repeat 
domains all approach each other (Jeganathan et al., 2006). Tau is overall a basic protein, 
however, the ~120 N-terminal residues are predominantly acidic, and the ~40-residue C 
terminus has an overall neutral charge (Goedert and Jakes, 1990). Tau has four distinct 
domains: an acidic projection region towards the N-terminus; a proline-rich region in the 
centre of the molecule; a microtubule-binding region, which contains either three or four 
carboxy-terminal repeat domains which facilitates the binding between microtubules and 
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the C-terminal tail (Figure 1-1) (Mandelkow et al., 1996). All of these structural features 
are vital for tau to carry out its proper function. Tau is known to be bound to microtubules 
and stimulate microtubule assembly in cell-free reactions (Shahani and Brandt, 2002). 
Studies have demonstrated that tau is capable of promoting microtubule nucleation, 
growth, and bundling (Shahani and Brandt, 2002), as well as greatly reducing the dynamic 
instability of microtubules (Shahani and Brandt, 2002). 
 
The N-terminal domain of tau projects away from microtubules, allowing tau to bind to 
other components in the cell. The N-terminal region of tau can interact with cell 
membranes. This region of tau is involved in regulating microtubule dynamics, the 
attachment and/or spacing between microtubules and other cell components, without 
binding to microtubules directly (Chen et al., 1992). For example, N-terminally truncated 
tau fragments showed altered microtubule interactions, even in the presence of an intact 
microtubule binding domain (Matsumoto et al., 2015). The N-terminal portion of tau 
additionally binds to the C terminus of the p150 subunit of the dynactin complex. This 
promotes the association of the microtubule motor dynein with membranous cargoes 
such as organelles (Magnani et al., 2007). Much remains unknown regarding the specific 
functions of the N-terminal inserts in tau, although these sequences appear to influence 
the distribution of tau because 0N, 1N, and 2N tau isoforms each show distinct subcellular 
localisations in mouse brain (Magnani et al., 2007). 
 
The proline-rich domain of tau harbours seven Pro-XX-Pro (PXXP) motifs, providing 
potential recognition sites for Src homology-3 (SH3)-containing proteins including the Src 
family of protein kinases, such as Lck, Fgr, and Fyn, bridging integrator 1 (Bin1), the p85α 
regulatory subunit of phosphatidylinositol 3-kinase (PI3K). This domain also serves 
additional functions including regulating actin binding and the assembly of microtubules 
(He et al., 2009), as well as being a key DNA and RNA interacting site, which may explain 
the presence of tau in the nucleus (Bukar Maina et al., 2016). 
 
 Very little is known about the function of the C-terminal region of tau, However, a few 
studies suggest that changes within this region such as phosphorylation might have an 
impact on the other domains of tau, thereby influencing their interactions with other 
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proteins and their availability for phosphorylation (Connell et al., 2001); Reynolds et al, 
2008). 
1.1.2 Functions of axonal, dendritic and nuclear tau 
In the axon, tau interacts with microtubules via its repeat-domain and flanking regions. 
Tau is therefore able to act as a stabiliser of microtubules, as well as a regulator of the 
dynamic instability of microtubules that leads to the reorganisation of the cytoskeleton 
(David et al., 2002; Davies et al., 1997). Once tau is bound to microtubules, it can form a 
local hairpin conformation through the interaction of residues 269-284 and 300-310, 
which contain the hexapeptide motifs 273VQINK280 and 306VQIVYK311 (Bhaskar et al., 2005). 
These two motifs are vital for tau aggregation, thereby implying that the stability of 
microtubules delays the aggregation of tau. Tau can additionally influence the function of 
motor proteins dynein and kinesin. Dynein functions as a retrograde transporter moving 
cargoes towards the cell body, whereas kinesin transports cargoes in an anterograde 
direction towards axon terminals (de Barreda and Avila, 2010). Tau has an inhibitory effect 
on both of these proteins by competing with them and binding to microtubules, slowing 
anterograde and retrograde axonal transport (de Barreda and Avila, 2010). This inhibition 
of transport leads to the build-up of multiple cargoes such as mitochondria. In addition, 
tau is able to regulate the release of cargo vesicles from kinesin by the activation of 
protein phosphatase (PP) 1 and glycogen synthase kinase-3β (GSK3β) through the N-
terminus of tau (de Silva et al., 2006). 
 
Work conducted on cultured rat neurons with a knockdown of tau led to an inhibition of 
neurite formation. In contrast the overexpression of tau facilitated neurite formation 
(Deming et al., 2016). This study highlights the importance of tau in the elongation and 
maturation of axons. To date, the physiological functions of the small amounts of tau 
present in the dendrites have not been well established. Dendritic tau may be involved in 
synaptic plasticity as synaptic activation leads to the translocation of endogenous tau to 
the post synaptic compartments from the dendritic shaft in acute hippocampal slices (Ding 
et al., 2008).  
 
Tau has been detected in the nuclei in a variety of different cell types such as neurons, 
fibroblasts and neuroblastoma cells (Dixit et al., 2008; Dolan and Johnson, 2010). It is 
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hypothesised that tau is required to maintain the integrity of genomic DNA, cytoplasmic 
RNA and nuclear RNA (Violet et al., 2014). In vitro gel-retardation experiments clearly 
demonstrated that tau has the capacity to bind to AT-rich satellite DNA sequences directly 
(Sjoberg et al., 2006). Interaction of tau with DNA has been reported to be aggregation-
dependent so that aggregated tau loses its capacity to interact with DNA. Since nuclear tau 
has also been found in neurons from patients with Alzheimer’s disease (AD), aberrant 
nuclear tau could affect the nucleolar organisation during the progression of AD (Sjoberg 
et al., 2006). 
1.2 Tauopathies 
The tauopathies are a group of heterogenous dementias characterised clinically by 
cognitive and motor dysfunction, and pathologically by aggregates of highly 
phosphorylated and cleaved tau protein that become redistributed from the axons into 
the cell bodies and dendrites of nerve cells (Wang et al., 2010). In these disorders, tau 
deposits likely begin to accumulate many years prior to the onset of clinical symptoms; 
making early diagnosis immensely challenging (Golde et al., 2011). The causes underlying 
disease onset in these disorders remains unclear. However, it is likely to include a 
combination of toxic gain-of-function acquired by tau aggregation, along with a loss of 
normal function of tau. Most tauopathies exhibit a sporadic onset, however there is also a 
genetic predisposition for the development of some tauopathies. The group of disorders 
comprising the tauopathies includes AD which is the most prevalent and well characterised 
member, as well as other neurodegenerative disease including corticobasal degeneration 
(CBD), progressive supranuclear palsy (PSP), Pick’s disease (PiD) and frontotemporal lobar 
degeneration (FTLD-tau) (Spillantini and Goedert, 2013). Interestingly, the tau profile 
detected on western blots in these diseases is greatly variable (Figure 1-2) and allow the 





Figure 1-2 Schematic representation of the banding pattern of tau isoforms in different 
tauopathies: AD contains both 4R and 3R tau isoforms, tau pathology in PSP and CBD 
contains mainly 4R tau, while in PiD mainly 3R tau is present. In FTLD-tau the pattern is 
more varied with some cases containing both 3R and 4R tau, and others characterised by 
predominantly 4R or 3R tau. (adapted from (Buee et al., 2000)). 
 
1.2.1 Alzheimer’s disease  
AD is an age-related condition with a higher propensity in the elderly (Misiak et al., 2013). 
Approximately 6% of the population and 50% of people over the age of 90, with 800,000 
people in the UK affected by this disorder (Wimo et al., 2013). It is predicted that AD will 
affect 1 in 85 people globally by 2050, making it a global epidemic (Brookmeyer et al., 
2007). 
 
 There are two major hallmarks of AD (summarised in Table 1-1). The first of these is the 
formation of amyloid plaques, whereby amyloid precursor protein (APP) can be split by 
either α secretase and then γ secretase or in tandem by β secretase and γ secretase 
(Crump et al., 2013). As a result, amyloid beta (Aβ) peptides of different lengths are 
formed. The peptide created from 42 amino acids (Aβ 42) has greater cytotoxicity and is 
deposited in amyloid plaques. This form of Aβ accumulates during AD (Figure 1-3) 
(Kuperstein et al., 2010). The second typical lesion of AD is the neurofibrillary tangle (NFT), 
made up of paired helical filaments (PHF) comprising highly phosphorylated tau (Goedert, 
2004). In AD, as in healthy human brain, both the 3R and 4R tau isoforms are present in an 
equal ratio. Studies by Braak (Braak and Braak, 1991) were the first of their kind to develop 
a staging pattern of AD which was based on the neuropathological similarities in the 
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pattern of NFT spreading in AD brains. They categorised their observations into six primary 
stages. They additionally correlated brain pathology to disease severity and clinical 
phenotypes. The robust consistency in NFT spreading provide the basis for a now widely 
used diagnostic tool for AD. Primarily, NFTs are observed in the transentorhinal/peripheral 
cortex (Braak stage I), followed by the CA1 region of the hippocampus (Braak stage II). 
Subsequently, these structures accumulate in the subiculum of the hippocampus (Braak 
stage III), then amygdala, thalamus and claustrum (Braak stage IV). Finally, in the late 
stages of disease, NFT pathology spreads to the isocortical areas, with associative areas 
affected first (Braak stage V), followed by the primary sensory, motor and visual areas 
(Figure 1-3) (Braak stage VI) (Braak and Braak, 1991; Hyman et al., 1984). 
 
Table 1-1 Summary of the two hallmarks of AD 
Pathology Amyloid plaques Neurofibrillary tangles 
Precursor Amyloid precursor protein 
(APP) 
Tau protein 
Enzymes involved in 
the pathology 
β-secretase and γ-secretase 
 
Phosphorylation by a wide group 
of kinases and cleavage by 
proteases (discussed below in 
section 1.3) 
 
Consequence of the 
precursor processing 
Formation of amyloid beta 
created from 42 amino acids, 
oligomerization into amyloid 
plaques 
 
Increased phosphorylation of tau, 
lowering of tau solubility, loss of 
tau affinity for microtubules 
 
References (Jankowsky et al., 2004; Korte 
et al., 2012) 





Figure 1-3 The accumulation of Aβ and tau in AD brain: A Brain section of β-amyloid (Aβ) 
plaques labelling which first appear in the neocortex, followed by the cortex and finally 
subcortical regions. B Brain section of paired helical filaments (PHF) and neuropathological 
staging of severity. NFT load in early AD (Braak stages I-II) occurs first in the locus 
coeruleus and trans entorhinal area (CA1, subiculum and entorhinal cortex). followed by 
spreading to neighbouring limbic system regions such as the amygdala and hippocampus 
in later stages of mild/moderate AD (Braak stages III and IV) and finally to connected 
neocortical brain regions and rest of the brain in late stage severe AD (Braak stages V-VI) 
as indicated by arrows (Jucker and Walker, 2011). 
 
1.2.2 Corticobasal degeneration 
CBD is a rare progressive neurodegenerative tauopathy that usually presents as a 
movement disorder in the clinic. In contrast to healthy control and AD brain, this disease is 
a 4R tauopathy, meaning that the proportion of 4R tau exceeds that of 3R tau. This disease 
is associated with a wide variety of motor, sensory, behavioural and cognitive symptoms 
including but not limited to rigidity, limb dystonia, focal reflex myoclonus and 
postural/action tremor, symptoms that can also occur in other tauopathies (Ludolph et al., 
2009). This clinical heterogeneity between CBD and other tauopathies makes differential 
diagnosis difficult and accurate identification of the disorder usually occurs post-mortem 
(Kouri et al., 2011). Important neuropathological features of CBD include cortical and 
nigral atrophy; microscopically there are numerous swollen cortical neurons as well as tau-
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immunoreactive astrocytic plaques not observed in other tauopathies (Ludolph et al., 
2009). 
1.2.3 Progressive supranuclear palsy 
PSP is another relatively uncommon neurodegenerative disease. According to the NIH 
reported prevalence is only about three to six in every 100,000 people worldwide. It is 
characterised clinically by parkinsonian symptoms together with other features, including 
postural instability, downward gaze supranuclear palsy, dysarthria and dysphagia (Steele 
et al., 1964). Pathologically, as with other tauopathies, the brains of PSP patients contain 
deposits of highly phosphorylated and aggregated tau. Unlike in AD, in post-mortem brains 
of PSP patients, tau is found to be formed predominantly into straight filaments (PSP-tau) 
in neurons and glia as opposed to forming PHFs. A classical and unique feature of PSP is 
the presence of fibrous aggregates of insoluble tau in tufted astrocytes (Bergeron et al., 
1997). These tau-positive structures are present in the pallidum, subthalamic nucleus, 
substantia nigra, pons and other subcortical structures. Unlike in AD, where PHF-tau 
appears on western blots as a triplet of 68, 64 and 62 kDa and an additional band of 72 
kDa, in PSP, tau appears as a doublet exhibiting bands at 68 and 64 kDa (Figure 1-2) 
(Flament et al., 1991). Like CBD and unlike AD, in PSP there is an increase in the ratio of 4R 
to 3R tau, making it a 4R tauopathy. In contrast to CBD, there are specific cleaved 
fragments of tau in PSP brain lacking the N-terminus that could be used to exclusively 
identify the disease (Arai et al., 2004). In addition, the cerebrospinal fluid (CSF) from PSP 
patients harbours reduced amount of C-terminally cleaved tau; an additional unique 
feature compared to other tauopathies (Borroni et al., 2007; Brandt et al., 2005; Reimann, 
2017). 
 
In post-mortem brains of PSP patients, tau is found to be in straight filaments in neurons 
and glia. Conversely, in AD, tau is primarily found as paired helical filaments (PHF) that 
make up the neurofibrillary tangles, which are typical lesions of the disease (Goedert, 
2004). Other differences include a variation in the ratio of the six tau isoforms in the 
tauopathies. In PSP and CBD brains, there is an increase in 4R tau.  
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1.2.4 Pick’s disease 
PiD is a rare disorder characterised by progressive dementia and personality deterioration. 
Early clinical symptoms include frontal disinhibition. Neuropathologically, this disease 
shows gliosis, neuronal loss, circumscribed atrophy of the frontal, frontotemporal, and 
frontoparietotemporal cortices and of ballooned neurons as well as Pick bodies, which are 
spheroidal aggregates of highly phosphorylated tau in neurons (Ludolph et al., 2009). Pick 
bodies are more abundant in the hippocampus compared to the neocortex (Delacourte et 
al., 1996). Within the hippocampus, Pick bodies are apparent in granular cell neurons of 
the dentate gyrus, in the CA1 region of the hippocampus, subiculum and entorhinal cortex, 
whereas in the neocortex, they are mainly found in layers II and VI of the temporal and 
frontal lobes (Avila et al., 2004; Robert and Mathuranath, 2007). Biochemical analyses of 
Pick’s disease by western blotting using phospho-specific tau antibodies showed the 
presence of three bands distinctive to the disease; a doublet of tau at 55 and 64 kDa, and a 
third, fainter band at 69 kDa (Botez et al., 1999). Further studies indicated that Pick bodies 
and the tau doublet at 55 and 64 kDa are not labeled with immunological probes directed 
against the sequence encoded by exon 10 indicating only 3R tau isoforms aggregate into 
Pick bodies, making this a 3R tauopathy (Braak et al., 1999). Contrasting with PSP and CBD, 
in Pick’s disease 3R tau is more abundant than 4R tau isoforms (Rockenstein et al., 2015). 
1.2.5 Frontotemporal lobar degeneration 
FTLD is a term for the group of non-Alzheimer degenerative dementias with focal cortical 
neuronal loss and gliosis (McKhann et al., 2001). The most common FTLD is associated 
with TAR DNA-binding protein 43 (TDP-43) pathology (FTLD-TDP), with tauopathies (FTLD-
tau) being slightly less common (Wider and Wszolek, 2008). As described above, there is 
preferential accumulation of 3R or 4R tau in various tauopathies, providing a biochemical 
sub-classification. The classifications of the most common forms of FTLD-tau compared to 
AD are summarised in Table 1-2. 
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Table 1-2 Classifications of the most common subtypes of FTLD-tau (Adapted from 
(Mackenzie et al., 2010)) 
Disorder Affected brain regions Major clinical features 
4R tauopathies 
CBD Cortex and basal ganglia Focal cortical syndrome and 
parkinsonism 
PSP Basal ganglia, brainstem and 
cerebellum 
Atypical parkinsonism 
FTLD-tau Cortex, basal ganglia and 
brainstem 
Focal cortical syndrome and 
parkinsonism 
3R tauopathies 
PiD Cortex and limbic lobe Dementia and focal cortical 
syndromes 
FTLD-tau Cortex, basal ganglia and 
brainstem 
Dementia and focal cortical 
syndromes 
3R-4R tauopathies 
AD Cortex and limbic lobe Dementia 
FTLD-tau Cortex and limbic lobe Dementia and psychosis 
1.3 Post-translational modification of tau 
Tau can undergo multiple post-translational modifications, some of which may lead to 
changes in tau conformation. These modifications include phosphorylation, isomerisation, 
glycation, nitration, addition of β-linked N-acetylglucosamine (O-GlcNAcylation), 
acetylation, oxidation, polyamination, sumoylation, ubiquitylation and proteolytic cleavage 
or truncation (Lee et al., 2001; Reyes et al., 2008; Rodriguez-Martin et al., 2013). Tau 
phosphorylation, acetylation and truncation, in particular, are associated with the 
development of tauopathy. 
1.3.1 Tau phosphorylation 
 The phosphorylation of tau has been the most widely investigated conformational change 
in relation to neurodegeneration (Hanger et al., 2009a). Tau contains 85 phosphorylation 
sites, including 45 serine (53% of phosphorylation sites of tau), 35 threonine (41%) and 
5 tyrosine (6%) residues (Figure 1-4) (Hanger et al., 2009a). In AD, tau is abnormally 
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phosphorylated at many sites, mostly within the microtubule-binding repeat and flanking 
domains. These phosphorylation sites are of diagnostic value because several antibodies 
against Alzheimer tau recognise these motifs, including antibodies AT8, PHF1, and AT100, 
amongst others (Hanger et al., 2009b; Simic et al., 2016). 
 
Under pathological conditions, there is a marked elevation in tau phosphorylation in all 
tauopathies. This results in a reduced affinity of tau to bind to microtubules, which leads 
to destabilisation of the cytoskeleton, particularly in neurons. Tau phosphorylated at 
Ser262, Ser293, Ser324 and Ser356 (each located in one of the four microtubule-binding 
repeats), and at Thr214, Thr231 and Ser235 (lying outside the microtubule-binding 
domain) leads to the dissociation of tau from the microtubules (Drewes et al, 1995; 
Ksiezak-Reding et al 2003). Ultimately the tau that detaches from the microtubules 
undergoes self-aggregation, forming oligomers and higher order tau aggregates (von 
Bergen et al., 2000). The phosphorylation of tau in the proline-rich domain disrupts its 
microtubule assembly activity and induces a slight increase in the propensity of tau to self-
aggregate (Eidenmuller et al., 2001). However, phosphorylation of the C-terminal region of 
tau dramatically increases the ability of tau to self-aggregate (Liu et al., 2007) 
 
In AD, abnormal phosphorylation of tau occurs prior to the appearance of NFTs (Braak and 
Braak, 1995). The expression of a pseudo-phosphorylated tau construct in neural cells 
reproduces structural and functional aspects of AD (Fath et al., 2002). Moreover, 
overexpression of pseudo-phosphorylated tau dramatically decreases microtubule 
interactions and disrupts the microtubule network, thereby exerting neurotoxic effects 
(Cho and Johnson, 2004a; Gong and Iqbal, 2008; Zhang et al., 2009b). 
 
In addition to the loss of microtubule binding ability and formation of toxic or oligomeric 
tau species, elevated tau phosphorylation can induce a neurodegenerative phenotype 
through alternative mechanisms. Primarily an increase in phosphorylated tau leads to tau 
mis-sorting from axons into the somatodendritic compartment, compromising axonal 
microtubule integrity and resulting in synaptic dysfunction (Hoover et al., 2010; Ittner and 
Götz, 2011). In addition, increased tau phosphorylation can have an impact on tau 
degradation. For example, tau phosphorylated on Ser262 or Ser356 is unable to undergo 
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degradation by the proteasome as the phosphorylation event prevents the recognition of 
the protein by the C terminus of heat shock protein 70-interacting protein-heat shock 
protein 90 (CHIP-HSP90) complex (Wyttenbach, 2004). In support of this view, inhibition of 
autophagy in neurons resulted in a three-fold accumulation of phosphomimic tau 
compared with wild type tau, and endogenous tau was unaffected; indicating that 
autophagy is the primary route for clearing phosphorylated tau in neurons (Rodriguez-





Figure 1-4 Putative phosphorylation sites on tau and epitopes specific for major tau 
antibodies: A schematic representation of the phosphorylation sites of tau. Sites marked 
in red indicate amino acids phosphorylated in AD brain, green in both AD and normal 
brain, blue in normal brain, and black refers to phosphorylation sites that have not been 
fully characterised yet. Tau antibodies specific for phospho-tau epitopes are shown in 
purple, while pink denotes antibodies specific for non-phosphorylated tau epitopes (Simic 
et al., 2016). 
 
One possibility behind the accumulation of phosphorylated tau in the tauopathies could be 
due to elevated kinase activity, such as GSK3, cyclin-dependent kinase 5 (CDK5) and/or 
microtubule-affinity regulating kinase (MARK), amongst others such as the thousand-and-
one amino acid kinases (TAOKs) 1 and 2  (Giacomini et al., 2018). In conjunction, a 
decrease in the activity of tau phosphatases such as PP1, PP2A and PP2B may also 
contribute to an increase in the phosphorylation of tau  (Billingsley and Kincaid, 1997). 
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1.3.1.1 Tau kinases 
Tau is a target of multiple protein kinases. Tau protein kinases can be grouped into three 
classes: proline-directed protein kinases (PDPK), protein kinases non-PDPK and tyrosine 
protein kinases (TPK). PDPK are kinases that phosphorylate serine and threonine preceding 
a proline residue (S/TP motif). Examples of such enzymes include GSK3, extracellular 
signal-regulated kinases 1 and 2 (ERK1/2) (discussed in more detail below), cyclin-
dependent protein kinase-5 (CDK5) and mitogen-activated protein kinases (MAPK) such as 
p38 and c-Jun N-terminal kinases (JNK) (Hanger et al., 2007; Tenreiro et al., 2014). 
 
The C-terminal portion of tau contains the KXGS motifs Figure 1-5 which can be 
phosphorylated by kinases such as the MARK, Ca2+-calmodulin dependent protein kinase II 
(CaMKII), protein kinase A (PKA) and TAOKs (Hanger et al., 2007; Tavares et al., 2013). 
Phosphorylation of KXGS motifs can reduce interaction between tau and microtubules and 
may constitute an early event in the pathogenesis of tauopathy (Biernat and Mandelkow, 





Figure 1-5 Schematic representation of residues that can be phosphorylated in the 
longest isoform of tau: Illustration of tau as being phosphorylated by tau kinases. KXGS 
motifs (shown in yellow text), and other sites (represented in grey) can be phosphorylated 
by proline-directed kinases (blue) and non-proline directed Ser/Thr kinases (green). 
Antibody epitopes AT8, AT100, AT180, and PHF-1 comprise dual and triple 
serine/threonine residues (indicated by brackets). GSK3: Glycogen synthase kinase 3β/a, 
Cdk5: Cyclin-dependent kinase5; CK1: casein kinase 1, MARK: MT affinity-regulating 
kinase; LRRK2: leucine-rich repeat kinase2; DAPK: Death-associated protein kinase; 
Dyrk1A: dual-specificity protein kinase 1, SAPK: stress-activated protein kinase, PSK: TAOKs 
(Tenreiro et al., 2014). 
 
There are two major isoforms of GSK3; α and β, which are encoded by different genes, but 
share approximately 85% sequence homology (Woodgett, 1991).  Alternative splicing of 
GSK3β at exon 8A generates two isoforms β1 and β2 (Woodgett, 1991). The β1 isoform is 
the more abundant form of GSK3β (Mukai et al., 2002). The β2   isoform of GSK3 is found 
in neuronal soma while the β1 isoform is found both in neuronal soma and in axons 
(Mukai et al., 2002). GSK3 phosphorylation can be catalysed by several protein kinases 
including protein kinase cAMP-dependent (PKA) (Fang et al., 2000), protein kinase B (PKB) 
(Cross et al., 1995), protein kinase C (PKC) (Goode et al., 1992), p70S6K/p85S6 kinase, p90-
ribosomal S6 kinase (Sutherland et al., 1993). P70S6K/p85S6 kinase and p90-ribosomal S6 
37 
kinase are activated in response to Akt/protein kinase B (PKB) and MAPK (p38 and 
ERK1/2), respectively. 
 
Several lines of evidence link the activation of GSK3 with the development of tauopathy. 
Tau phosphorylation by GSK3 has been identified at 42 sites, with 29 of these being 
phosphorylated in AD brain (Hanger et al., 2009b). In AD patients, GSK3β was found to co-
localise with NFT (Yamaguchi et al., 1996), and the active form of GSK3β (phosphorylated 
at tyrosine 216) increases in the frontal cortex of AD brains (Leroy et al., 2007). GSK3β 
phosphorylates tau at Thr231 and primes the C-terminus of tau for subsequent 
phosphorylation, promoting NFT formation (Cho and Johnson, 2004b; Rudrabhatla and 
Pant, 2010). In a study in cultured neurons, lithium (an inhibitor of GSK3β activity) reduced 
the phosphorylation of tau, enhanced the binding of tau to microtubules, and promoted 
microtubule assembly (Marchand et al., 2015). GSK3 inhibition also induces pro-survival 
signals through increased activity of the autophagy/lysosomal networks (Marchand et al., 
2015). An additional study done in transgenic mice showed that the inhibition of GSK3β 
reduces tau phosphorylation (Caccamo et al., 2007; Engel et al., 2006; Nakashima et al., 
2005), tauopathy and neurodegeneration (Noble et al., 2005), blocks NFT formation (Engel 
et al., 2006; Leroy et al., 2010) and rescues neuronal loss (Serenó et al., 2009) 
 
ERK1 and ERK2 exhibit 83% homology and they regulate cell division, growth, proliferation, 
cell migration, cell differentiation, and apoptosis (Guise et al., 2001). ERK1/2 becomes 
activated by dual phosphorylation at Thr202 and Tyr204 for ERK1 and at Thr184 and 
Tyr186 for ERK2 (Roux and Blenis, 2004). This activation occurs through the activity of the 
upstream MAP kinase kinase (MEK). The increased phosphorylation of tau in AD has been 
proposed to involve the activation of ERK. A study carried out by Pei et al, found that 
increasingly phosphorylated (activated) MEK1/2 and ERK1/2 were present in the initial 
stages of neurofibrillary degeneration in the projecting neurons in AD brain (Pei et al., 
2002). Further work revealed that the accumulation of phosphorylated MEK1/2 and 
ERK1/2 was initiated in the cytoplasm of pretangle neurons and correlated with the 
progressive development of neurofibrillary tangles (Pei et al., 2002). 
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1.3.1.2 Tau phosphatases 
Tau phosphatases belong to PPP group, which dephosphorylates either serine and 
threonine residues (PP1, PP2A, PP2B and PP5) and PTP group, which dephosphorylate 
tyrosine residues (PTEN). Physiologically in the human brain, without the development of a 
neurodegenerative pathology, PP2A accounts for more than 70% of cellular phosphatase 
activity in the brain (Liu et al., 2005a). PP2A dephosphorylates tau and is implicated in the 
regulation of tau phosphorylation. PP2A activity is decreased by approximately 50% in AD 
brain, which could contribute to increased tau phosphorylation (Liu et al., 2005b).  
 
Interestingly, the inhibitory phosphorylation of PP2A at Tyr307 is stimulated by the activity 
of GSK3β. These data provide a strong link between PP2A and GSK3β and suggest that the 
inactivation of PP2A could be due to the GSK3 (Yao et al., 2011; Zhang et al., 2008). In 
addition, In vivo studies showed that PP2A inhibition induces an increase in tau 
phosphorylation and spatial memory deficits (Zhang et al., 2008), and these effects are 
reversed by the addition of acetyl-l-carnitine (Yin et al., 2010). Moreover, PP2A inhibition 
by okadaic acid in rats increases tau phosphorylation in neurons and impairs spatial 
memory retention (Sun et al., 2003). 
1.3.2 Tau acetylation 
Unlike phosphorylation, which involves serine, threonine and tyrosine residues, 
acetylation involves lysine residues and acetylation has been suggested to be an early step 
in the aggregation of phosphorylated tau (Fontaine et al., 2015). Tau acetylation is 
elevated in patients with AD and this event prevents degradation of phosphorylated tau 
(Min et al., 2010). This study also found that, when looking at the frontal cortex of patients 
with varying degrees of AD, the patients at earlier stages had high levels of acetylated tau, 
and it wasn’t until the later stages of the disease that increasingly phosphorylated tau was 
detected (Min et al., 2010). This suggests that tau acetylation may precede the 
phosphorylation of tau and NFT formation (Min et al, 2010). Furthermore, a recent study 
by Cohen et al (2011) used mass spectrometric analysis in cell and mouse models to 
demonstrate that tau acetylation at specific lysine residues (especially K280) inhibits tau 
function by disrupting microtubule binding, as well as promoting the aggregation of 
phosphorylated tau (Cohen et al., 2011; Russell et al., 2014). However, another study. 
found that KXGS motifs, located in the microtubule-binding domain of tau, were 
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hypoacetylated in people with AD, as well as in mouse models, suggesting an opposite 
relationship where decreased acetylation of tau increases vulnerability to tau 
phosphorylation (Cook et al., 2014a). Together, these contradictory results demonstrate 
that although acetylation does appear to play a role in the development of AD, the nature 
of that role is not well understood and requires further investigation. Perhaps, the 
different interactions between post-translational modification of tau at different sites 
could explain these different results, as they evidently have a complex relationship. 
Further, due to the complex relationships of post-translational modification of tau, it has 
been suggested that the degree of tau acetylation may also influence the extent of tau 
ubiquitination (Marcus and Schachter, 2011). 
1.3.3 Tau truncation 
In addition to highly phosphorylated and aggregated tau, truncated tau has additionally 
been reported in tauopathies including AD, PiD, CBD and PSP. These fragments can lack  
either the N- and C-termini of tau, or both (Garcia-Sierra et al., 2008). Specifically, a 
caspase-cleaved tau species (cleaved at D13 by caspase-6 and at D421 by caspase-3), 
termed Δtau,, has previously been reported.  This fragment of tau is recognised by an 
antibody specific to this fragment, which labels NFTs in the CA1 layer of the hippocampus 
in AD (Garcia-Sierra et al., 2008). Several other lines of evidence reveal the role of 
truncated tau in the development of a neurodegenerative phenotype. For example, tau 
truncated at Asp421 colocalises with tangles in AD brain as well as in a number of 
transgenic mouse models of AD, which may indicate that the generation of this tau 
fragment may be an early event in tangle formation (Basurto-Islas et al., 2008; Horowitz et 
al., 2004). A further study revealed that the mutation of Ser422 in full-length tau to 
glutamate (S422E), which mimics a permanent state of phosphorylation, prevents caspase 
cleavage at Asp421 (Guillozet-Bongaarts et al., 2006). These findings support the view that 
caspase degradation of tau can be inhibited by phosphorylation of residues adjacent to the 
caspase cleavage site (Hanger and Wray, 2010). Additional studies reveal that while both 
increased tau phosphorylation and truncation are found in NFTs in AD, cleavage occurs 
following tau phosphorylation  (Guillozet-Bongaarts et al., 2005; MondragónRodríguez 
et al., 2008). Conversely, tau cleavage has been suggested to drive aggregation of tau and 
any associated disease-modifying proteins, leading to a loss of tau function. Supporting 
40 
this statement is the fact that truncated protein fragments can form the initial seeds 
required for aggregation and appear to be upstream in the proteopathic cascade that 
occurs in neurodegenerative disease (Zilka et al., 2006a). Some of the truncated tau 
fragments that may be involved in the development of human tauopathies are 
summarised in Table 1-3. 
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Table 1-3 Tau fragments identified in human brain that may be involved in the 
development of human tauopathy (Adapted from (Guo et al., 2017)). 
Tau fragment 
(residues) 










AD brain Tangle formation, 
amyloid plaques, 
synaptic dysfunction, tau 
filament formation 








(Amadoro et al., 
2011) 
(I151-A391) AD brain Tangle formation (Filipcik et al., 2012) 
(Q124-L441) Control brain Increased acetylation 
and detyrosination of 
tubulin 
(Garg et al., 2011) 
(A125- R230) AD brain 
Control brain 
Elevated levels of 
phosphorylated and 
aggregated tau 







cognitive and motor 
dysfunction 






Tau pathology, synapse 
loss 






A particular study found a significantly higher numbers of phospho-tau positive NFTs when 
compared with cleaved tau in Braak III, IV and V brains. Consistent with these findings, in a 
double transgenic mouse model (Tet ⁄ GSK-3β ⁄ VLW) overexpressing GSK-3β and tau with 
a triple FTLD-tau mutation (VLW) with AD-like phenotypes, it was apparent that there 
were elevated levels of tau phosphorylated at sites Ser199⁄Ser202/Thr205, when 
compared to the levels of truncated tau (Mondragon-Rodriguez et al., 2008). 
 
Nonetheless, the role of truncated tau in neurodegeneration has multiple roles as 
illustrated by an array of findings. The presence of a 17 kDa tau fragment (Tau73-315) was 
identified in cerebellar granule neurons undergoing apoptosis as a result of caspase-3 and 
calpain-mediated cleavage (Canu et al., 1998). In parallel, a different 17 kDa tau fragment 
(Tau45-230) was found in hippocampal neurons treated with Aβ (Park and Ferreira, 2005).  
 
N-terminally truncated tau has additionally been linked with the development of 
tauopathy. The NH2-tau fragment (Tau26-230), was identified in human SH-SY5Y cells 
undergoing apoptosis and in the hippocampus of 15 month-old AD11 transgenic mice, 
exhibiting AD-like pathology (Corsetti et al., 2008). Moreover, more recently, a C-terminal 
tau fragment (Tau243-441), termed Tau-CTF24, was found in the Tg601 mouse model of 4R 
tauopathy (Matsumoto et al., 2015). A 35 kDa C-terminal tau fragment (Tau187-441) lacking 
the N-terminus of tau, but containing all four microtubule-binding repeats (4R), was found 
to be solely present in 4R tauopathies such as PSP (Wray et al., 2008). Subsequent 
characterisation of this fragment by low-level expression in a transgenic mouse model, 
revealed progressive cognitive and motor deficits, as well as aggregated and increasingly 
phosphorylated tau (Bondulich et al., 2016). 
 
Tau can be cleaved by a variety of proteolytic enzymes including caspases, cathepsins, 
calpains, thrombin and puromycin-sensitive aminopeptidase. Caspases and cathepsins are 
discussed briefly below. 
1.3.3.1 Caspases 
Tau can be cleaved by caspases at three distinct sites, residues Asp25, Asp348 and Asp421, 
of which Asp421 is the preferred cleavage site (Guo et al., 2004). The consensus sequence 
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at Asp421 is recognised by caspases-3 and -7 and mutation of this residue to glutamate 
inhibits caspase-mediated tau proteolysis (Chung et al., 2001). In addition, Asp421 in tau is 
targeted by caspases-1, -6, and -8, generating tau fragments that are approximately 5 kDa 
smaller than full-length tau due to the removal of C terminus (Gamblin et al., 2003). To 
date, truncation of tau at Asp421 by caspases has been validated both in vitro and in vivo, 
and appears to be directly related to the development of tau pathology (Amadoro et al., 
2010). Studies corroborate this observation as a tau fragment cleaved at Asp421 by 
caspase-3 is found in rodent primary cultured neurons (Garwood et al., 2011), and htau 
transgenic mice (Noble et al., 2009). The presence of these caspase-cleaved tau products 
in AD brain was identified using antibodies TauC3 and α-ΔTau, which are specific for 
caspase-cleaved tau (Gamblin et al., 2003).  
1.3.3.2 Cathepsins  
Cathepsins are synthesised in membrane-bound ribosomes as N-glycosylated precursors. 
Subsequently, they are transferred into the endoplasmic reticulum (ER) and later into the 
Golgi complex. During transport to the Golgi complex, pro-cathepsins (inactive) acquire 
modification of their carbohydrate moieties, which includes the formation of the mannose 
6-phosphate (M6P) residues and are transported to late endosomes. Upon fusion with late 
endosomes, the dissociation of ligands occurs (Nakanishi, 2003). The major part of the 
enzyme is then transported to the lysosome where the pro-peptides of the cathepsins are 
removed due to the acidic environments of late endosomes and lysosomes. Thus active 
cathepsins are formed (Zhang et al., 2009a). 
 
Lysosomal dysfunction has been demonstrated in aged brain, leading to leakage into the 
cytoplasm of lysosomal enzymes (Lloyd-Evans and Haslett, 2016). The cathepsins are a 
group of lysosomal proteases. Cathepsin D is an aspartyl protease that has been most 
associated with the development of tauopathy (De Strooper, 2010). Several groups have 
shown in vitro that tau is cleaved by cathepsin D between amino acids 200 and 257, 
resulting in the generation of a 29 kDa tau species (Bendiske and Bahr, 2003). Defects in 
the activity of cathepsin D have additionally been reported in several studies on AD. The 
presence of C-terminally truncated tau has been reported in the brains of CLN10 
(cathepsin D null) mice (Khurana et al., 2010). Moreover, the complete loss of cathepsin D 
in patients has been shown to lead to a devastating form of a lysosomal 
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neurodegenerative disorder that is autosomal recessive and can manifest in early 
childhood, causing neuronal ceroid lipofuscinosis (Steinfeld et al., 2006). The pH optimum 
of cathepsin D is narrow and is within the range of ∼pH3.1–3.5. The extremely narrow pH 
optimum means that cathepsin D will likely become less functional with age as the pH of 
lysosomes is elevated (Cuervo and Dice, 2000). Consequently, there is, therefore, a clear 
association between loss of optimal function of this enzyme and common 
neurodegenerative diseases of ageing.  
 
The role of other cathepsins in relation to neurodegeneration has also been suggested, in 
particular cathepsins B and L (Felbor et al., 2002). In human neuroblastoma cells inducibly 
expressing tau, disruption of lysosomes with chloroquine results in inhibition of tau 
degradation and the appearance of tau aggregates (Wang et al., 2009). This study also 
implicated the involvement of cathepsins B and L in generating two amyloidogenic tau 
fragments in a cell model of tau aggregation expressing a tau fragment, tauRDΔK280 
(microtubule binding repeats with ΔK280 mutation). These findings imply that cathepsins B 
and L may play a role in tau aggregation (Hamano et al., 2008a; Wang et al., 2009). 
Moreover, in cathepsin B−/−/L−/− mice, a large degree of brain atrophy was observed. This 
was due to apoptosis of select neurons in the cerebral cortex and the cerebellar Purkinje 
and granule cell layers. Neurodegeneration in the mice was accompanied by pronounced 
reactive astrocytosis and is preceded by an accumulation of ultrastructurally and 
biochemically unique lysosomal bodies in large cortical neurons and by axonal 
enlargements (Felbor et al., 2002). 
1.4 Mouse models of tauopathy 
Transgenic rodents have been used to investigate pathogenic mechanisms in diseases of 
the CNS, and animal models of disease are vital for pre-clinical investigations of potential 
therapeutic strategies (Noble et al., 2010). There are now a multitude of animal models 
that aim to investigate different disease-associated proteins and their post-translational 
modification in relation to the neurodegenerative tauopathies. Several strategies have 
been used to create such models including overexpression of individual wild-type or 
mutant tau isoforms, knock-in of human tau or knock-out of rodent tau, regulatable 
expression of mutant human tau and over-expression of the entire wild-type mouse or 
human MAPT gene (Noble et al., 2010) Most existing transgenic mouse models of 
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tauopathy rely on over-expression of wild-type or mutant forms of tau. While these 
models provide useful insight on the mechanistic understanding of tau, they do not mimic 
the levels of tau expression in human tauopathies., which usually exhibit only modest 
changes in steady state levels of tau. For example, a number of different mouse lines 
expressing P301L mutant tau have been created (McGowan et al., 2006). The expression of 
0N4R tau with the P301L mutation under the control of the mouse prion promoter, leads 
to the build-up of increasingly phosphorylated and insoluble tau (van Swieten et al., 2004). 
Moreover, NFTs and Pick-body like inclusions form from 4.5 months of age in the 
brainstem and spinal cord of P301L tau mice (Lewis et al., 2000). These changes are 
accompanied by progressive motor and cognitive abnormalities (Lin et al., 2003). The 
P301S mutation causes the formation of NFTs and glial tangles containing straight tau 
filaments. In contrast to P301L mice, the overexpression of 0N4R or 1N4R tau with the 
P301S mutation, results in accelerated neurofibrillary pathology (Allen et al., 2002; 
Yoshiyama et al., 2007). 
 
Melis et al (2015) generated two mouse models of tauopathy over-expressing tau. L66 
mice model the FTLS-tau spectrum of diseases, and these animals over-express human 
MAPT cDNA containing two point mutations (equivalent to P301S and G335D).  L66 mice 
have abundant tau pathology distributed throughout the brain, with a high proportion of 
affected neurons seen in the hippocampus and entorhinal cortex. The pathology is 
neuroanatomically static and declines with age. The second mouse model: L1 expresses a 
truncated 3-repeat tau fragment which constitutes the bulk of the PHF core in AD 
corresponding to residues 296–390. These mice model cognitive changes seen in AD (Melis 
et al., 2015). L1 mice display a much weaker histopathological phenotype in comparison 
with L66 mice, but show evidence of tau spreading that resembles the Braak staging of 
AD. Behaviourally, the mice exhibit minimal motor deficits but shows severe cognitive 
impairments (Melis et al., 2015). 
 
However, a mouse model that does not depend on excessive over-expression of tau was 
generated by McMillan et al (2011). In this model, mice express at approximately twice the 
amount of endogenous tau, a 4R tau truncation construct, lacking the C-terminus as it 
terminates at residue E391. These mice exhibit a sufficient build-up of insoluble and 
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phosphorylated tau to generate a “pre-tangle”-like pathology (McMillan et al., 2011). 
Importantly however, these mice failed to show accumulation of tangles and no cognitive 
studies were conducted on these animals, which significantly limits the validity and 
characterisation of this potential model of tauopathy. 
 
A 35 kDa tau fragment that is highly phosphorylated at the C-terminus and lacking the N 
terminus was identified in PSP brain (Wray et al., 2008). This tau fragment contained all 
four MTB domains of tau and was found in the brains of PSP, CBD, and FTDP-17 patients, 
but was absent from AD brain (Wray et al., 2008). Based on these findings, Tau35 mice 
were generated by targeted insertion of Tau35, which is controlled by the human tau 
promoter at the Hprt (hypoxanthine phosphoribosyl transferase) locus on the X 
chromosome (Bondulich et al., 2016). This tau fragment has a haemagglutinin (HA) tag 
that allows its discrimination from endogenous mouse tau. Tau35 mice differ from many 
other models of tauopathy that over-express mutant forms of tau. This particular mouse 
model expresses a human tauopathy-associated 35 kDa tau fragment at a level that is 
<10% of endogenous mouse tau (Bondulich et al., 2016).  
 
Tau35 mice exhibit age-related limb clasping, kyphosis and a reduced life span (Bondulich 
et al., 2016). This is consistent with other mouse models of tauopathies (Lalonde and 
Strazielle, 2011; Laws and Hoey, 2004; Wu et al., 2012). Tau35 mice show a loss of 
hindlimb grip strength as well as a progressive clasping of either their hindlimbs or all four 
limbs. In addition, abnormal spine curvature is seen in Tau35 mice and the kyphotic index 
is reduced, demonstrating progressive, age-related kyphosis (Bondulich et al., 2016). 
Tau35 mice additionally had a  reduced latency to fall from the rotarod, which decreases 
with age, possibly caused by reduced muscle strength and motor ability. Furthermore, 
Tau35 mice exhibit spatial learning and hippocampal-dependent memory deficits. These 
changes in learning and memory were apparent in the Morris water maze. No differences 
were found in non-associative short-term memory, olfaction or anxiety (Bondulich et al., 
2016). These mice additionally showed a reduced median survival of 717 days, compared 
to 788 days in WT mice (Bondulich et al., 2016). 
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Tau35 expression also alters the intrinsic excitability of CA1 pyramidal neurons in mice, 
leading to an induction of higher cell capacitance and rise of action potential rate 
(Tamagnini et al., 2017). Tau35 accumulation leads to hyperexcitability and 
hypoexcitability at polarised and depolarised potentials, respectively (Tamagnini et al., 
2017). Moreover findings indicate that Tau35 mice exhibit a significant increase in short-
term facilitation of the synaptic response without changing long-term synaptic plasticity 
(Tamagnini et al., 2017). 
1.5 Protein degradation mechanisms 
The abnormal protein inclusions present in several neurodegenerative diseases contain a 
large amount of misfolded or unfolded proteins, which leads to organelle stress. 
Consequently, this group of disorders is often referred to as diseases of protein misfolding 
(Ciechanover and Kwon, 2015). Several studies have reported that neuronal death in AD 
and PD originates in the ER, which is the organelle that is responsible for regulating correct 
protein folding, assembly, secretion and the formation of protein complexes (Matus et al., 
2008). 
1.5.1 Tau degradation 
The ubiquitin–proteasome system (UPS) and the autophagy-lysosomal system are the two 
major pathways responsible for the degradation of intracellular proteins. Initially tau was 
considered to be primarily a proteasomal substrate (Lee et al., 2013). However, more 
recently studies found that the UPS may not be the primary degradation machinery for 
endogenous tau (Brown et al., 2005; Feuillette et al., 2005). It is now well established that 
tau is a substrate for the autophagy-lysosomal system. Using an inducible mouse 
neuroblastoma N2a cell model of tauopathy expressing the repeat domain of Tau with a 
FTLD-tau mutation (Tau RD ΔK280), it was shown that the autophagy-lysosomal system 
can efficiently degrade both soluble mutant tau as well as tau aggregates (Wang et al., 
2009). In addition, inhibition of autophagy leads to enhanced aggregation and cytotoxicity 
of mutant tau (Krüger et al., 2012). Using an inducible N2a cell line expressing the full-
length wild-type isoform hTau40, it was further demonstrated that autophagy can also 
degrade full-length tau (Wang et al., 2009). Phosphorylation in the repeat domain, which 
regulates the affinity of tau for microtubules, does not alter its sensitivity to autophagy–
lysosomal degradation (Wang et al., 2009). 
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An additional study found that soluble PHF-tau isolated from human AD brain was not 
degraded by the proteasome but instead it inhibited proteosomal activity (Keck et al., 
2003). Moreover, in a different study, tau was degraded by the proteasome in vitro, but 
not in primary neurons or in neuroblastoma cells (Brown et al., 2005). In the latter 
systems, tau proteins in a variety of forms had been reported to be degraded through the 
autophagy-lysosome system. Inhibitors of various autophagy processes, such as 
ammonium chloride, chloroquine, and 3-methyladenine (3-MA), delayed tau degradation 
and enhanced the formation of high molecular weight species of tau (Hamano et al., 
2008b). On the other hand, rapamycin facilitated the degradation of insoluble forms of tau 
in a Drosophila model (Berger et al., 2007). These findings therefore suggest that while tau 
is degraded by the proteasome in some instances, it is predominantly degraded via the 
autophagy and lysosomal system. 
1.6 The ubiquitin proteasome system (UPS) 
The UPS has received particular attention in the study of neurodegenerative disorders due 
to its role as a critical regulator of proteostasis. The function of the UPS is to rid cells of 
misfolded, defective, and aggregation-prone proteins, which have been found to 
accumulate in neurodegenerative diseases (Ciechanover and Brundin, 2003). The pathway 
is predominantly responsible for the clearance of short-lived, damaged, and misfolded 
proteins in the nucleus and cytoplasm (Ciechanover and Brundin, 2003).  
 
In the UPS, proteins are committed to degradation by their ligation to ubiquitin (Hershko, 
1991). An enzymatic cascade composed of ubiquitin activator, conjugase, and ligase 
catalyse the covalent attachment of ubiquitin to a substrate protein. Ubiquitin is 
conjugated via its carboxy-terminal Gly to an internal Lys residue or, less commonly, to the 
free N-terminus of the substrate (Dantuma and Bott, 2014). At least three rounds of 
ubiquitylation lead to the formation of a polyubiquitin chain (Figure 1-6). This acts as a 
signal for the proteasome, which in turn can go on to perform its degradative function 
through its 20S catalytic core (Bedford et al., 2010). The proteasome unfolds substrates, 
breaking them up into short peptides (Bhattacharyya et al., 2014). The peptides are then 
released and are rapidly processed into amino acids by cellular aminopeptidases and 




Figure 1-6 Schematic diagram of the ubiquitin proteasome system (UPS): The UPS 
involves at least three enzymes (E1, E2, and E3). These catalyse the addition of ubiquitin to 
lysine residues on the substrate protein. Polyubiquitinated substrates are subsequently 
identified by the proteasome or proteasome associating protein, and the ubiquitin 
removed by deubiquitinases and the substrate unfolded and translocated in the 20S core 
for proteolysis (Suh et al., 2013) 
 
The initial clue for the pathological link between tau and the UPS was derived from the 
observation of co-localisation and accumulation of ubiquitin in PHFs and NFTs (Morishima-
Kawashima et al., 1993). Subsequently, it was shown that blocking the activity of the 20S 
catalytic core inhibits tau degradation in transfected SH-SY5Y cells expressing exogenous 
human tau (David et al., 2002). It is thought that the ubiquitination of tau weakens its 
microtubule-binding affinity, similar to the effects of tau phosphorylation. PHF-tau isolated 
from human AD brain was also found to co-immunoprecipitate with various proteasome 
subunits (Keck et al., 2003), further supporting a role for the UPS in tau degradation. 
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1.7 Autophagy and lysosomal degradation 
Unlike the UPS, the autophagy/lysosomal pathway is primarily responsible for degrading 
long-lived proteins and organelles such as mitochondria, that are unnecessary or even 
detrimental for cell survival (Damme et al., 2015). There are three main types of 
autophagy (Figure 1-7); macroautophagy (herein referred to as autophagy), 
microautophagy, and chaperone-mediated autophagy. In starved organisms, autophagy 
prolongs survival through providing necessary energy and dietary components by the 
recycling of intracellular proteins and organelles (Metaxakis et al., 2018). 
 
Induction of autophagy initiates the formation of an isolation membrane (phagophore). 
Phagophore formation involves the localisation of autophagy proteins to pre-
autophagosomal structures (Nixon and Yang, 2011). The phagophore elongates 
sequestering protein aggregates, lipid droplets and organelles and finally closes off to form 
a double-membrane vesicle, the autophagosome. During maturation, autophagosomes 
can fuse with late endosomes (Rab7-positive structures), generating a hybrid organelle 
called an amphisome, or can directly fuse with lysosomes forming an autolysosome. 
Finally, acidic hydrolases such as cathepsin D degrade the sequestered content (Figure 1-7) 
(Deng et al., 2017; Kang et al., 2011). 
 
Phagophore membrane formation occurs through a beclin-1-dependent mechanism, 
positioning beclin 1 as a marker of early autophagy activation. Beclin-1 is a novel Bcl-2-
homology (BH)-3 domain only protein (Czabotar et al., 2014). Increasing evidence suggests 
that nuclear factor (NF)-κB, E2F transcription factors (E2F) and microRNAs (miRNAs) are 
involved in regulation of beclin-1 expression in autophagy (Kang et al., 2011). Upon 
autophagy stimulation, beclin-1 is released from Bcl-2 at the ER, forms complex with 
UVRAG/AMBRA (ultra-violet radiation resistance-associated gene/activated molecule in 
beclin 1 regulated autophagy/) ( Figure 1-7) (Kang et al., 2011).  
 
More than 30 evolutionarily conserved autophagy related genes (Atgs) have been 
identified and shown to play a vital role in phagophore formation and elongation of the 
autophagosome (Mizushima, 2007). The activation of Atg13 is particularly important for 
this step. This protein is negatively regulated by the mammalian target of rapamycin 
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complex 1 (mTORC1) and interacts with the mammalian homolog of yeast Atg1 kinase 
complex (ULK1) complex to facilitate early autophagy (Jung et al., 2010). Once the 
phagophore forms, there are two ubiquitin-like systems that are key to autophagy 
progression. The first is the Atg5– Atg12 conjugation and the LC3 (microtubule-associated 
protein 1A/1B-light chain 3) processing step (Axe et al., 2008; Hayashi-Nishino et al., 2009; 
Yla-Anttila et al., 2009). In the first of these systems, Atg7 activates Atg12 in an ATP-
dependent manner by binding to its C-terminal Gly. Atg12 is then transferred to Atg10, 
that potentiates the linkage of Atg12 to Atg5. Conjugated Atg5 – Atg12 complexes in pairs 
with Atg16L dimers to form a multimeric Atg5 – Atg12 – Atg16L complex that associates 
with the extending phagophore. The association of Atg5 – Atg12 – Atg16L complexes is 
thought to induce curvature into the growing phagophore (Figure 1-7) (Kirkin et al., 2009). 
 
The autophagy pathway is additionally regulated by the autophagy substrate 
p62/sequestosome 1 (p62/SQSTM1). P62 is involved in the degradation of protein 
aggregates and cytoplasmic bodies via selective autophagy through its PB1 (Phox/Bem 1p), 
LIR (LC3 interacting), and UBA (ubiquitinated protein aggregates) domains to maintain 
homeostasis in the cell (Lin et al., 2013). P62 binds Atg8/LC3 through a region termed the 
LC3-interacting region. p62 along with its PB1 partner, NBR1 (neighbor of BRCA1 gene 1), 
have been proposed to regulate the packing and delivery of polyubiquitinated, misfolded, 
aggregated proteins and damaged organelles for their clearance through autophagy (Kirkin 
et al., 2009). In addition, evidence reveals that p62 regulates cell survival, as the disposal 
of toxic aggregates is essential for the prevention of cell death in several pathological 
situations in which p62 is a component of these aggregates (Figure 1-7) (Zatloukal et al., 
2002). 
 
Autophagosome formation is dictated by the processing of LC3B, which is encoded by the 
mammalian homologue of Atg8. Upon autophagy induction, LC3B is cleaved by Atg4; a 
cysteine protease, to generate LC3B-I. The carboxyterminal glycine exposed by Atg4-
dependent cleavage is then activated in an ATP-dependent manner by Atg7 (Kabeya et al., 
2000). Activated LC3B-I is then transferred to Atg3. Subsequently, 
phosphatidylethanolamine (PE) is conjugated to the carboxyl glycine of activated LC3B-1 to 
generate LC3B-II. Recruitment and integration of LC3B-II into the growing phagophore is 
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dependent on Atg5–Atg12 (Kabeya et al., 2000). LC3B- II is found on both the internal and 
external surfaces of the autophagosome, where it plays a vital role in both 
autophagosome membrane formation and in selecting cargo for degradation. The 
synthesis and processing of LC3 is markedly increased during autophagy, making it a 
robust indicator of levels of autophagy in cells (Barth et al., 2010). It has previously been 
shown that both LC3-I and LC3-II interact with microtubule-associated proteins and this 
facilitates their association with microtubules (Figure 1-7) (Wang and Mandelkow, 2012a). 
 
In the context of autophagosomal-lysosomal fusion, pleckstrin homology domain–
containing protein 1 functions as a tethering factor by simultaneously binding both to LC3 
on autophagosomal membranes via an LC3-interacting region and to the homotypic fusion 
and vacuolar sorting (HOPS) complex on the lysosomal membrane (McEwan et al., 2015). 
The Atg14 protein also acts as a tether between autophagosomes and lysosomes by 
interacting with syntaxin 7 (STX7) and synaptosomal associate protein 29 (SNAP29), which 
are soluble N-ethylmaleimide-sensitive factor attachment protein receptors (Q-SNAREs), 
located on the autophagosomal membrane. Consequently, the two structures fuse and 
form an autolysosome (Figure 1-7) (Diao et al., 2015). 
 
Ultimately, upon fusion, the ∼60 acid hydrolases within the lysosome digest all classes of 
macromolecules, such as proteins, lipids, nucleic acids, and carbohydrates.(Chapel et al., 
2013). Afterwards, the end products of lysosome-mediated digestion are actively or 
passively transported by integral membrane proteins of the lysosomal membrane to the 






Figure 1-7 Schematic diagram of macroautophagy, microautophagy and chaperone-
mediated autophagy: Summary of microautophagy, chaperone-mediated autophagy, and 
macroautophagy. Macroautophagy begins with cargo recognition and the formation of a 
phagophore that matures into autophagosomes. Autophagic cargo may include material 
incorporated via endocytosis and transported via endosomes and multivesicular bodies for 
lysosomal degradation. The autophagosome can fuse with an endosome to generate an 
amphisome, which fuses with a lysosome leading to an autolysosome. However, the 
autophagosome can fuse directly with the lysosome also generating an autolysosome. The 
lysosomes maintain an acidic pH through the proton (H+) vacuolar ATPase (V-ATPase) and 
are characterized by their expression of lysosomal associated membrane proteins (LAMP). 
Macroautophagy is inhibited by mTORC1 activation and activated AMPK via 
phosphorylation of ULK1 complex that includes ATG13, ATG101, and focal adhesion kinase 
(FAK) family kinase-interacting protein of 200 kD (FIP200). The next complex involved in 
autophagosome formation is the PI3K complex, which includes beclin 1, AMBRA, ATG14, 
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and VPS 34 and VPS15. ULK1 phosphorylates AMBRA1, enabling the PI3K class III complex 
to relocate from the cytoskeleton to the phagophore and generate PI3P. PI3P catalyses the 
conjugation of ATG5 and ATG12 (in the presence of ATG7 and ATG12); attachment of the 
ATG5/ATG12/ATG16 complex induces the conjugation of LC3 to PE. The cargo selectivity 
for protein of aggregates or damaged organelles such as mitochondria involves one or 
several cargo receptors, including the ubiquitin-binding adaptor protein 
p62/sequestosome 1.  
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1.8 Regulators of autophagy 
Autophagy is shown to be mainly regulated through a wide range of upstream metabolic 
pathways and food consumption. Such pathways additionally affect ageing as well as age-
related neurodegenerative diseases. Such pathways include but are not limited to, 
mTORC1, the ULK1 complex, AMPK and ERK pathways as well as transcription factor EB  
(TFEB) and GSK3. 
1.8.1 Mammalian target of rapamycin complex 1 (mTORC1) 
mTOR is a serine/threonine kinase, which is a master regulator of cellular metabolism and 
promotes cell growth in response to environmental cues (Jung et al., 2010). mTOR forms 
two distinct signaling complexes; mTORC1 and mTORC2, of which the mTORC1 complex is 
relevant to autophagy (Kim and Guan, 2015). mTORC1 integrates nutrient and growth 
factor signaling to promote anabolic metabolism, such as protein synthesis and lipid 
synthesis, and to inhibit catabolic pathways, such as lysosome biogenesis and autophagy 
(Kim and Guan, 2015). The mTORC1 complex comprises mTOR, G protein β-subunit-like 
protein (GβL), proline-rich Akt substrate of 40 kDa (PRAS40), and the regulatory-associated 
protein of TOR (raptor). Notably, rapamycin solely binds to mTORC1, and inhibits mTORC1-
mediated phosphorylation of ribosomal S6 kinase (Kim et al., 2002). Notably, mTORC1 
deficiency has been shown to resemble rapamycin treatment, which activates autophagy 
(Figure 1-8) (Kim et al., 2002). 
 
Under nutrient-rich conditions, mTORC1 negatively regulates autophagy by 
phosphorylating ULK1/2 and Atg13, thereby inhibiting the kinase complex (Figure 1-8) 
(Ganley et al., 2009; Hosokawa et al., 2009). Moreover, under such conditions, PRAS40 is 
phosphorylated by protein kinase B (PKB or Akt) and dissociates from raptor to activate 
mTORC1. In response to starvation, the mTORC1-dependent phosphorylation sites in 
ULK1/2 are rapidly dephosphorylated, and ULK1/2 then autophosphorylates and 
phosphorylates Atg13 and FIP200 (an ULK-1 interacting partner) (Hosokawa et al., 2009). 
Therefore, under nutrient rich conditions, mTORC1 activation inhibits autophagy 
activation. Conversely, upon starvation, mTORC1 activity is inhibited, thereby activating 
autophagy. 
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1.8.2 AMP-activated protein kinase (AMPK)  
AMPK is a serine/threonine kinase that is the major energy-sensing kinase that activates a 
wide variety of catabolic processes. The phosphorylation of a conserved threonine residue 
(Thr172) in the activation loop of the catalytic α-subunit by upstream kinases such as LKB1 
and Ca2+-activated Ca2+-calmodulin-dependent kinase kinase β (CaMKKβ), is a prerequisite 
for the activity of AMPK (Hawley et al., 2005; Woods et al., 2005). The increased 
phosphorylation of AMPK at Thr172 has been associated with increased autophagy 
activation as it was shown to correlate with rises in the levels of LC3-II in colorectal cancer 
cells (Sueda et al., 2016). 
 
AMPK and mTORC1 both regulate the vesicular protein sorting 34 (VPS34) (an ATG14L-
associated) complex, a class III PI3K whose activity is crucial for autophagosome formation 
(Jung et al., 2010). VPS34 forms multiple complexes and has critical roles in cellular vesicle 
trafficking and autophagy induction (Figure 1-8). Under starvation conditions, AMPK 
activates the pro-autophagy VPS34 complex by phosphorylating beclin-1. AMPK 
additionally leads to the phosphorylation of Thr163/Ser165 of the VSP34 complex, which 
acts to inhibit autophagy. On the other hand, mTORC1 phosphorylates ATG14L in the 
VPS34 complex and inhibits the lipid kinase activity of VPS34, providing another mTORC1-
mediated mechanism in autophagy inhibition (Alers et al., 2012). 
1.8.3 The mammalian homologue of Atg1, ubiquitin like kinase (ULK1) complex 
The ULK1 complex plays a central role in autophagy induction. The mTORC1 complex, 
functions in part, by phosphorylating Ser758 (Ser757 in mouse) of ULK1 and inhibiting 
ULK-1. On the other hand, AMPK, a positive regulator that stimulates autophagy in 
response to energy depletion, directly regulates autophagy through phosphorylating and 
activating ULK1 (Figure 1-8) (Egan et al., 2011). mTORC1-dependent phosphorylation 
appears to antagonise AMPK activity by preventing the physical association of AMPK with 
ULK1 (Figure 1-8) (Kim et al., 2011). mTORC1 phosphorylation of ULK1 at Ser757 disrupts 
the physical interaction between AMPK and ULK1 thereby inhibiting autophagy. These 
findings highlight the physiological role of ULK1 phosphorylation by AMPK. In contrast the 
phosphorylation of ULK1 at Ser317, Ser555 and Ser777 by AMPK, mediates the 
translocation of ULK1 and activates autophagy and mitophagy (Tian et al., 2015). mTORC1 
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Figure 1-8: Schematic representation of the role of mTORC1, AMPK and the ULK1 
complex in autophagy activation: Activated mTORC1 phosphorylates ATG13, ULK1, and 
ATG14 to inhibit autophagy. AMP-AMPK activates autophagy by directly phosphorylating 
ULK1/2 and beclin 1. BCL-2 and BCL-XL bind to beclin 1 to inhibit autophagy. JNK 
phosphorylates BCL-2 to prevent its interaction with beclin 1, whereas MST1 
phosphorylates beclin 1 to increase its interaction with BCL-2 and BCL-XL, inhibiting 
autophagy. 3-MA inhibits VPS34 and suppresses autophagy. 
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1.8.4 Transcription factor EB (TFEB) 
Transcription factor EB (TFEB) is considered to be the master regulator of autophagy, since 
it regulates the expression of genes required for autophagosomal and lysosomal 
biogenesis (Napolitano and Ballabio, 2016). TFEB is a basic helix-loop-helix leucine zipper 
transcription factor (Roczniak-Ferguson et al., 2012b). It binds to a promoter motif 
responsible for coordinating the expression of lysosomal genes; the coordinated lysosomal 
expression and regulation (CLEAR) network. This comprises of genes involved in 
autophagy, lysosomal biogenesis, lysosomal exocytosis, endocytosis, and membrane repair 
(Palmieri et al., 2011). Once bound, TFEB results in autophagosome formation and 
autophagosome–lysosome fusion (Figure 1-9) (Settembre et al. (2011). In addition, TFEB 
augments cellular clearance through lysosomal exocytosis, a process mediated by 
activation of the lysosomal Ca2+ channel transient receptor potential (TRPM2), also known 
as  Mucolipin-1 (Medina et al., 2011; Xiao et al., 2015a). 
 
Under normal conditions, TFEB is located in the cytoplasm. However, conditions of stress, 
such as starvation/autophagy activation, result in the translocation of TFEB to the nucleus, 
where it promotes the transcription of its target genes (Martina et al., 2014). The 
activation state of TFEB and its phosphorylation state at Ser142 and Ser211 are directly 
correlated. The phosphorylation of TFEB is facilitated either by ERK2 or mTORC1 (Figure 
1-9). When TFEB is in the cytoplasm, it can often be found on the surface of lysosomes. 
Under nutrient-rich conditions, mTORC1 binds to the TFEB on the lysosomal surface, 
thereby facilitating its phosphorylation and cytoplasmic sequestration. Inhibiting mTORC1 
with torin 1 results in TFEB nuclear accumulation (Settembre et al., 2012). 
 
TFEB also regulates its own expression through a starvation-induced autoregulatory loop 
(Settembre et al, 2013). The TFEB promoter contains multiple CLEAR elements. TFEB itself 
binds to these elements, leading to additional TFEB expression (Settembre et al., 2013). 
Moreover, Mucolipin-1 leads to TFEB dephosphorylation and its ultimate nuclear 
translocation due to an increase in local Ca2+ levels, which activates calcineurin (a protein 




Figure 1-9 Role of TFEB in autophagy/lysosomal degradation: In nutrient-rich conditions, 
the V-ATPase, Ragulator, and Rag GTPases form an active complex that binds tomTORC1 at 
the lysosomal surface and activates it. mTORC1 then phosphorylates TFEB which leads to is 
cytoplasmic sequestration. Under starvation conditions and lysosomal stress, mTORC1 is 
released from the lysosomal surface and inactivates it. Because mTORC1 can no longer 
phosphorylate TFEB, the unphosphorylated TFEB translocates to the nucleus to bind to the 
CLEAR sequence of its target genes, leading to the upregulation of autophagy and 
lysosomal genes. The TFEB gene also has numerous CLEAR sequences in its promoter, and 
thus TFEB upregulates its own expression in an autoregulatory loop. Another positive 
feedback loop deals with Mucolipin-1, that is a transcriptional target of TFEB. Mucolipin-1 
creates high Ca2+ concentration near the lysosomal surface. The higher Ca2+concentration 
then activates the phosphatase calcineurin, which dephosphorylates TFEB, promoting its 
activation.  
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1.9 Autophagy and disease 
Several reports find a strong association between ageing and downregulation or 
deregulation of autophagic activity (Metaxakis et al., 2018; Nixon, 2013; Rubinsztein et al., 
2007). A role for autophagy in the clearance of protein aggregates has been suggested for 
several proteins, including β-amyloid, α-synuclein, tau, prion protein and huntingtin 
(Casarejos et al., 2011; Sarkar et al., 2007b). In neurodegenerative diseases, autophagy 
dysfunction arises at various points along the pathway, giving rise to distinct pathologic 
patterns with different implications for modulating autophagy as a therapy (Nixon, 2013). 
This dysfunction is observed in many neurodegenerative diseases (summarised in Table 
1-4). Studies in human brain reveal downregulation of Atg5, Atg7, and beclin 1 autophagy 
genes (Lipinski et al., 2010), as well as an increased mTOR activity, accompanied by a 
decline in Atg proteins in brains of aged rodents (Ott et al., 2016). In addition, in AD brain, 
autophagic vacuoles accumulate without degradation of their contents by lysosomes 
(Nixon et al., 2005a; Yu et al., 2004), suggesting autophagic dysfunction. A series of 
dysfunctions that can occur in the autophagy pathway in various neurodegenerative 
diseases are outlined in Table 1-4. 
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Parkinson's disease Rab1A-mediated Atg9 mislocalisation (Winslow et al., 2010) 
 
Huntington's disease Mutant huntingtin-mediated aggregation of beclin-1 or mTOR; impaired engagement of cargo 
by autophagosomal membrane (Shibata et al., 2006)  







SQSTM1 (p62) mutations (Fecto and Siddique, 2011) 
 
Inclusion body myopathy, 
Paget's disease of the 
bone and frontotemporal 
dementia (IBMPFD) 
VCP (p97) mutations lead to decreased autophagosome maturation and mitophagy (Ritz et al., 
2011; Tresse et al., 2010) 
 
Parkinson's disease PINK and parkin mutations lead to impaired mitophagy; LRRK2 mutations lead to decreased 
CMA; mutation or duplication of synuclein-encoding genes leads to decreased CMA (Alvarez-





Lower motor neuron 
disease 
Dynactin (DCTN1) mutations lead to impaired autophagosome and lysosome transport (Ferrucci 




  ALS Dynactin mutations; mutant ALS2-mediated Rab5 suppression (Otomo et al., 2011) 
 
Spinal and bulbar muscular 
atrophy 
Mutations in dynein motor complex components (for example, DYNC1H1) (Ferrucci et al., 2011) 
 
Frontotemporal dementia CHMP2B mutation leads to impaired amphisome formation (Ganley et al., 2011) 
Lysosomal 
digestion 
Alzheimer's disease Presenilin 1 (PSEN1) mutations cause a deficiency in V-ATPase, leading to increased lysosome 
pH; ApoE4 variant or Aβ leads to increased LMP; APP mutations or duplications, increased 
cholesterol or the ApoE4 variant lead to activation of Rab5 or Rab7 activation and substrate 
overload in lysosomes (Cataldo et al., 2004; Glabe, 2001)  
Parkinson's disease Duplications or mutations of synuclein genes or ATP13A2 mutation lead to lysosome pH 
elevation and hydrolase inhibition; MPTP treatment leads to increased LMP; β-glucosidase 






CLN3 mutation leads to decreased autolysosome maturation; cathepsin D mutation leads to 
decreased proteolysis (Siintola et al., 2006) 
 
Niemann-Pick type C (NPC) NPC1 mutation leads to decreased proteolysis from stored lipid (Elrick, 2002)  
Mucolipidosis type IV MCOLNl (TRPML1) mutations lead to a lysosomal pH elevation (Curcio-Morelli et al., 2010)  
Gaucher's disease β-glucosidase (GBA) mutation leads to decreased lysosomal hydrolysis (Sardi et al., 2011) 
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Disruption in early autophagy has been shown to be linked to the development of AD. APP 
transgenic mice with a heterozygous deletion of beclin 1 have an increase in Aβ plaque 
deposition, neuronal loss, and the accumulation of abnormal lysosomes containing 
electron-dense material (Pickford et al., 2008b). These findings indicate that autophagy 
plays a central role in APP transport and metabolism, as well as the degradation of APP 
metabolites (Jaeger and Wyss-Coray, 2010). 
 
Increased mTOR activation is linked to several neurogenetic disorders characterised by 
abnormal synaptic plasticity (Gipson and Johnston, 2012). Using 3xTg-AD mice, it was 
shown that increased mTOR signaling correlated with tau accumulation. There was an 
overt correlation between genetically increasing mTOR signaling and elevated tau levels 
and phosphorylation. Moreover, the reduction of mTOR signaling with rapamycin 
ameliorates tau pathology and rescues motor deficits, suggesting that mTOR signaling 
regulates tau phosphorylation (Caccamo et al., 2013a; Meske et al., 2008). 
 
Dysregulation of the ULK1 complex has previously been associated with the development 
of neurodegeneration. For example, ULK1 kinase activity is deregulated in Huntington’s 
disease (HD) (Sarkar and Rubinsztein, 2008). In addition, increased mTOR independent 
ULK1 activity via phosphorylation of p62/SQSTM1 while ULK1 mediated ATG14/Beclin-1 
phosphorylation is decreased in Huntington’s disease (Wold et al., 2016). Moreover, CBD 
and PSP brains show abnormal accumulation of p62, as well as LC3 and colocalisation of 
both LC3 and p63 with phosphorylated tau (Piras et al., 2016a). In addition, in vivo work on 
P301S tau mice showed that stimulation of autophagy reduced the amount of tau 
aggregates and improved nerve cell survival (Schaeffer et al., 2012a).  
 
A mouse model with tissue-specific knockdown of Atg7 in the CNS showed accumulation 
of inclusion bodies in autophagy-deficient neurons, however no changes in proteasome 
function were evident (Komatsu et al., 2006). Inclusion bodies were increasing in size and 
number with age leading to vast neuronal loss in comparison to controls. These mice were 
dead within 28 weeks of birth revealing the adverse effect of Atg7 knockdown on life span 
(Komatsu et al., 2006). 
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Taken together, these results highlight the vitality of the autophagic pathway for the 
survival of neural cells and that inadequate level of autophagy can lead to the 
pathogenesis of neurodegenerative disorders. 
 
The mislocalisation of proteins including TFEB has been reported in several 
neurodegenerative diseases including AD, PD, HD and ALS (Barber et al, 2010; Nunomura 
et al, 2006). TFEB has been proposed as a key component in the degradation of highly 
phosphorylated and misfolded tau (Polito et al., 2014) and activation of TFEB by fisetin, a 
naturally occurring flavonol, increases degradation of phosphorylated tau in neurons (Kim 
et al., 2016). In addition, enhancing the activation of autophagy lysosomal pathway 
through exogenous TFEB expression in the brains of P301L tau mice dramatically reduces 
tau pathology, neurodegeneration, and behavioural deficits (Polito et al., 2014). The 
proposed mechanism of action in this study operates via a TFEB–PTEN (phosphatase and 
tensin homolog)–Akt–mTOR–TFEB feedback regulatory loop. As such, TFEB activates 
autophagy through upregulation of PTEN and inhibition of Akt and mTOR, which further 
activates TFEB (Polito et al., 2014). On the other hand, the role of TFEB in the development 
of neurodegeneration has been shown to have both positive and negative effects. On the 
one hand, the cytoplasmic sequestration of TFEB could result in deficiency in the clearance 
of accumulated, potentially toxic proteins. On the other hand, TFEB could be upregulated 
in response to lysosomal stress resulting from a pre-existing insult such as mutation or 
dysfunction in other components of the autophagy pathway (Martini-Stoica et al., 2016a). 
 
There are likely to be numerous mechanisms that could explain the altered subcellular 
distributions of proteins such as TFEB in degenerating neurons. A key mechanism for 
which there is increasing evidence is impairment in nucleocytoplasmic transport. The role 
of the nuclear pore complexes and nuclear transport has been investigated in a number of 
human diseases. The importin family of proteins control he import of proteins into the 
nucleus and comprises importin α and β (Pemberton and Paschal, 2005).  Zhu and 
colleagues examined the localisation of importin-α1 in post mortem AD cases and found 
that there was little to no importin-α1 in NFT or amyloid plaques in hippocampal CA1 
neurons, compared to the cytoplasmic localisation of importin-α1 in age-matched control 
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brain (Lee et al, 2008). Importin-α is a key player in nucleocytoplasmic transport and the 
mislocalisation of this protein can have profound impacts on cell survival (Lee et al, 2008).  
 
Lysosomal dysfunction is apparent in AD, PD and HD. Recent findings indicate that 
different neurodegenerative diseases exhibit varying amounts of lysosomal associated 
membrane proteins (LAMP 1 and LAMP2) in comparison to controls. Studies of CSF from 
people with PD show significant decreases in both LAMP1 and LAMP2 compared with 
control CSF (Boman et al., 2016). In contrast, CSF from people with CBD showed increases 
in LAMP1 and LAMP2 compared to controls (Boman et al., 2016). Lysosome size also 
correlates with normally functioning lysosomes. Work by Yang and colleagues using 
TgCRND8 (APP overexpressing) mice indicated that enlarged autolysosomes in this model 
are filled with incompletely digested autophagic substrates, reflecting inefficient 
degradation by lysosomal hydrolases compared to controls. Furthermore, lysosome 
fractions isolated from the brains of TgCRND8 mice contain abnormally high levels of LC3-
II, ubiquitinated proteins and Aβ (Yang et al., 2011). Moreover, it has been shown that 
experimentally induced lysosomal dysfunction triggers the development of characteristic 
features of the aged human brain. These include proliferation of endosomes–lysosomes, 
increased tau phosphorylation, production of tau protein fragments resembling those 
found in NFTs, and the accumulation of 16–30 kDa tau fragments (Oyama et al., 1998; 
Zhang et al., 2009a). Cathepsin D inhibitors block the formation of phosphorylated tau 
fragments in AD hippocampus (Bi et al., 2000). In addition, recent evidence showed that 
the autophagic-lysosomal system also plays a role in the clearance of tau, whereas 
dysfunction of this system results in the formation of tau insoluble aggregates in 
lysosomes (Hamano et al., 2008b). 
1.10 The unfolded protein response (UPR) 
The UPR pathway is an adaptation to organelle stress and this is activated when the 
normal function of the ER is disrupted by intrinsic or extrinsic insults, in order to prevent 
ongoing protein synthesis upon accumulation of unfolded proteins (Schonthal, 2012). 
Activation of the UPR involves the upregulation of genes encoding chaperones such as 
immunoglobulin heavy-chain binding protein (BiP), foldases, and proteins involved in the 
degradation of ER localised proteins by the proteasome (Matus et al., 2008).  
 
 66 
 A growing body of evidence shows an association of the UPR pathway with the 
development of both genetic and sporadic forms of neurodegeneration, including AD and 
PD (Imaizumi et al., 2001). This pathway has also been identified as a key player in the 
pathology in models of neurodegeneration such as prion disease (Halliday and Mallucci, 
2014). The function of the UPR is to enhance the protein folding capacity of the ER and this 
can be activated by amino acid deprivation, viral replication and the presence of unfolded 
proteins (Radford et al., 2015). 
 
The UPR has three main arms, comprising inositol requiring enzyme 1 (IRE1), protein 
kinase RNA (PKR)-like ER kinase (PERK) and activating transcription factor 6 (ATF6) (Figure 
1-10). When cells are not stressed, BiP is bound to IRE1, PERK and ATF6, thereby inhibiting 
activation of the UPR pathway (Halliday and Mallucci, 2014). Upon accumulation of 
misfolded/unfolded proteins, these three proteins dissociate from BiP as the 
misfolded/unfolded proteins bind to and sequester BiP. Therefore, the three branches of 
the UPR can be active and it has been shown that all three branches of the UPR can be 
simultaneously activated when there is excessive ER stress (Wu and Kaufman, 2006). The 
more immediate initiation of the pathway is through the activation of PERK, which is 
followed by the slower activation of the other two arms, IRE1 and ATF6. Activation of PERK 
results from its autophosphorylation, which causes the subsequent phosphorylation of 
eukaryotic initiation factor 2α (eIF2α) and has the effect of reducing protein synthesis to 
counteract the increased load on the ER (Smith and Mallucci, 2016). This phosphorylation 
has two outcomes: either a repression in protein translation which stops protein synthesis 
of most proteins, or conversely the upregulation of activating transcription factor 4 (ATF4) 
which is involved in the regulation of protein folding genes such as C/EBP homologous 
protein (CHOP) which eventually leads to apoptosis (Figure 1-10) (Radford et al., 2015). 
 
The accumulation of unfolded proteins causes the cytoplasmic domain of ATF6 to 
translocate from the ER to the Golgi apparatus. Once it reaches the Golgi, ATF6 is cleaved 
by site 1 and site 2 proteases at the transmembrane site into a 50 kDa fragment. The 
cleavage event results in the formation of nuclear activated ATF6 (nATF6) which is then 
transported to the nucleus where it activates central UPR genes (Figure 1-10) (Smith and 
Mallucci, 2016) 
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The presence of unfolded proteins in the cell leads to the trans-autophosphorylation of 
IRE1, resulting in its activation. Subsequently, IRE1 goes on to activate the splicing of 
mRNA that encodes X-box binding protein 1 (XBP1). sXBP1 is a transcription factor that 
directly targets genes that facilitate the refolding and degradation of misfolded proteins, 
including ER chaperones such as Grp78/BiP, Grp58, Grp94, ER-associated degradation 
(ERAD) components (Figure 1-10) (Ron and Hubbard, 2008). The aforementioned splicing 
event results in the alteration of the reading frame of the XBP1 mRNA, forming a 
transcription factor that regulates multiple UPR related genes as well as genes involved in 






Figure 1-10 Schematic representation of the three arms of the UPR: The three branches 
of the unfolded protein response (UPR) pathway. The binding of unfolded proteins to BiP 
causes the dissociation and activation of PERK, IRE1 and ATF6. Activation of the PERK 
branch leads to the phosphorylation of eIF2α which leads to reduced protein synthesis 
through activation of CHOP. Activation of IRE1 leads to alternative slicing of XBP1 causing 
transcription of chaperones and ERAD protein. ATF6 is cleaved forming nATF6 leading to 
the expression of UPR target genes (adapted from (Hetz and Mollereau, 2014)). 
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Once the UPR is activated, the ultimate outcome will depend on the levels of stress. Thus, 
mild ER stress will lead to an adaptive ER response, whereby cells return to their normal 
physiological state. On the other hand, chronic ER stress can prove to be a burden on the 
cell thereby leading to cell death (Hetz and Mollereau, 2014). Therefore, acute activation 
of the UPR appears to be a protective mechanism adopted by cells, however prolonged 
UPR activation is detrimental to cell health and survival. Consequently, increasing links are 
being drawn between UPR activation and neurodegenerative diseases such as AD, PD, HD 
and ALS (Hoozemans et al., 2012). In agreement with these findings, a close association 
has been proposed between the occurrence of neurodegeneration and the upregulation of 
ER stress markers in animal models of AD, PD, ALS and HD (Mercado et al., 2013; Vidal et 
al., 2011). 
 
In a Drosophila model of AD, the enforced expression of active XBP1 was shown to protect 
against amyloid-β toxicity, possibly through reduced release of Ca2+ from the ER (Casas-
Tinto et al., 2011). Furthermore, using genetic mouse models of AD (APPswe/PS1dE9) that 
express familial Alzheimer's disease–related mutant APP and mutant presenilin 1 
(PS1) with a deletion of exon 9), ablation of PERK in the brain improved memory 
impairment (Ma et al., 2013a). In contrast, another study proposed that phosphorylation 
of eIF2α in AD occurs through RNA-activated protein kinase (PKR; also known as eIF2αK2) 
rather than PERK. However, to date these findings have not been confirmed (Lourenco et 
al., 2013).  
 
Increased activation of the UPR has additionally been correlated with tau pathology. In AD, 
it is suggested that UPR activation may precede pathogenesis of the disease (Nijholt et al., 
2012b). In a specific study in AD brain, increase in UPR markers closely correlated with the 
presence of phosphorylated tau and GSK3β (Nijholt et al., 2012b). This suggests that 
prolonged UPR activation in neurons may be involved in detrimental tau phosphorylation 
(Hoozemans et al., 2009). 
1.11 Apoptosis 
Apoptosis (programmed cell death) is activated as a final resort of the cell to deal with an 
irreparable amount of damage. Initiation of this pathway commences with the activation 
 70 
of caspases, a process that is very tightly regulated by the Bcl-2 family of proteins. This 
family of proteins is composed of pro- and anti-apoptotic proteins that are defined by the 
presence of up to four conserved domains ((Matus et al., 2008),  
1.11.1 Apoptosis and autophagy 
It was shown by Wirawan et al. (2010) that beclin-1 and PI3K, two components of the 
autophagy-inducing complex, are direct substrates of caspases. The cleavage of beclin-1 
and PI3K by caspases (caspases 3, 7 and 8) was observed in response to different inducers 
of the intrinsic (mitochondrial) and extrinsic (death receptor-mediated) pathways of 
apoptosis (Wirawan et al., 2010). Moreover, c-Jun N-terminal kinase (JNK1) or ERK-
mediated phosphorylation of Bcl-2, or DAPK-mediated phosphorylation of beclin-1 
regulate dissociation of beclin-1 and Bcl-2/Bcl-XL during autophagy (Tang et al., 2010; Wei 
et al., 2008). Such observations highlight a possible crosstalk between autophagy has 
additionally been shown in HeLa that the overexpression of Bax (activates the intrinsic 
pathway of apoptosis) and TRAIL (a death receptor ligand) in Hela cells leads to the 
caspase-mediated cleavage of beclin 1 (Cho et al., 2009; Lao et al., 2009). However, recent 
studies indicate that active caspase-8 can be degraded by autophagy. This further implies 
the existence of a feedback mechanism that cross-regulates autophagy and apoptosis (Hou 
et al., 2010). 
 
Beclin-1 is unable to neutralise the anti-apoptotic function of Bcl-2, which is exerted at the 
mitochondrial membrane. Concurrently, Bcl-2 or Bcl-XL reduces the pro-autophagic 
activity of beclin-1 (Pattingre et al., 2005). Interestingly, ER-localised Bcl-2, but not 
mitochondrial-localised Bcl-2, inhibits autophagy, which is consistent with the notion that 
ER-associated class III PI3K activity may be crucial in the nucleation of autophagosome 
formation (Pattingre et al., 2005). In addition to the apoptosis-associated cleavage of 
beclin-1, there is an additional apoptotic-associated cleavage of more autophagic proteins 
including Atg5 and Atg4D by caspase-3. Similar to the cleavage of beclin-1, cleavage of 
Atg5 inactivates autophagy. Conversely Atg4D cleavage generates a fragment with 
increased autophagic activity (Galluzzi et al., 2010), indicating that this may be an 
important regulatory mechanism in coordinating the activity of autophagy and apoptosis. 
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1.11.2 Apoptosis and the UPR 
Under pathological conditions, the protective effect of sXBP1 is masked by the build-up of 
pro-apoptotic factors, thereby driving activation of apoptosis. All three branches of the 
UPR have been implicated in ER stress-induced apoptosis. Firstly, the activation of CHOP 
by PERK/eIF2α phosphorylation ultimately drives the cell to apoptosis. Moreover, Both 
CHOP and JNK control the activation of pro- and anti-apoptotic Bcl-2 proteins by increasing 
the expression of pro-apoptotic Bak and Bax, resulting in permeabilisation of the outer 
mitochondrial membrane and execution of the intrinsic apoptotic process (Dhanasekaran 
and Reddy, 2008; Jager et al., 2012). In addition, IRE1 can elicit the activation of apoptosis 
signal-regulating kinase 1(ASK1)/JNK. ASK1-deficient cells have been shown to be resistant 
to ER stress-induced apoptosis, as well as JNK activation, indicating that ASK1 acts 
upstream of the site of JNK activation (Kadowaki et al., 2005). 
 
IRE1 is additionally able to activate caspase-12 (Kim et al., 2006). Caspase-12 is synthesised 
as a pro-enzyme and solely responds to ER stress, as shown by studies that revealed that 
caspase-12 deficient cells are resistant to ER stress-induced apoptosis, but not apoptosis 
induced by alternative stimuli (Kaneko et al., 2003). IRE1 within the cytosol recruits TRAF2, 
which interacts with caspase-12, resulting in the formation of the IRE1/TRAF2/caspase-12 
complex and subsequent cleavage of activated caspase-12 (Yoneda et al., 2001). These 
mechanisms all result in downstream caspase activation and elicit the execution of ER 
stress-induced cell death (van der Kallen et al., 2009). 
1.12 Aims and objectives 
Since the identification of the Tau35 fragment in brains of 4R tauopathies including PSP, 
CBD and FTLD-tau (Wray et al., 2008), extensive work has gone into characterising the 
effects of this form of truncated tau (see Figure 1-11) and establishing the role of tau 





Figure 1-11 Schematic representation of Tau35 compared to 2N4R tau: 2N4R tau (amino 
acids 1-441) contains two inserts (N1, N2), followed by proline-rich domain and the MT 
binding domain, consist of four MTB repeats (R1-R4). Tau35 (amino acids 187-441) retains 
the majority of the proline-rich domain, four MTB repeats and an intact C-terminus. 
 
Findings from the transgenic mouse model expressing Tau35 showed that these mice 
manifest several key features of tauopathies, including accumulation of abnormally 
phosphorylated tau along with deregulated GSK3β, autophagic dysfunction, and 
progressive cognitive and motor deficits (Bondulich et al., 2016). Follow up work carried 
out by Tong Guo (King’s College London) in a cell model showed that Tau35 expression 
disrupts microtubule binding and compromises the cytoskeleton, as well as increasing 
activation of the UPR. Consequently, this study aims to extend studies on aged Tau35 
mouse brain in order to further investigate underlying molecular mechanisms that give 
rise to a tauopathy phenotype. Using the Tau35 cell model, this study aimed to elucidate 
underlying processes involved in tau degradation that contribute to the potentially 
harmful effects of tau fragmentation.  
 
The specific objectives of this study are to investigate cellular mechanisms affected by tau 
fragmentation in tauopathies by: 
• Assessing changes in tau phosphorylation and UPR activation in different brain 
regions of aged Tau35 mice. 
• Investigating the effects of tau fragmentation on cell viability and autophagic 
pathways in cells expressing Tau35. 
• Determining the effects of Tau35 expression on lysosome biogenesis and lysosome 
functionality in cells. 
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Chapter 2 Materials and Methods 
2.1 Materials 
All reagents were from Sigma Aldrich and all solutions were prepared in ultra-high purity 
(UHP) water, unless otherwise stated. 
2.1.1 Animals 
Control mice used in this study were all male wild type (WT) C57BL/6J (Charles River, UK). 
All transgenic mice were bred on a 75%; 25% C57BL/6J; 129/Ola mice background reared 
in-house. Tau35 hemizygous male mice expressing Tau35 cDNA with a haemagglutinin 
(HA) tag under the control of the human tau promoter with targeted insertion into the 
Hprt locus were generated by genOway (Lyons, France) using “Quick Knock-inTM” 
technology.  
 
Mice were weaned at 3 weeks of age and had unlimited access to water and rodent chow 
(RM1 for all mice except breeders, which received RM3, Special Diet Services, Essex, UK). 
Mice were singly or group housed with a 12-hour light-dark cycle with constant room 
temperature. All of the studies were completed under appropriate Home Office Project 
and Personal Licenses. 
2.1.2 Plasmids  
cDNA sequences corresponding to human FL-tau (2N4R isoform) orTau35 (4R isoform, 
residues 187-441) were each inserted into the multiple cloning site of the pcDNA 3.1D/V5-
His-TOPO vector (Invitrogen) for mammalian expression. These plasmids express FL-tau or 
Tau35 with a V5-His epitope tag fused to the C-terminus of the expressed protein. 
 
A mammalian expression plasmid encoding human transcription factor EB (TFEB) fused to 
green fluorescent protein (EGFP) was obtained from Addgene.   
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2.1.3 Primers used for polymerase chain reaction (PCR) genotyping 
 
Table 2-1 List of PCR primers 
Primer Primer sequence 5’ to 3’ (number of bases) 
Forward Tau35 CGTATGTGATGGACATGGAGATGGAGG (27) 
Reverse Tau35 GCCTCCCTCTTATTAAGGACGCTGAGG (27) 
Forward HPRT TGTCCTTAGAAAACACATATCCAGGGTTTAGG (32) 
Reverse HPRT CTGGCTTAAAGACAACATCTGCAGAAAAA (30) 
 
2.1.4 Buffer solutions  




Phosphate-buffered saline (PBS) 137mM NaCl 
2.7mM KCl  
10mM disodium phosphate (Na2HPO4) 
2mM monopotassium phosphate (KH2PO4) 
pH 7.4 
 
Extra strong lysis buffer (ESLB) 10mM Tris-HCl 
75mM NaCl  
0.5% (w/v) sodium dodecyl sulphate (SDS) 
20mM sodium deoxycholate 
1% (v/v) Triton X-100  
2mM sodium orthovanadate  
1.25mM NaF 
1mM sodium pyrophosphate 
10mM ethylenediaminetetraecetic acid 
(EDTA) 
Complete Mini protease inhibitor cocktail, 
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EDTA-free (Roche Diagnostics, 1 tablet/10ml 
buffer) 
1% (w/v) PhosSTOP phosphatase inhibitor 




Isolation buffer 250mM mannitol 
5mM HEPES 
0.5mM EGTA 
Complete protease inhibitor cocktail, EDTA-
free (Roche Diagnostics, 1 tablet/10ml 
buffer) pH 7.4 
 
2.1.5 Bicinchoninic acid Assay (BCA) protein assay 
BCA assay kit (Thermo Fisher Scientific)   
 
Albumin standard (Thermo Fisher Scientific)   
The kit was used according the manufacturer’s instructions. 
  
2.1.6 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blotting (WB) 
Laemmli buffer (2x) 65.8mM Tris-HCl 
2.1% (w/v) SDS 
26.3% (w/v) glycerol 
0.01% (w/v) bromophenol blue  
5% (v/v) β-mercaptoethanol (BME) 
pH 6.8 
 
Resolving gel 10% (w/v) acrylamide (National Diagnostics) 
25% (v/v) resolving buffer (National 
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Diagnostics) 
 0.01% (w/v) ammonium persulphate (APS, 
National Diagnostics)  
0.1%(v/v) 
N,N,N’,N’tetramethylethylendiamine 
(TEMED, National Diagnostics) 
pH 8.8 
 
Stacking gel 4% (w/v) acrylamide (National Diagnostics) 
25% (v/v) stacking buffer, (National 
Diagnostics) 
0.075% (w/v) APS  
0.15% (v/v) TEMED 
pH 6.8 
 
Running buffer 25mM Tris base, (National Diagnostics) 
192mM glycine (National Diagnostics) 
0.1% (w/v) SDS 
pH 6.8 
 









25mM Tris base 
192mM glycine 
20% (v/v) methanol 
pH 6.8 
 
NuPAGE 4-12% Bis-Tris gels (Thermo Fisher 
Scientific) 
 
Running buffer for precast gels 
 
NuPAGE Novex 4-12% Bis-Tris Protein gels, 
1.5 mm, 15 well (Thermo Fisher Scientific) 
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Blocking solution (milk) 
 
 
Blocking solutions (Odyssey) 
 
 
3% (w/v) skimmed milk powder in TBS + 
0.1% (v/v) Tween 20 
 
Odyssey (TBS) blocking buffer (Li-Cor) 
Blocking solution (BSA) 
 
2% (w/v) bovine serum albumin (BSA) in TBS  
Wash solution TBS + 0.1% (v/v) Tween 20 
 
2.1.7 Immunocytochemistry (ICC)   
Fixation solution (PFA) 4% paraformaldehyde (PFA) in PBS 
pH 7.4 
 
Blocking solution (BSA) 
 
Blocking solution (serum) 
2% (w/v) bovine serum albumin (BSA) in PBS 
 
10% (v/v) goat serum in 0.5% (w/v) Triton-










0.5% (v/v) Hoechst 33342 in PBS 
 
Fluorescence mounting medium (DAKO) 
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2.1.8 Primary antibodies for WB and ICC 
Antibody Species Epitope Dilution Source 
β-Actin Mouse monoclonal β-Actin WB: 1/5000 Sigma Aldrich 
β-Actin Rabbit polyclonal β-Actin WB: 1/3000 Abcam 
12E8 Mouse monoclonal Tau phosphorylated at 
Ser262/Ser356 
WB: 1/40000 Prothena Corporation 
AT-180 Mouse monoclonal Tau phosphorylated at Thr231 WB: 1/1000 Invitrogen 
PHF-1 Mouse monoclonal Tau phosphorylated at 
Ser396/Ser404 
WB: 1/1000 Peter Davies (Albert Einstein College 
of Medicine) 





Tau-1 Mouse monoclonal Tau dephosphorylated at 
Ser195, 198, 199, and 202 
WB: 1/1000 Merck Millipore 
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Anti-V5 Mouse monoclonal V5 tag (GKPIPNPLLGLDST) WB: 1/5000 Invitrogen 
Atg 13 Rabbit polyclonal Atg 13 WB: 1/1000 Cell Signalling Technology 
Atg 5 Rabbit polyclonal Atg 5 WB: 1/500 Cell Signalling Technology 
Atg 7 Rabbit polyclonal Atg 7 WB: 1/1000 Sigma Aldrich 
Beclin 1 Rabbit polyclonal Beclin 1 WB: 1/500 Cell Signalling Technology 
Cathepsin D Goat polyclonal Cathepsin D ICC: 1/100 Santa Cruz Biotechnology 
Cathepsin L Rabbit polyclonal Cathepsin L ICC: 1/100 Abcam 
CHOP Mouse monoclonal CHOP WB: 1/500 Cell Signalling Technology (CST) 
GAPDH Mouse monoclonal GAPDH WB: 1/500 Santa Cruz Biotechnology 
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GT1b Mouse monoclonal Ganglioside GT1b ICC: 1/50 Developmental Studies Hybridoma 
Bank 
HA Mouse monoclonal HA tag (YPYDVPDYA) WB: 1/1000 Sigma Aldrich 
Importin α7 Rabbit polyclonal Importin α7 WB: 1/1000 Abcam 
LAMP-2 Mouse monoclonal LAMP-2 ICC: 1/50 Santa Cruz Biotechnology 
LBPA Mouse monoclonal LBPA ICC: 1/100 Merck Millipore 
LC3-B Rabbit polyclonal LC3-B I and II WB: 1/1000 
ICC: 1/200 
Sigma Aldrich 
P62 Mouse monoclonal P62 ICC: 1/100 Novus Biological 
Phospho eIF2α Rabbit polyclonal Phosphorylated eIF2α at Ser51 WB: 1/500 Cell Signalling Technology 
Phospho GSK3 Rabbit polyclonal Phosphorylated (inactive) GSK3α 
and GSK3β 
WB: 1/1000 Cell Signalling Technology 
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Phospho IRE-1 Rabbit polyclonal IRE1 phosphorylated at Ser724 WB: 1/500 Novus Biologicals 
Phospho mTOR Rabbit polyclonal mTOR phosphorylated at Ser2448 WB: 1/1000 Cell Signalling Technology 
Phospho PERK Rabbit polyclonal Phosphorylated PERK at Thr980 WB: 1/500 Cell Signalling Technology 
Phospho AMPK Rabbit polyclonal AMPK phosphorylated at Thr172 WB: 1/1000 Cell Signalling Technology 
Phospho ERK Rabbit polyclonal Dually phosphorylated active 
forms of ERK (ERK1 and ERK2) 
WB: 1/1000 Promega 
Total AMPK Rabbit polyclonal Total AMPK WB: 1/1000 Cell Signalling Technology 
Total eIF2α Mouse monoclonal Total eIFf2α WB: 1/1000 Cell Signalling Technology 
Total ERK Mouse monoclonal Total ERK WB: 1/1000 Cell Signalling Technology 
Total GSK3 Mouse monoclonal Total GSK3α and GSK3β WB: 1/1000 Santa Cruz Biotechnology 
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Total IRE-1 Rabbit polyclonal Total IRE-1 WB: 1/1000 Cell Signalling Technology 
Total mTOR Rabbit polyclonal Total mTOR WB: 1/500 Cell Signalling Technology 
Total PERK Rabbit polyclonal Total PERK WB: 1/500 Cell Signalling Technology 
 
 
Abbreviations: AMPK: AMP-activated protein kinase, Atg-5: autophagy related gene 5, Atg-7: autophagy related gene 7, Atg-13: autophagy 
related gene 13, CHOP: C/EBP homologous protein, eIF2α: eukaryotic initiation factor 2α, ERK: extracellular signal–regulated kinase, GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase, GSK3: glycogen synthase kinase 3, HA: hemagglutinin, IRE1: inositol-requiring enzyme 1, LAMP2: 
lysosomal associated membrane protein 2, LBPA: Lysobisphosphaditic acid: LC3, microtubule-=associated protein 1 light-chain 3; mTOR: 
mammalian target of rapamycin, PERK: protein kinase RNA (PKR)-like ER kinase. 
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Table 2-2 Secondary antibodies for WB 
Antibody Dilution Source 
Alexa Fluor 680 
(goat, anti-mouse) 
1/5,000 Invitrogen 
IRDye 800 (goat anti-rabbit) 1/5,000 Invitrogen 
 
Table 2-3 Secondary antibodies for ICC 
Antibody Dilution Source 
Alexa Fluor 488 
(goat, anti-mouse) 
1/1,000 Invitrogen 
Alexa Fluor 568 
(goat, anti-rabbit) 
1/1,000 Invitrogen 




2.1.9 Agarose gel electrophoresis 
50x TAE buffer (Tris-acetate-EDTA) 40 mM Tris, pH 7.6 
20 mM Acetic acid  
1 mM EDTA  
pH 8.0 
 
Nuclear acid molecular weight marker 1 kb DNA ladder (New England Biolabs) 
Molecular weight sizes: 0.5, 1, 2, 3, 4, 5, 6, 8 
and 10kb 
2.1.10 E. coli culture 
LB 20 g/L Luria-Bertani (LB) powder  
sterilised by autoclaving 
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LB agar 32 g/L agar  
sterilised by autoclaving 
100 µg/ml Ampicillin 
50 µg/ml Kanamycin 
 
2.1.11 Plasmid DNA preparation 
Plasmid DNA was prepared using a QIAprep Maxiprep Kit (Qiagen). 
 
2.1.12 Cell culture  
Table 2-4 Cell culture reagents 
CHO cell culture media Ham’s F-12 medium (PAA Laboratories Ltd) 
10% (v/v) foetal bovine serum (FBS) (PAA 
Laboratories Ltd) 
2mM L-glutamine (PAA Laboratories Ltd) 
100 U/ml penicillin (PAA Laboratories Ltd) 
100µg/ml streptomycin (PAA Laboratories 
Ltd) 
Trypan blue 0.4% (w/v) Trypan blue solution 
HBSS without Ca2+/Mg2+ (Invitrogen) Hank's Balanced Salt Solution without 
Ca2+/Mg2+ 
Trypsin 0.25% trypsin solution (PAA Laboratories 
Ltd) 





Table 2-5 Cell culture treatments and stains 




HBSS with Ca2+ /Mg2+ (Invitrogen) Hank's Balanced Salt Solution with 
Ca2+/Mg2+ 
 
Dithiothreitol (DTT) (Thermo Fisher) Final concentration: 20 mM in Ham’s F12 
 
Thapsigargin (Thermo Fisher) Final concentration: 1 µM in Ham’s F12 
 
Calcein AM cell viability (eBioscience) 
 
500 nM – 1 µM 
Rapamycin 
 
Final concentration: 1 µM in Ham’s F12 
AR-A014418 
 
Final concentration: 100 nM in Ham’s F12 
Trehalose 
 
Final concentration: 100 mM in Ham’s F12 
Bafilomycin A1 
 
Final concentration: WB: 400 nM in Ham’s 
F12 
ICC: 200 nM in Ham’s F12 
 
LysoTracker Red DND-99 (Thermo Fisher) 
 
Final concentration: 800 nM in Ham’s F12 





2.2.1 Mouse brain dissection 
Wild-type and Tau35 male mice aged 16-18 months were culled by cervical dislocation. 
The brains were extracted and dissected into 4 regions: hippocampus and associated 
cortex; amygdala and associated cortex; frontal region; and brainstem and cerebellum. 
Samples were frozen at -80 °C until required. 
2.2.2 Preparation of brain homogenates 
Samples of hippocampus and associated cortex; amygdala and associated cortex; frontal 
brain; and brainstem and cerebellum, from mice aged 16-18 months, were thawed on ice, 
weighed and homogenised in 4 volumes (w/v) ESLB using a Dounce homogeniser. The 
amount of protein present in each homogenate was measured using a BCA assay. Samples 
were diluted in the appropriate volume of 2X Laemmli sample buffer to provide 20 µg total 
protein/lane for analysis on western blots. For western blotting, n=6 for each genotype. 
Tau phosphorylation experiments had 3 technical replicates and UPR experiments had 6 
technical replicates. 
2.2.3 Genotyping and PCR 
DNA was extracted from mouse ear notches using the KAPA mouse genotyping kit. Lysis 
and enzyme inactivation was then performed in a heating block at 75°C for 10 minutes, 
and 95°C for 5 minutes, respectively. Samples were centrifuged at 6000g for 1.5 minutes 
to pellet cellular debris and a 10-fold dilution with nuclease-free H20, samples were cycled 
using primers for the transgene (Table 2-1). The following cycling conditions were used:  
• One denaturing cycle at 94°C for 3 min  
• 35 cycles of 95°C for 15 s, 55 ºC for 15 s, and 72°C for 1 min 
• One extension cycle at 72°C for 5 min 
PCR products were electrophoresed on 1.5% (w/v) agarose gels at 150V for 40-45 min and 
bands were detected by imaging with a benchtop 2UV transilluminator. 
2.2.4 Generation of stable CHO cell lines 
Mycoplasma negative Chinese hamster ovary (CHO) cells, acquired from the European 
Collection of Authenticated Cell Cultures were grown at 37°C with 5% CO2 in Ham’s F12 
culture medium. 24 h before transfection, CHO cells were  seeded at a density of 150,000 
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cells/well in a 12-well plate. CHO cells were transiently transfected with 2N4R tau or V5 
tagged-Tau35 plasmids (1 μg plasmid/well for 12-well plate) using jetPEITM (Polyplus 
Transfection) according to the manufacturer’s instruction. 48 h after transfection the 
medium was replaced by Ham’s F-12 medium, with the addition of 800 μg/mL G418 (Santa 
Cruz Biotechnology). After selection, G418-resistant cells were transferred to 145 mm 
diameter dishes for clonal isolation. Cell clusters were isolated using cloning cylinders and 
transferred to 6-well plates for clonal expansion. Further characterization of the G418-
resistant cells was undertaken using western blots to examine the stable expression of tau 
protein and immunocytochemistry to assess the homogeneity of the cell lines. Clonal cells 
homogenously expressing 2N4R tau or Tau35, termed CHO-FL and CHO-Tau35, respectively, 
were selected and maintained in CHO cell growth medium without G418 at 37°C in 5% CO2. 
This work was done by Tong Guo. 
2.2.5 Cell culture 
CHO cells stably expressing FL-tau (FL-CHO) or Tau35 (Tau35-CHO), and untransfected CHO 
cells were maintained as monolayer cultures in Ham’s F-12 culture medium at 37°C in an 
atmosphere of 5% CO2. Cells were passaged when they reached 80-90% confluence. After 
rinsing in HBSS, cells were trypsinised and counted prior transferring them into new flasks 
or plates using fresh CHO cell culture medium. To count CHO cells, 10 µl of cell suspension 
was added to 90 µl of Trypan blue solution and 10 µl was loaded into a haemocytometer. 
The cell density was determined using the following equation: 
 
 !"##	%"&'()* = ,-,./	01//	0-23,	452.614	0-23,17 	8	10;/=# 
 
For western blotting and cell viability experiments using CHO cells, n= independent cell 
cultures. For imaging experiments, n= independent experiments foe each cell line where 
30 cells were quantified in each experiment. 
2.2.6 Transient transfection of CHO cells 
CHO cells were transfected using JetPEI transfection kit (Polyplus-transfection) according 
to the manufacturer’s protocol. 100,000 cells/well were transferred to a 12-well plate 24 h 
prior to transfection. Immediately before transfection, media in the wells was replaced 
with fresh Ham’s F-12 culture medium. For each well of a 12-well plate, 1 µg of DNA was 
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diluted in 150 mM NaCl to a final volume of 50 µl. In a separate tube, 3 µl of JetPEI was 
diluted in 150 mM NaCl to a final volume of 50 µl. The JetPEI solution was added to the 
DNA solution and incubated for 30 min at ambient temperature. The transfection complex 
was added to each well, followed by gentle swirling of the plate and the cells were 
incubated at 37°C in an atmosphere of 5% CO2 for a further 24 h. Cells were rinsed twice 
with PBS and fixed with the fixation solution for 20 min for immunocytochemistry. 
2.2.7 DNA transformation 
Library Efficiency DH5α competent cells (Invitrogen) were used for DNA transformation, 
according to the manufacturer’s protocol. 
2.2.8 Plasmid extraction 
Glycerol stocks of bacteria harbouring tau or TFEB plasmids were removed from -80°C 
storage and incubated in 200 ml autoclaved LB medium containing 100 μg/mL ampicillin or 
50 µg/mL kanamycin, overnight at 37°C, with shaking at 220 rpm. Plasmids were prepared 
using the Plasmid Midi Kit (Qiagen), according to the manufacturer’s protocol. The 
concentration and purity of the DNA was calculated by measuring absorbance at 260 nm 
and 280 nm (NanodropTM UV-Vis spectrophotometer). 
2.2.9 Freezing and recovery of CHO cells 
To freeze cells for long-term storage, CHO cells were trypsinised and resuspended in Ham’s 
F-12 medium, as described above. Cell suspensions were centrifuged at 700 g(av) for 5 min 
at ambient temperature. The supernatant was discarded and the pellet was resuspended 
in pre-cooled 10% (v/v) DMSO containing Ham’s F-12 media, at 4°C and dispensed into 1 
ml aliquots in cryogenic tubes. Tubes were maintained at 4°C for 20-30 min, then at -20°C 
for 1 h, and finally at -80°C overnight, before being transferred to liquid nitrogen. 
 
1ml aliquots of frozen CHO cells were thawed at 37°C and immediately transferred into 
75cm2 tissue culture flasks containing 10 ml pre-warmed Ham’s F-12 culture medium. After 
24 h incubation at 37°C, the medium was replaced with fresh Ham’s F-12 culture medium. 
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2.2.10 CHO cell treatments 
FL-CHO, Tau35-CHO and untransfected CHO cells were seeded at the following densities: 
10 cm diameter dish 700,000 cells/well 
6-well plate 300,000 cells/well 
12-well plate 50,000 cells/well 
96 well plate 10,000 cells/well 
 
Treatments for cell viability assay 
24 h after seeding CHO cells, the medium was replaced with 20 mM DTT or 1 µM 
thapsigargin in fresh culture medium. Cells were treated with DTT for 4 h or thapsigargin 
for either 6 h or 24 h. Following treatment, cells were washed with pre-cooled PBS at 4oC. 
 
Autophagy-modulating treatments 
24 h after seeding CHO cells, autophagy was induced by replacing the medium with HBSS 
(with Ca2+ and Mg2+) and cells were starved for 3 h. To activate autophagy through an 
mTOR-dependent route, cells were treated with 1 µM rapamycin for 6 h. To activate 
autophagy through an mTOR-independent route, cells were treated with 100 mM 
trehalose for 24 h. To block the fusion of autophagosomes with lysosomes by inhibiting v-
ATPase, cells were treated with 200 nM bafilomycin A1 for 2 h and examined by 
immunocytochemistry, or were treated with 300 nM bafilomycin A1 for 2 h and examined 
on western blots.  
 
Inhibition of glycogen synthase kinase-3β (GSK-3β) 
24 hours after seeding CHO cells, the medium was replaced with the 100 nM AR-A014418 
and cells were incubated for 16 h at 37°C 
2.2.11 Cell viability assay using a plate reader 
Calcein Violet 450 AM dye was diluted to 1 μM in 1X pre-warmed (37°C) Calcein AM DW 
buffer. CHO cells in a 96-well plate were washed 3 times with PBS. 100 µl of diluted calcein 
AM dye was added per well and from this point onwards the plate was protected from 
light. Cells were incubated at 37°C for 30 min, after which the fluorescence intensity was 
recorded using a 490/520 nm excitation/emission filters in an Omega plate reader. 
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2.2.12 Cell viability assay using fluorescence activated cell sorting (FACS) 
For cell survival assay, CHO cells were grown on a 6-well plate for 24 h before the start of 
the experiment. F-12 medium from the plate was collected to account for floating/dying 
cells. Cells were trypsinised and resuspended in double the volume of F-12 medium and 
were pooled with previously collected medium. Cells were centrifuged at 700 g(av) for 5 
min at ambient temperature. The supernatant was discarded and the pellet was stained 
with Calcein Violet 450 AM Viability Dye (500 nM, eBioscience) in PBS for 30 min at room 
temperature. After washing twice with PBS, cells were resuspended in PBS and analysed 
with the BD FACSCanto II (BD Biosciences). 
2.2.13 Nuclear and cytoplasmic fractionation 
Cells grown in 10 cm diameter tissue culture dishes were scraped into 1 ml PBS and 
centrifuged at 600 g(av) for 5 min at 4°C. The cell pellet was resuspended in 100 μl 
isolation buffer and sonicated at 40% intensity for 4 pulses (1 s per pulse). Nuclei were 
pelleted by centrifugation at 1,000 g(av) for 10 min at 4°C. The pellet (nuclear fraction) was 
resuspended in 100 μl PBS, centrifuged at 1,000 g(av) for 10 min at 4°C and the final pellet 
was resuspended in isolation buffer, discarding the wash supernatant. The first 1,000g(av) 
supernatant was centrifuged at 100,000 g(av) for 60 min at 4°C and the resulting 
supernatant corresponded to the cytoplasmic fraction, the final pellet was discarded. 
2.2.14 Preparation of cell lysates 
After removing the culture medium, cells were washed three times with cold PBS. To lyse 
the cells, they were scraped into 2X or 4X Laemmli sample buffer containing protease and 
phosphatase inhibitors (250 µl of buffer/well of a 6-well plate). Cell lysates were analysed 
on western blots.  
2.2.15 SDS-PAGE and western blots 
Samples of brain homogenates and CHO cell lysates were heated at 95°C for 5 min and 
centrifuged at 13,000 g(av) for 5 min at ambient temperature prior to loading on 7.5% 
(w/v), 10% (w/v) or 12% (w/v) polyacrylamide gels. 7.5% and 10% gels were run at 150 V 
for 55-60 min and 80-90 min, respectively, and 12% gels were run at 120 V for 100-110 
min using the Bio-Rad system. Precast gels were run at 110 V fir 100-110 min using the 
Invitrogen system. Separated proteins were transferred onto 0.2 μm nitrocellulose 
membranes (GE Healthcare) using a wet transfer system (Bio-Rad) whereby the membrane 
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along with filter paper and sponges (Whatman) were pre-soaked in transfer buffer. 
Sponge, filter papers (4-5), gel, membrane, filter papers (4-5), and sponge were fitted into 
a transfer cassette. Proteins were transferred at 100 V for 60 min on ice, then blocked with 
either Odyssey (TBS) blocking buffer or milk blocking solution for 60 min to minimise non-
specific binding of antibodies. All antibodies from Cell Signaling Technology were diluted in 
Odyssey blocking buffer. All other antibodies were diluted in 3% (w/v) milk solution. 
Blocked membranes were incubated in primary antibodies overnight at 4°C, then washed 
(3 x 10 min) in TBS + Tween 20 and incubated with secondary antibody for 60 minutes at 
ambient temperature in the dark. Blots were washed in TBS (3 x 10 minutes) and antigens 
were visualised using the Odyssey infrared imaging system (Li-Cor Biosciences). 
2.2.16 Immunocytochemistry for LC3 
Cells grown on coverslips in a 12-well plate were rinsed twice with pre-cooled PBS. Cells 
were fixed and permeablised using ice-cold methanol for 5 minutes at -20°C. Cells were 
blocked using 2% (v/v) BSA in PBS overnight at 4°C. Cells were then incubated with the LC3 
antibody diluted in 2% (v/v) BSA in PBS for 1 hour at ambient temperature. Cells were 
washed with 2% (v/v) BSA in PBS (3 X 5 minutes), followed by incubation with the 
secondary antibody diluted in 2% (v/v) BSA in PBS for 30 minutes at ambient temperature. 
Cells were washed with 2% (v/v) BSA in PBS (3 X 5 minutes) and were incubated 0.5% (v/v) 
Hoechst in PBS for 2 min followed by washes with PBS, H2O and a rinse with 70% ethanol. 
Fixed cells were mounted onto slides with mounting media (DAKO). 
2.2.17 Immunocytochemistry for other antibodies  
For immunocytochemistry, most experiments included cells cultured on coverslips in 12-
well plates. Cells were washed with PBS and were fixed in 4% PFA for 20 min at ambient 
temperature. Cells were permeablised in 0.5% (v/v) Triton X-100 in PBS (3 x 5 minutes) and 
preincubated in blocking buffer (serum) for 30-60 min at ambient temperature. Cells were 
exposed to primary antibodies diluted in the blocking buffer (serum) overnight at 4°C. Cells 
were washed with 0.5% (w/v) Triton X-100 in PBS (3 x 5 min) and then incubated with the 
appropriate secondary antibody diluted in 0.5% (w/v) Triton X-100 in PBS for 1 h at 
ambient temperature. Cells were washed with 0.5% (w/v) Triton X-100 in PBS (3 x 5 min) 
and incubated 0.5% (v/v) Hoechst in PBS for 2 min, followed by brief washes with PBS, UHP 
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water and 70% (v/v) ethanol. Fixed cells were mounted onto slides using fluorescence 
mounting medium (DAKO). 
2.2.18 Lysotracker staining 
CHO cells grown on coverslips on 12-well plates were treated with 300 nM Bafilomycin A1 
in Ham’s F12 for 2 h at 37°C, as described above. Bafilomycin-treated cells serve as a 
negative control because Bafilomycin blocks autophagy by inhibiting V-ATPases and 
lysosomal acidification. After treatment, cells were incubated with 800 nM Lysotracker in 
Ham’s F12 culture medium at 37°C for 10 min. Medium was replaced with fresh Ham’s F12 
and cells were incubated for 10 min at 37°C to avoid cell death. Cells were fixed with 
fixation solution for 30 min at 37°C. Cells were washed with PBS (2 X 5 min) and incubated 
in permeabilising solution for 10 min followed by washes with PBS (2 X 5 min). Cells were 
incubated 0.3% (v/v) Hoechst in PBS for 2 min followed by washes with PBS. Fixed cells 
were mounted onto slides with mounting media (DAKO). 
2.2.19 Boron-dipyrromethene (BODIPY) staining 
Cells grown on coverslips on 12-well plates were washed with PBS. To label intracellular 
lipids, cells were treated with 2 μM BODIPY 493/503 (Invitrogen) staining solution in PBS 
for 15 min at 37°C. Cells were washed with PBS 2 X 5 min and fixed with fixation solution 
for 30 min at ambient temperature. Cells were washed with PBS 3 X 5 min. Cells were 
incubated 0.3% (v/v) Hoechst in PBS for 2 min followed by washes with PBS. Fixed cells 
were mounted onto slides with mounting media (DAKO). 
2.2.20 Data analysis 
Western blot analysis 
Western blots were quantified using Fiji-ImageJ (https://imagej.net/Fiji). 
 
FACS data analysis 
Data was analysed using FLOWJO-LLC software. Collected data points were subjected to 2 
stages of gating to exclude unwanted cell populations.  
• The first cell population (P1) was identified by excluding cellular debris. 
• From P1, the second cell population (P2) was identified by excluding 
groups/clusters of cells (Figure 2-1). 
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Two parameters were used for gating cell populations: 
• FSC (Forware Scatter) parameter. This parameter is a measurement of the amount 
of the laser beam that passes around the cell. This gives a relative size for the cell. 
• SSC (Side Scatter) parameter. This parameter is a measurement of the amount of 
the laser beam that bounces off of particulates inside of the cell. This is a 
measurement of cell complexity. 
 
 
Figure 2-1 Example of identification of P1 and P2: Dot blot of A total cell population and 
the definition of P1, B P1 and the definition of P2. 
Finally, the P2 cell population was plotted onto a histogram to determine the percentage 
of Calcein Violet 450 AM positive cells (viable cells). 
 
Image analysis  
The numbers, sizes and circularity of intracellular puncta were analysed using the GFP-LC3 
macro (NIH) on Fiji-ImageJ. The number of puncta was normalised to cell area (μm2). Signal 
intensity measurements were determined using Fiji-ImageJ.  
 
Intensity distribution analysis of LC3 puncta was assessed using NIS-Elements Advanced 
Research software. This was done by firstly defining the nucleus and excluding this region 
from the analysis. Concentric circles were then drawn around the nucleus at intervals of  3 




Figure 2-2 Example image of LC3 distribution analysis: Screenshot image of intensity 
distribution analysis of CHO cells stained with LC3 antibody. The red central circle is the 
defined nuclear region. The coloured rings surrounding this region are the intensity-
analysis regions. 
 Colocalisation analysis was performed using NIS-Elements Advanced Research software. 
This was done by measuring the linear correlation between the GFP and RFP channels, 
thereby determining the Pearson correlation coefficient. 
 
Statistical analysis 
Data was collated using Microsoft Excel. Statistical analyses were performed using 
GraphPad Prism 7. Data were analysed using Student’s t-test, one-way analysis of variance 
(ANOVA), or two-way ANOVA, as appropriate. Tukey’s test (post-hoc analysis) was used in 




Chapter 3 Increased tau phosphorylation and activation of the unfolded 
protein response in Tau35 mice 
3.1 Introduction 
Neurodegenerative tauopathies exhibit several pathological characteristics including the 
accumulation of highly phosphorylated, aggregated and truncated forms of tau protein 
(Brandt et al., 2005). Truncation of tau can have detrimental effects as it leads to a build-
up of toxic tau fragments that can lead to cellular dysfunction, neuronal loss and cell death 
(Amadoro et al., 2004). To validate the pathological role of truncated tau, this laboratory 
generated a Tau35 transgenic mouse expressing Tau35 fused to a HA tag under the control 
of the human tau promoter with targeted insertion into the Hprt locus. This model was 
developed following the discovery of the presence of the Tau35 fragment in post-mortem 
human brains of people affected by 4R tauopathies (Wray et al., 2008). 
 
Numerous behavioural studies carried out on Tau35 mice revealed both motor and 
cognitive impairments. Tau35 mice exhibit clasping commencing at 4 months of age, 
increasing dramatically to include 25% of mice clasping at 5–6 months, and with all Tau35 
mice showing paresis by 18 months of age (Bondulich et al., 2016). In addition, abnormal 
spine curvature was observed in Tau35 mice as early as 4 months of age. Testing on the 
accelerating rotarod revealed that Tau35 mice have a reduced latency to fall, which 
decreased with age, indicating an age-related defect in motor coordination. Tests carried 
out using the Morris water maze showed that by 8 months of age, Tau35 mice exhibit 
spatial learning and hippocampal-dependent memory deficits. Tau35 mice also have a life 
span of approximately 18-20 months, which is significantly reduced compared to that of 
their WT littermates (Bondulich et al., 2016). 
 
immunohistochemical staining of hippocampal and cortical brain sections from groups of 
mice aged 2, 8, and 14-16 months revealed tau-positive labelling of inclusions in Tau35 
mouse brain. The tau inclusions included dystrophic neurites and neuropil threads, which 
were labelled with tau antibodies PHF-1, TOC1, MC1, AT8 and TP007 in Tau35 mice aged 
14-16 months (Bondulich et al., 2016). PHF-1 revealed increased cytoplasmic labelling at 2 
months and tau-containing inclusions from 8 months, which were more abundant at 14–
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16 months in Tau35 mouse brain, which was not apparent in WT hippocampal brain 
sections (Bondulich et al., 2016). Western blots of 14 month old Tau35 mouse 
hippocampal homogenates showed a progressive increase in tau phosphorylation at 
several sites including PHF-1, TG3 and AT270. Additionally, Tau-1 immunoreactivity was 
reduced, indicating increased tau phosphorylation at this epitope in Tau35 mice (Bondulich 
et al., 2016). There were no changes apparent in tau phosphorylation in other brain 
regions in Tau35 mice aged 14 months.  
 
Protein degradation mechanisms are responsible for the re-establishment of homeostasis 
under conditions of cell stress. The ER uses these mechanisms to prevent the accumulation 
of toxic protein aggregates (Katayama, et al, 2004), including through activation of the UPR 
(Katayama et al., 2004; Nijholt et al., 2012a). Since it has previously been established that 
Tau35 mice exhibit increased tau phosphorylation at numerous disease-relevant epitopes, 
it is important to determine the underlying causes and/or consequence of the build-up of 
these abnormal tau inclusions. The effects of Tau35 expression on protein degradation 
have not previously been identified. 
 
This chapter describes the effects of Tau35 expression on tau phosphorylation in different 
regions of aged Tau35 mouse brain. In parallel, molecular mechanisms such as the UPR, 
that may be responsible for the accumulation of phosphorylated tau species in Tau35 mice 
were also investigated. 
 
3.2 Results 
3.2.1 Changes in tau phosphorylation in aged Tau35 mouse brain 
Since changes in tau phosphorylation in Tau35 mice were observed only in the 
hippocampus and associated cortex at 14 months, tau phosphorylation was examined in 
this and other brain regions (amygdala and associated cortex, brainstem and cerebellum, 
and the frontal brain region) in older Tau35 mice (aged 16-18 months). 
 
Firstly, to confirm that Tau35 is expressed in the mice, western blots of homogenates 
prepared from hippocampus and associated cortex of Tau35 and WT mice aged 16-18 
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months were probed with an antibody recognising the HA tag (Figure 3-3-1). The results 









Figure 3-3-1 Verifying the presence of the HA-tagged Tau35 in mouse brain: Western 
blots of homogenates of hippocampus and associated cortex from wild-type (WT) and 
Tau35 mouse brain (aged 16-18 months) probed with antibodies to HA and β-actin 
(loading control). Molecular weights (kDa) are shown on the left. 
 
To determine the effect of Tau35 expression on changes in tau pathology in aged animals 
(16-18 month), homogenates of hippocampus and associated cortex, amygdala and 
associated cortex, brainstem and cerebellum, and frontal region brain samples were 
prepared from 16-18 months old WT and Tau35 mice. Brain region homogenates were 
analysed on western blots probed with antibodies that detect disease-relevant tau 
epitopes: 12E8 (tau phosphorylated at Ser262/Ser356), AT180 (tau phosphorylated at 
Thr231), PHF-1 (tau phosphorylated at Ser396/Ser404) and Tau-1 (tau dephosphorylated 
at Ser195, 198, 199, and 202) and were normalised to total tau (phosphorylation-
independent) (Figure 3-2). In the hippocampus and associated cortex, Tau35 mice exhibit 
significantly increased tau phosphorylation at the 12E8, AT180 and PHF-1 epitopes, 
compared to age matched WT mice (Figure 3-2A-C, P<0.05). Tau35 mice also exhibit 
reduced Tau-1 immunoreactivity, indicating a decrease in the amount of 




Figure 3-2 Tau phosphorylation in hippocampus and associated cortex of aged Tau35 
mice: Western blots of homogenates prepared from wild-type (WT) and Tau35 mouse 
hippocampus and associated cortex (16-18 months), probed with antibodies A 12E8, B 
AT180, C PHF-1, D Tau-1 and total tau. Molecular weights (kDa) are shown on the left. 
Graphs show the amount of phosphorylated tau relative to total tau. Values represent 
mean ± SEM., n=6; Student’s t-test, *P<0.05. 
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In contrast to the hippocampus and associated cortex, there were no significant changes in 
tau phosphorylation in the amygdala and associated cortex at the 12E8, AT180, or Tau-1 
epitopes in Tau35 mice (Figure 3-3 A, B and D, P>0.05). However, Tau35 mice exhibited a 
statistically significant increase in tau phosphorylation at the PHF-1 site in the amygdala 
and associated cortex compared to WT mice (Figure 3-3 C, P<0.01).  
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Figure 3-3 Tau phosphorylation in 16-18 month old amygdala and associated cortex of 
mice: Western blots of homogenates prepared from wild-type (WT) and Tau35 mouse 
amygdala and associated cortex (16-18 months), probed with antibodies A 12E8, B AT180, 
C PHF-1, D Tau-1 and total tau. Molecular weights (kDa) are shown on the left. Graphs 
show the quantitation of the different phospho tau sites relative to total tau. Values 
represent mean ± SEM, n=6; Student’s t-test, **P<0.01. 
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Western blots of homogenates of brainstem and cerebellum revealed significantly 
increased tau phosphorylation at the 12E8 and AT180 epitopes (Figure 3-4 A and B 
P<0.05). In contrast, there were no significant differences in tau phosphorylation at the 
Tau-1 and PHF-1 epitopes (Figure 3-4 C and D, P>0.05). 
Western blots of homogenates prepared from the frontal brain region of 16-18 month old 
WT and Tau35 mice show a significant elevation of phosphorylated tau at the 12E8 and 
Tau-1 epitopes compared to the age-matched WT mice (Figure 3-5 A and D, P<0.01). There 
was no significant difference in the amount of tau phosphorylated at the AT180 or PHF-1 
epitopes (Figure 3-5 B and C, P>0.05).  
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Figure 3-4 Tau phosphorylation in brainstem and cerebellum of mice aged 16-18 months: 
Western blots of homogenates prepared from wild-type (WT) and Tau35 mouse brainstem 
and cerebellum (16-18 months), probed with antibodies A 12E8, B AT180, C PHF-1, D Tau-1 
and total tau. Molecular weights (kDa) are shown on the left. Graphs show the 
quantitation of the different phospho tau sites relative to total tau. Values represent mean 
± SEM, n=6; Student’s t-test, *P<0.05. 
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Figure 3-5 Tau phosphorylation in 16-18 month old frontal brain region of mice: Western 
blots of homogenates prepared from wild-type (WT) and Tau35 mouse frontal brain region 
(16-18 months), probed with antibodies A 12E8, B AT180, C PHF-1, D Tau-1 and total tau. 
Molecular weights (kDa) are shown on the left. Graphs show the quantitation of the 
different phospho tau sites relative to total tau. Values represent mean ± SEM, n=6; 
Student’s t-test, *P<0.05, **P<0.01. 
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Table 3-1 below summarises the changes in Tau phosphorylation observed in the four 
different brain regions of Tau35 mice. Tau-1 was decreased in the hippocampus and 
associated cortex, and frontal region of aged Tau35 mice. AT180 levels were increased in 
the hippocampus and associated cortex, and in the brainstem and cerebellum. Increases in 
PHF-1 phosphorylation were exclusively noted in the hippocampus and associated cortex 
of Tau35 mice. Finally, 12E8 was increased in the hippocampus and associated cortex, and 
amygdala and associated cortex of Tau35 mice compared to age-matched WT mice. 
 
Table 3-1 Summary of changes in tau phosphorylation in different brain regions of aged 
Tau35 mice: Changes in tau phosphorylation at the 12E8, AT180, PHF-1 and Tau-1 epitopes 
in the hippocampus and associated cortex, amygdala, brainstem and cerebellum and 











Frontal region  
Tau-1 
(199/202) 
Decreased No change No change Decreased 
AT180 
(231) 
Increased No change Increased No change 
12E8 
(262/356) 
Increased No change Increased Increased 
PHF-1 
(396/404) 
Increased Increased No change No change 
 
Taken together, the results from this section demonstrate that the expression of Tau35 
has variable effects on tau phosphorylation in different brain regions of Tau35 mice aged 
16-18 months. The hippocampus is the most affected brain region as changes in tau 
phosphorylation were detected using all of the four phosphorylation-dependent tau 
antibodies tested. Conversely, the amygdala is the least effected region with changes in 
tau phosphorylation only detected at the PHF-1 site. 
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3.2.2 Investigating UPR activation in aged Tau35 mice 
The changes observed in tau phosphorylation between 16-18 month old WT and Tau35 
mice are not consistent between the four brain regions examined (Table 3-1). In particular, 
the hippocampus and associated cortex (hereinafter referred to as hippocampus) in Tau35 
mice harbours the most consistent increase in tau phosphorylation compared to WT mice, 
with changes in tau phosphorylation observed at all the four epitopes measured. In 
contrast, in the amygdala and associated cortex (hereinafter referred to as amygdala), 
increased tau phosphorylation is apparent only at PHF-1 epitope in Tau35 mice. The 
brainstem and cerebellum, and frontal region of Tau35 mice each showed changes in Tau 
phosphorylation at two out of the four epitopes measured (Table 3-1). However as in the 
amygdala, there were no changes in Tau phosphorylation at the PHF-1 site in either of 
these regions. Therefore, the hippocampus and amygdala were selected to examine the 
effects of Tau35 expression on the UPR to determine whether changes in tau 
phosphorylation correlate with UPR activation. 
 
To assess the degree of activation of the PERK and IRE1 branches of the UPR, hippocampus 
and amygdala homogenates were prepared from 16-18 month old WT and Tau35 mice 
(n=6 for each genotype). Proteins were separated on either 7.5% (PERK and IRE1) or 10% 
(eIF2α and CHOP) SDS-PAGE. Western blots were probed with antibodies to total and 
phosphorylated PERK, total and phosphorylated eIF2α, CHOP, total and phosphorylated 
IRE1 to determine if there are any changes in these proteins that represent different 
points of the UPR pathway. 
 
Once the PERK arm of the UPR becomes activated, PERK undergoes phosphorylation by 
dissociating from BiP (chapter 1, Figure 1-10) and hence phosphorylated PERK is an 
indicator of UPR activation. Figure 3-6 A shows that there is a statistically significant 
increase in the total amount of PERK relative to β-actin, in the hippocampus of Tau35 mice 
aged 16-18 months compared to WT mice (P<0.05). In contrast, phosphorylated PERK 
(relative to total PERK) in Tau35 mice is not significantly different from WT mice (P=0.06). 
PERK phosphorylation leads to the subsequent phosphorylation and activation of eIF2α. 
Western blots showed no difference in the amount of total eIF2α relative to the amount of 
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β-actin (Figure 3-6 B, P>0.05) and a marked reduction in the amount of phosphorylated to 
total eIF2α (Figure 3-6 B, P<0.01). 
 
Finally, CHOP, the most downstream protein in the UPR pathway, was examined in order 
to determine if there is a difference in the amount of this protein in the hippocampus of 
16-18 month old Tau35 mice. Western blots of CHOP showed a significant two-fold 
elevation in the amount of CHOP, relative to b-actin, in the hippocampus of Tau35 mice 
compared to WT mice (Figure 3-6 C, P<0.001).  
 
 
Figure 3-6 Activation of the PERK arm of the UPR in 16-18 month hippocampus and 
associated cortex mouse brain: Western blots of homogenates prepared from wild-type 
(WT) and Tau35 mouse hippocampus and associated cortex (16-18 months), probed with 
antibodies A phospho PERK and total PERK, B phospho eIF2α and total eIF2α, C CHOP and 
β-actin (loading control). Molecular weights (kDa) are shown on the left. Graphs show the 
quantitation of the western blots. Values represent mean ± SEM, n=6; Student’s t-test, 
*P<0.05, **P<0.01, ***P<0.001. 
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The IRE1 branch of the UPR was next investigated in the hippocampus of Tau35 mice. In 
the absence of cell stress, IRE1 is bound to BiP; whereas under stress conditions, BiP 
dissociates from IRE1, which then autophosphorylates. Western blots of IRE1 show a 
statistically significant elevation in the amount of phosphorylated relative to total IRE1 
(Figure 3-7, P<0.05), indicating activation of this arm of the UPR in aged Tau35 mice. 
 
 
Figure 3-7 Activation of the IRE1 arm of the UPR in 16-18 month hippocampus and 
associated cortex of Tau35 mice: Western blots of homogenates prepared from wild-type 
(WT) and Tau35 mouse hippocampus and associated cortex (16-18 months), probed with 
antibodies phospho IRE1 and total IRE1. Molecular weights (kDa) are shown on the left. 
The graph shows the quantitation of the western blot. Values represent mean ± SEM,  n=6; 
Student’s t-test, *P<0.05. 
 
In order to determine if UPR activation is localised to specific brain regions, the same 
components of the PERK arm of the pathway were measured on western blots of 
homogenates from the amygdala of 16-18 month WT and Tau35 mice (n=6). Western blots 
of the amygdala probed with total PERK and β-actin antibodies showed no statistically 
significant difference in the total amount of PERK in Tau35 mice compared to the WT mice 
(Figure 3-8 A, P>0.05). Bands corresponding to phosphorylated PERK were not detectable 
in the amygdala of either WT or Tau35 mice aged 16-18 months (not shown). 
 
Figure 3-8 B shows western blots of the amygdala from WT and Tau35 mice aged 16-18 
months probed with antibodies to total and phosphorylated eIF2α, and β-actin. The blots 
show no statistically significant difference in the total amount of eIF2α in the amygdala of 
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Tau35 mice compared to WT mice. In addition, the results revealed that that there is no 
statistically significant difference in the amount of phosphorylated eIF2α, relative to total 
eIF2α in Tau35 compared to WT mice (Fig. 3.8B, P>0.05). However, the amount of 
phosphorylated eIF2α detected in these samples was very low and barely detectable in the 
amygdala.  
 
Western blots of the amygdala probed with antibody to CHOP showed no statistically 
significant difference between Tau35 and WT mice aged 16-18 months (Figure 3-8 C, 
P>0.05). The intensity of the band corresponding to CHOP was very weak in the amygdala 
of both WT and Tau35 mice, indicating very low CHOP expression in comparison to the 





Figure 3-8 No change in the PERK arm of the UPR in the amygdala and associated cortex 
of Tau35 mice: Western blots of homogenates prepared from wild-type (WT) and Tau35 
mouse amygdala and associated cortex (16-18 months), probed with antibodies A total 
PERK, and β-actin, B phospho eIF2α and total eIF2α, C CHOP and β-actin (loading control). 
Molecular weights (kDa) are shown on the left. Graphs show the quantitation of the 




The overall aims of this chapter were to gain an understanding of the biochemical changes 
in tau phosphorylation in the brains of aged Tau35 mice. Moreover, since increased tau 
phosphorylation was noted only in the hippocampus and associated cortex of Tau35 mice 
aged 14 months (Bondulich et al, 2016), it was important to determine whether tau 
phosphorylation also occurred in different brain regions in older mice. In addition, since 
tau phosphorylation influences its ability to be degraded, it was of interest to identify 
whether underlying protein degradation mechanisms were affected as these may be 
responsible for the accumulation of phosphorylated tau in the brains of Tau35 mice. 
 
 The main findings of this chapter include the following changes in Tau35 mouse brain 
from animals aged 16-18 months: 
• Increased phosphorylated tau in hippocampus at the 12E8, AT180, Tau-1, and 
PHF-1 epitopes. 
• Increased tau phosphorylation detected solely at the PHF-1 epitope in the 
amygdala. 
• Increased tau phosphorylation detected only at the 12E8 and AT180 epitopes in 
brainstem and cerebellum. 
• Increased tau phosphorylation detected only at the 12E8 and Tau-1 epitopes in the 
frontal brain region. 
• Evidence of increased activation of the PERK and IRE1 arms of the UPR in the 
hippocampus.  
• No change in the PERK arm of the UPR in the amygdala. 
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3.3.1 Brain region specific changes in tau phosphorylation in aged Tau35 mice 
It is well known that the accumulation of phosphorylated and abnormally modified tau can 
result from the presence of truncated tau species, leading to numerous neuropathological 
changes observed in human tauopathy (Delobel et al., 2008). Proteases including caspases, 
calpains, cathepsins, thrombin, asparagine endopeptidase (AEP), puromycin-sensitive 
aminopeptidase (PSA), human high temperature requirement serine protease A1 (HTRA1), 
and proteasomal proteases have been proposed as likely candidates that contribute to tau 
truncation, which in turn can generate potentially toxic fragments and even initiate the 
aggregation of tau (Hanger and Wray, 2010; Wang et al., 2010; Zhang et al., 2014). The 
results from this chapter provide evidence for a build-up of phosphorylated tau in the 
brains of Tau35 mice. In particular, the most affected region in Tau35 mice appears to be 
the hippocampus, whereas the amygdala is the least affected region. 
 
There are substantial increases in tau phosphorylation in the hippocampus of Tau35 mice 
compared to age-matched WT control mice. In fact, elevation in tau phosphorylation at 
the PHF-1 epitope had been previously reported in Tau35 mice from as early as two 
months of age (Bondulich et al., 2016). The presence of phosphorylated tau inclusions in 
the hippocampus could also explain some of the cognitive changes previously described in 
Tau35 mice. Since the hippocampus is the brain region responsible for spatial learning 
(Clelland et al., 2009), the biochemical changes seen in this brain region could account for 
the observed memory deficits in Tau35 mice (Bondulich et al., 2016). Previous studies have 
shown a correlation between the presence of abnormally phosphorylated and aggregated 
tau species and cognitive decline in mouse models of tauopathy and also in human disease 
(Armstrong et al., 2009; Ramsden et al., 2005). 
 
 The amygdala appeared to be the least affected region in Tau35 mice aged 16-18 months 
as changes in tau phosphorylation were only detected at the PHF-1 site. An increase in tau 
phosphorylation at the PHF-1 site was not observed in the amygdala of Tau35 mice at 14 
months of age (Bondulich et al., 2016). Therefore, the results from this chapter suggest 
that the expression of Tau35 drives changes in tau pathology at a later stage in the 
amygdala and associated cortex. A significant tau burden has been reported in the 
amygdala of rTg4510 mice, which harbour the P301L tau mutation (Cook et al., 2014b). 
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However, tau pathology in rTg4510 mice has predominantly been described in the 
hippocampus and studies have shown profound impairments in hippocampal-dependent 
learning and memory tests, including contextual fear conditioning in rTg4510 mice (Berger 
et al., 2007; O'Leary et al., 2010; Yue et al., 2011). To date, the Tau35 mice have been 
tested exclusively for motor and memory impairments, rather than for amygdala-
dependent behaviours (Bondulich et al., 2016). However, rTg4510 mice also display an 
abnormal hyper-exploratory phenotype in the open-field, elevated plus maze, light-dark 
exploration, and cued fear conditioning, indicative of amygdala dysfunction (Cook et al., 
2014b). In addition, another tau transgenic mouse that expresses human tau truncated at 
E391 (a fragment associated with the development of AD), shows increased tau 
phosphorylation in both the hippocampus and amygdala (McMillan et al., 2011). However, 
it is worth noting that, unlike in Tau35 mice in which truncated tau is expressed at <10% of 
endogenous mouse tau (Bondulich et al., 2016)., in E391 mice, total tau was 1.9-fold 
higher than endogenous mouse tau (McMillan et al., 2011), which corresponds to a 
significant overexpression of the transgenically expressed E391 tau fragment. 
 
People with FTLD-tau present with a wide variety of clinical symptoms, that may include 
loss of social inhibition, inappropriate emotional responses, and restlessness (Lynch et al., 
1994; Spillantini et al., 1997; Yamaoka et al., 1996). This suggests that the involvement of 
amygdala dysfunction is a possible contributing factor in some cases. Tau35 has been 
detected in several different 4R tauopathies including FTLD-tau, which may go some way 
towards explaining why tau pathology is observed in Tau35 mice. 
 
The brainstem and cerebellum of Tau35 mice aged 16-18 months showed increased tau 
phosphorylation at two out of the four phosphorylated tau epitopes examined. These sites 
correspond to 12E8 (tau phosphorylated at Ser262/Ser356) and AT180 (tau phosphorylated 
at Thr231) sites. Similar to the amygdala, the brainstem and cerebellum has not been 
reported to be affected in the brains of Tau35 mice aged 14 months (Bondulich et al., 
2016). Consequently, the changes detected here in older Tau35 mice could indicate a 
delay in tau phosphorylation in this brain region. The cerebellum controls motor activity, 
including voluntary movement, balance and motor co-ordination (Buckner, 2013). Tau35 
mice exhibit  a motor learning deficit on the accelerating rotarod, and they are more likely 
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to fall as they age, compared to WT mice (Bondulich et al., 2016). This suggests that the 
decline in motor co-ordination is progressive, and may explain the delayed changes seen in 
this region as perhaps there is a correlation between the decline in motor activity and tau 
phosphorylation in Tau35 mice. 
 
 It is common for other animal models of tauopathy to demonstrate more pronounced 
differences in tau phosphorylation as the mice age, which validates the results described in 
this chapter. One example of such age-dependent differences in tau phosphorylation is the 
pR5 P301L tau mouse model, where more brain regions show increased tau 
phosphorylation as the mice age. Similar to the Tau35 mice, the brain regions affected in 
pR5 P301L mice include the hippocampus as well as the amygdala and brainstem (Gotz et 
al, 2001; David et al, 2005; Pennanen et al, 2006). The results obtained from the frontal 
brain region of aged Tau35 mice revealed significant increases in tau phosphorylation at 
the 12E8 and Tau-1 epitopes, compared to age-matched WT control mice. The frontal 
region of Tau35 mice appears to be more affected by tau phosphorylation than the 
amygdala, although this is less than that seen in the hippocampus. As was the case for 
both the amygdala, and the brainstem and cerebellum, no change had been reported 
previously in the frontal brain region of Tau35 mice aged 14 months. Taken together, 
these results indicate an age-dependent increase in tau phosphorylation in Tau35 mice.  
 
The changes in tau phosphorylation observed in the Tau35 mice may be explained at least 
in part, by differential Tau35 expression in each brain region. Work in this laboratory has 
shown that Tau35 protein expression in the mice is highest in the hippocampus, and 
brainstem and cerebellum, and lowest in the amygdala and frontal brain regions (Natalia 
Yankova, personal communication). Similar findings have been documented by Höfling et 
al, who found differential transgene expression patterns in an amyloid precursor protein 
(APP) mouse model of Alzheimer’s disease (Hofling et al., 2016). Such observations are 
also noted in tauopathy models. For example, the regional vulnerability observed in the 
rTg4510 mouse brain, such as neuronal death and neurofibrillary lesions in the 
hippocampus, and neuronal loss of dentate gyrus granule cells, show some correlation 
with the regional vulnerability observed in human FTLD-tau, in which the subiculum and 
hippocampus are the most affected brain regions (Spires et al., 2006). 
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3.3.2 Brain region specific activation of the UPR 
Investigation of UPR activation in the hippocampus and amygdala of aged Tau35 mice 
showed that the UPR is selectively activated in specific brain regions. Thus, UPR activation 
was observed in the hippocampus, but not in the amygdala of Tau35 mice aged 16-18 
months. These findings are corroborated by a study of brain tissue from people with AD 
and PSP, in which UPR activation was observed exclusively in neuropathologically affected 
brain regions (Stutzbach et al., 2013). In PSP brain, the UPR was activated as indicated by 
increased staining of phosphorylated PERK and phosphorylated eIF2α, primarily in the 
pons and medulla, and to a much lesser extent in the hippocampus. In PSP 
neuropathological changes such as intracellular neurofibrillary and glial tangles made up of 
tau, and neuronal degeneration occur in the brainstem, particularly the pons and medulla, 
thereby revealing a correlation between neuropathology and UPR activation (Stutzbach et 
al., 2013). In AD on the other hand, the UPR was extensively activated in the hippocampus, 
which is consistent with this region being affected early in disease pathogenesis (Stutzbach 
et al., 2013). In Tau35 mice, abnormalities in motor, cognitive and pathological 
abnormities have been predominantly associated with changes in hippocampal-dependent 
activity. Notably, the build-up of misfolded proteins has been proposed to be a primary 
trigger of UPR activation in neurodegenerative diseases such as AD (Ho et al., 2012). Since 
there is a greater proportion of phosphorylated tau in the hippocampus of Tau35 mice 
compared to the amygdala, this may explain the differences in UPR activation between 
different regions as increased phosphorylated tau in the hippocampus may drive UPR 
activation. These findings therefore suggest that there may be a relationship between 
increased tau phosphorylation and aggregation, and activation of the UPR in the 
tauopathies. 
 
Accumulation of tau in AD brain results in the eventual loss of neurons and cognitive 
dysfunction (LaFerla and Oddo, 2005; Selkoe, 2001). The number of dying neurons in AD 
brain exceeds the number of tau tangles (Ferreiro and Pereira, 2012b). This suggests the 
involvement of a secondary route that leads to cell death that may be initiated or 
accelerated by the accumulation of phosphorylated tau. Recently, it has been suggested 
that prolonged UPR activation could be a pathway through which soluble tau species 
contribute to neuronal death, thereby implying that activation of the UPR could contribute 
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to the progression of several neurodegenerative diseases (Ferreiro and Pereira, 2012b). 
Over-activation of the UPR in the hippocampus of Tau35 mice leads to the subsequent 
increase in the expression of CHOP (Figure 3-7 C), which may go on to activate apoptotic 
pathways in these cells (Tabas and Ron, 2011). However, there is no evidence of overt 
neuronal cell death in Tau35 mice up to the age of 16 months (Marie Bondulich, personal 
communication). Alternatively, elevated CHOP may have the opposite effect by activating 
sXBP1 (chapter 1, Figure 1-10), which targets several genes, including ER chaperones to 
facilitate refolding of misfolded proteins and reduce ER stress (Scheper and Hoozemans, 
2015; Schonthal, 2012). XBP1 can also be activated by IRE1 activation which was shown to 
be increased in the brains of Tau35 mice as indicated by increased IRE1 phosphorylation. 
This observation may further contribute to the lack of changes seen in neuronal cell death 
in Tau35 mice. 
 
Mitigation of global protein translation can lead to synaptic failure in the rTg4510 mouse 
model of frontotemporal dementia (Radford et al., 2015). Similarly, reductions in synapsin 
1 and synaptobrevin, synaptic vesicle proteins involved in fusion and interaction with 
vesicle membranes and regulating the reserve pool of synaptic vesicles (Gitler et al., 2004) 
have been shown in Tau35 mice (Bondulich et al., 2016). Therefore, activation of the PERK 
branch of the UPR may be an important factor underlying the reduction in the levels of 
these synaptic proteins and the integrity of synapses. 
 
These findings demonstrate that activation of the PERK and IRE1 branches of the UPR are 
brain region-dependent in Tau35 mice, and this activation may be related to the observed 
increases in tau phosphorylation in the same brain regions. Markers of UPR activation are 
also elevated in AD brain, particularly in the hippocampus, and UPR activation has also 
been reported in neurons with abnormally phosphorylated tau protein (Chang et al., 2002; 
Hoozemans et al., 2009; Unterberger et al., 2006). Taken together, this implies a possible 
relationship between the appearance of phosphorylated and misfolded tau, and activation 
of the UPR that could be involved in disease pathogenesis in human tauopathies. 
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Chapter 4 The effect of Tau35 expression on cell viability and autophagy 
activation 
4.1 Introduction 
A characteristic feature of neurodegenerative tauopathies is the build-up of abnormal 
inclusions, which contain misfolded and unfolded proteins. One system that is responsible 
for restoring homeostasis when such inclusions accumulate is the autophagy and 
lysosomal degradation system (Maiuri et al., 2007). Autophagy is a self-degradative 
process that clears protein aggregates and damaged organelles, such as mitochondria, the 
endoplasmic reticulum, and peroxisomes (Maiuri et al., 2007; Yu et al., 2018). Autophagy 
begins with an initiation phase, during which the proteins to be degraded are identified 
(chapter 1, Figure 1-7) (Yu et al., 2018). Initiation of autophagy is followed by the 
formation of a double-membrane structure known as the autophagosome, that sequesters 
the proteins to be degraded. The autophagosome then fuses with the lysosome to form an 
autolysosome and the degraded proteins are then recycled and fed back into the cell 
(Eskelinen, 2005). If autophagy fails to achieve homeostasis, this can lead to chronic ER 
stress, which ultimately results in the activation of cell death through apoptosis (Rao et al., 
2001). Due to this, crosstalk between autophagic and apoptotic pathways determine the 
eventual fate of the cell. Beclin-1 has a prominent role in the initiation of autophagy, as it 
regulates the autophagy-promoting activity of Vps34, a Class III PI3-kinase. Beclin-1 
additionally plays a role in the localisation of autophagic proteins to a pre-autophagosomal 
structure and is involved in membrane recruitment for the autophagosome, which is 
required for autophagosome formation (Criollo et al., 2007). Beclin-1 can also interact with 
Bcl-2 and is involved in the determination of cell survival (Chu et al., 2007). 
 
There are several components upstream of the autophagy pathway that play a critical 
regulatory role. One such example is the primary nutrient-sensing complex, mammalian 
target of rapamycin complex 1 (mTORC1), including mTOR kinase, raptor, and mammalian 
lethal with SEC13 protein 8 (MLST8) (Hoeffer and Klann, 2010). Decreased mTORC1 
activity is normally accompanied by upregulation of autophagy (Duran et al., 2011). 
Another component upstream of autophagy is adenosine monophosphate-activated 
protein kinase (AMPK), a conserved sensor of intracellular energy that is activated in 
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response to low nutrient availability and environmental stress, thereby activating 
autophagy (Hardie, 2011). The Atg1/ULK (autophagy related gene 1/Unc-51-like kinase) 
complex additionally plays an essential role in the initiation of autophagy as it receives 
signals of cellular nutrient status (Mizushima, 2010). When ULK1 senses an excess of 
nutrients, it recruits downstream Atg proteins to the autophagosome formation site, and 
increases autophagosome formation (Mizushima, 2010). 
 
It is important to determine whether Tau35 expression affects protein degradation 
mechanisms, such as autophagy, as well as assessing the effect of Tau35 on cell survival. 
Some studies have reported that excess amounts of tau may be toxic to cells. For example, 
an excess of hTau induced mitotic arrest, with the presence of monopolar spindles, and 
apoptotic cell death in a Drosophila model (Bouge and Parmentier, 2016). Several studies 
have shown that a failure in autophagy in multiple neurodegenerative diseases including 
ALS, AD and PD, may be responsible for the build-up of proteins inside affected neurons 
(Chamoux et al., 2013; Fecto et al., 2011; Lee et al., 2010c). In particular, knockdown of 
Atg5 and Atg7 in mouse brain results in a neurodegenerative phenotype, with the 
accumulation of protein aggregates containing ubiquitin-positive inclusions in the absence 
of disease-causing proteins (Reggiori, 2012). In addition, autophagy was activated in brain 
regions in which the number of neurons containing tau inclusions was significantly 
reduced, as was the amount of insoluble tau, in transgenic mice expressing human P301S 
tau (Schaeffer et al., 2012a). 
 
To examine the effects of Tau35 expression on the autophagy pathway and cell viability, 
CHO cell models that stably express either V5 tagged-Tau35, or the 2N4R isoform of 
human tau, were generated (Tong Guo, King’s College London). These cell lines provide a 
means of understanding the molecular changes that occur along different stages of the 
autophagy pathway, as well as the opportunity to modify them using inhibitors and 
activators. Although CHO cells do not express tau, they have long been used to investigate 
changes in the cytoskeleton, including in relation to exogenous tau expression. For 
instance, they have been used to study physiological functions and pathological changes in 
tau (Gallo et al., 1992). Moreover, stable CHO cell lines have been used extensively to 
study the different roles of various microtubule-binding proteins such as human MAP4, 
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which also stabilises microtubules (Barlow et al., 1994). In addition, CHO cells stably 
expressing tau harbouring different frontotemporal dementia (FTLD-tau) mutations 
replicate several disease-associated pathological features, such as formation of insoluble 
filamentous tau aggregates and reduced interaction of tau with microtubules (Vogelsberg-
Ragaglia et al., 2000). Therefore, stably transfected CHO cells represent a useful model in 
which to study the effects of tau and Tau35 on cellular functions. 
4.2 Results 
4.2.1 The effect of Tau35 expression on CHO cell viability  
Firstly, to confirm the successful transfection and expression of FL-tau and Tau35 in CHO 
cells, western blots of total cell lysates were probed with an antibody recognising total tau. 
Figure 4-1 shows that CHO cells stably transfected with FL-tau show a band corresponding 
to tau just below 75kDa. Cells stably transfected with Tau35 show multiple bands when 






Figure 4-1 verifying the expression of FL-tau and Tau35 in CHO cells: Western blots of total 
cell lysates from CHO cells stably transfected with FL-tau or Tau35, probed with antibodies 






To determine whether Tau35 expression impacts on cell survival, a cell viability assay was 
performed on CHO-Tau35, CHO-FL and untransfected CHO cells using calcein violet 450 
AM. Calcein violet AM is a membrane-permeable dye that is taken up by live cells and 
hydrolysed by intracellular esterases into the green fluorescent, membrane-impermeable 
anion calcein. Non-viable cells are unable to retain the dye due to their compromised cell 
membrane integrity (Gillissen et al., 2016). 
 
The first approach to measure cell viability involved using fluorescence activated cell 
sorting (FACS) in CHO-FL, CHO-Tau35 and untransfected CHO lines under basal conditions. 
Cells were exposed to 500 nM Calcein 450 AM for 30 min and calcein fluorescence was 
measured (BD FACSCanto II). Figure 4-2 shows representative histograms of calcein 
fluorescence recorded in the three cell lines. The peak corresponding to viable CHO-FL 
cells (Figure 4-2 A right) is almost two-fold higher than that corresponding to non-viable 
cells (Figure 4-2A left). Figure 4-2 B is the histogram corresponding to the count of Tau35-
CHO cells. The peak corresponding to viable CHO-Tau35 cells (Figure 4-2 B right) is almost 
three-fold higher than that corresponding to non-viable cells (Figure 4-2 B left). Figure 4-2 
C is a representative histogram for the data recorded for the untransfected CHO cells. The 
peak corresponding to viable CHO cells (Figure 4-2 C right) is approximately three-fold 
higher than that corresponding to non-viable cells (Figure 4-2 C left). Figure 4-2 D is data 
recorded from untransfected CHO cells without calcein AM (negative control). The single 
peak on the left shows the detection of a cell population. The results from this FACS 
analysis indicate that the population of viable cells far exceeds the number of non-viable 
cells in all three cell lines. The percentage of viable cells in each cell line (Figure 4-2E) 
shows that there is no statistically significant difference in the basal viability of CHO-FL, 




Figure 4-2 Calcein AM cell viability assay using FACS: A-D show histograms of cell viability 
assays performed on A CHO-FL, B CHO-Tau35, C CHO cells, D CHO cells without calcein 
(negative control).  Calcein AM negative cells are shown with reduced fluorescent intensity 
for calcein AM (as gated). E Quantitation of viable cells, expressed as a percentage of the 




A second approach used to measure cell viability was using a plate reader to detect the 
amount of calcein AM fluorescence taken up by each cell line. As had been previously 
shown using the FACS method (Figure 4-2), all three cell lines showed similar viability using 
this method (Figure 4-3A, P>0.05). This demonstrates that expression of either FL-tau or 
Tau35 does not induce cell death in CHO cells. These findings validate the previous results 
obtained from measuring calcein fluorescence in untreated cells using FACS and indicate 
that assay of cell viability by calcein AM uptake using the plate reader provides reliable 
and robust data. 
 
The three CHO cell lines were subsequently treated with DTT or thapsigargin to determine 
how the cells respond to extrinsic UPR inducers. DTT is a strong reducing agent, which 
blocks the formation of disulfide bonds, thereby leading to ER stress (Carpio et al., 2015). 
Thapsigargin is a specific inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 
that reduces ER calcium, thereby hindering the functionality of Ca2+dependent ER 
chaperones, and causing the accumulation of unfolded proteins (Halliday et al., 2017). 
Measurement of cell viability using the plate reader method, after treating the CHO cell 
lines with 20 mM DTT for 4 h, showed a statistically significant increase in the viability of 
CHO-Tau35 cells compared to both CHO-FL and untransfected CHO cells (Figure 4-3 B, 
P<0.05). However, there was no significant difference between the number of viable CHO-
FL and untransfected CHO cells (Figure 4-3 B). In CHO cells treated with thapsigargin (1 
µM, 6 h), there was no statistically significant difference in cell viability between CHO-FL, 
CHO-Tau35 and untransfected CHO cells (Figure 4-3 C). Extending the time of thapsigargin 
treatment (1 µM, 24 h) showed a statistically significant increase in cell viability in CHO-FL 
and CHO-Tau35 cells, compared to untransfected CHO cells (Figure 4-3 D; P<0.05). 
However, there was no significant difference in cell viability between CHO-FL and CHO-
Tau35 cells (Figure 4-3 D). Taken together, these results indicate that cell viability is 
significantly enhanced in CHO-Tau35 cells following induction of ER stress by DTT and also 
by extended thapsigargin treatment. In comparison, CHO-FL cells are not affected by ER 
stress in response to DTT as they respond similarly to untransfected CHO cells. However, 
CHO-FL cells are more sensitive than untransfected CHO cells to prolonged thapsigargin 
treatment and expression of FL-tau results in enhanced cell viability that is similar to that 
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of CHO-Tau35 cells under these conditions. The results suggest that at least in CHO cells, 






Figure 4-3 Cell viability assay using calcein AM: Cell viability assay performed on CHO-FL, 
CHO-Tau35 and untransfected CHO cells (%). A Untreated, B DTT (20 mM, 4 h), C 
Thapsigargin (1 µM, 6 h), D Thapsigargin (1 µM, 24 h). Values represent the percentage (%) 
of viable CHO-FL and CHO-Tau35 cells, relative to that of untransfected CHO cells (mean ± 
SEM, n=4; one-way ANOVA, *P<0.05). 
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4.2.2 Early autophagy in CHO-Tau35 cells 
Previous work has shown that CHO-Tau35 cells exhibit increased tau phosphorylation at 
several different epitopes, including PHF-1 and AT180, compared to CHO-FL cells (Tong 
Guo, King’s College London). This accumulation of phosphorylated tau suggests that 
autophagy might be disrupted in Tau35-CHO cells, thereby hindering protein clearance.  
 
To measure changes in early autophagy, western blots of CHO-FL, CHO-Tau35 and CHO cell 
lysates were probed with an antibody against beclin-1. The amount of beclin-1 present in 
CHO-Tau35 cells, relative to β-actin, was decreased by approximately 30-40%, compared 
to CHO-FL and CHO cells (Figure 4-4; P<0.01 and P<0.05, respectively). In contrast, the 
amount of beclin-1 was unchanged in CHO-FL cells compared to CHO cells. These results 
show a selective loss of beclin-1 in CHO-Tau35 cells, suggesting that Tau35 expression 




Figure 4-4 Early autophagy dysfunction indicated by reduced beclin-1 in CHO-Tau35 cells: 
Western blots of CHO-FL, CHO-Tau35 and untransfected CHO cell lysates probed with 
antibodies to beclin-1 and β-actin (loading control). Molecular weights (kDa) are shown on 
the left. The graph shows the quantitation of the western blot. Values represent mean ± 
SEM, n=4; one-way ANOVA, *P<0.05, **P<0.01. 
 
To further investigate autophagy initiation in CHO-Tau35 cells, the amounts of three Atg 
proteins (Atg5, Atg7, and Atg13), each involved at different stages of autophagy activation, 
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were measured in the three cell lines. Western blots of CHO-FL, CHO-Tau35 and CHO cell 
lysates were probed with antibodies to Atg5, Atg7, or Atg13 and the amount of each 
protein was standardised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The 
blots showed immunoreactive bands at the expected molecular weights for Atg5 (50 kDa), 
Atg7 (77 kDa) and Atg 13 (72 kDa) in all three CHO cell lines. The results showed no 
statistically significant differences in the amounts of Atg5, Atg7, or Atg13 in CHO-FL, CHO-
Tau35 and CHO cells (Figure 4-5). Overall, these findings indicate that expression of either 
FL-tau or Tau35 does not influence autophagy initiation in CHO cells and that any effect of 
Tau35 on autophagy likely lies downstream. 
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Figure 4-5 No changes in the amount of Atg5, Atg7, or Atg13 in CHO-Tau35 cells: Western 
blots of CHO-FL, CHO-Tau35 and untransfected CHO cell lysates probed with antibodies to 
A Atg5, B Atg7 C Atg13 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Molecular weights (kDa) are shown on the left. The graphs show the quantitation of the 
Atg proteins on western blots, relative to GAPDH. Values represent mean ± SEM, n=3; one-
way ANOVA. 
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4.2.3 Autophagosome formation and maturation in CHO-Tau35 cells 
The amounts of LC3 in CHO-FL, CHO-Tau35 and CHO cells were measured to assess 
whether Tau35 expression induces changes in autophagosome formation. Western blots 
of lysates from each of the three cell lines were probed with an antibody detecting both 
LC3-I and LC3-II. The results showed a pronounced decrease in the basal amount of LC3-II 
in CHO-Tau35 cells, compared to CHO-FL and CHO cells (Figure 4-6 A; P<0.01 and P<0.05, 
respectively). Moreover, there was also a significant increase in the amount of LC3-II in 
CHO-FL compared to CHO cells (P<0.05). This implies that CHO-Tau35 cells contain fewer 
autophagosomes than CHO cells, whereas CHO-FL cells harbour an increased number of 
autophagosomes. 
 
To confirm these effects of Tau35 and FL-tau expression on LC3-II, and to observe the 
cellular distribution of LC3 puncta CHO-FL, CHO-Tau35 and CHO cells were fixed in 
methanol and labelled with the same LC3 antibody used on the western blots. LC3 was 
visualised in the three cell lines using immunofluorescence and the fluorescence intensity 
of LC3 was determined. The results showed a marked reduction in LC3 
immunofluorescence in CHO-Tau35 cells, compared to both CHO-FL and CHO cells (Figure 
4-6 B; P<0.01 and P<0.05, respectively). Furthermore, there was a significant increase in 
LC3 intensity in CHO-FL cells compared to CHO cells (Figure 4-6 B, P<0.05). The findings 
from these experiments are consistent with those from the western blots, confirming the 
overall reduction in LC3 caused by Tau35 expression in CHO cells, indicating a deficit in 
basal autophagy. 
 
The distribution of cytosolic LC3 puncta in CHO cells was determined for each cell line 
using a series of six concentric rings, positioned 3 µm apart, extending up to 18 µm out 
from the perimeter of the nucleus in each cell. The fluorescence intensity of LC3 inside 
each concentric ring was measured and plotted against the distance from the nucleus 
(Figure 4-7). Tau35-CHO cells showed a pronounced reduction in puncta compared to 
CHO-FL and CHO cells, at almost all distances from the nucleus. In comparison to 
untransfected CHO cells, CHO-Tau35 cells showed a mean significant reduction of 32% at 
the edge of the nucleus (0-3 µm distance), whereas CHO-FL cells only showed a 13% 
reduction, which was not significantly different from LC3 localisation in untransfected CHO 
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cells. Moreover, compared to CHO cells, CHO-Tau35 cells showed a mean reduction of 35% 
at a distance of18µm from the nucleus and CHO-FL cells showed a reduction of 10% in LC3 
puncta at this distance. The results of the distribution of LC3 puncta in the three CHO cell 
lines are summarised in Table 4-1. Taken together, the distribution analysis results show 
that the number of LC3 puncta is reduced throughout the perimeter of CHO-Tau35 cells; 
however, the overall trend of LC3 puncta distribution appears to be similar across the 




Figure 4-6 Reduced amount of the autophagosome marker LC3 in CHO-Tau35 cells: A 
Western blot and quantitation of LC3-I and LC3-II, relative to β-actin, in CHO-FL, CHO-
Tau35 and CHO cell lysates, n=6. B immunofluorescence of methanol-fixed CHO-FL, CHO-
Tau35 and CHO cells labelled with LC3 antibody, scale bar=10 µm. C Quantification of LC3 
intensity. For the quantification, a total of 30 cells were analysed per condition, n=3 for 





Figure 4-7 Trend of LC3 puncta distribution: Distribution analysis of LC3 
immunofluorescence in CHO-FL, CHO-Tau35, and CHO cells. For each cell type, a total of 50 
cells were counted. Values represent mean ± SEM, two-way ANOVA, *P<0.05, **P<0.01, 
***P<0.001. Black bars: FL, grey bars: Tau35, white bars: CHO. 
Table 4-1 Summary of the mean percentage reduction in puncta distribution in CHO-
Tau35 and CHO-FL cells compared to CHO cells 
Distance from nucleus (µm) Percentage reduction in 
puncta intensity between 
CHO-Tau35 and CHO cells 
Percentage reduction in 
puncta intensity between 
CHO-FL and CHO cells 
0-3 32 13 
3-6 29 9 
6-9 23 -2 
9-12 22 1 
12-15 21 5 
15-18 24 -1 
18+ 35 10 
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There are several different extrinsic autophagy activators that have been used to study 
autophagy in in vitro systems. One example is nutrient starvation, induced by depleting 
amino acids and/or growth factors, which is widely used to elicit an acute autophagic 
response by dephosphorylating ULK1. Therefore, to test the effects of inducing autophagy 
by effectively starving cells of nutrients, cell culture medium was replaced with HBSS 
(containing Mg2+ and Ca2+) in the three cell lines. Western blots of CHO-FL, CHO-Tau35 and 
CHO cells, either untreated or exposed to HBSS, were probed with antibodies to LC3 and β-
actin to assess autophagy activation. The amount of LC3-II was significantly elevated in 
starved cells compared to untreated cells in all three cell lines (Figure 4-8, P<0.05). 
Furthermore, upon cell starvation, the amount of LC3-II in CHO-Tau35 cells reached 
approximately half of that in the CHO cells (Figure 4-8, P<0.05). In addition, the amount of 
LC3-II in CHO-FL cells was approximately three-fold higher than that of CHO-Tau35 cells 
upon starvation (Figure 4-8, P<0.01). HBSS also induced an increase in LC3-II in CHO-FL 
cells, compared to CHO cells (Figure 4-8, P<0.05). Taken together with the earlier finding of 
reduced basal LC3-II in CHO-Tau35 cells, these data suggest that Tau35 expression 
attenuates activation of autophagy in CHO cells, even after stimulation of autophagic 
processes induced by cell starvation. The expression of FL-tau in CHO cells does not have 
the same effect on the amount of LC3-II, indicating that the inhibition of autophagy 





Figure 4-8 Reduced induction of LC3-II in CHO-Tau35 cells upon starvation: Western blots 
of CHO-FL, CHO-Tau35 and untransfected CHO cell lysates (untreated or treated with HBSS 
for 3 h to induce starvation) probed with antibodies to LC3 and β-actin (loading control). 
Molecular weights (kDa) are shown on the left. The graph shows the quantitation of the 
western blots. Values represent mean ± SEM, n=6; two-way ANOVA, *P<0.05, **P<0.01. 
 
Autophagic flux measures the dynamic process of autophagy: autophagosome formation, 
maturation, fusion with lysosomes, subsequent breakdown and the release of 
macromolecules back into the cytosol (Zhang et al., 2013). Bafilomycin A1 inhibits V-
ATPase, thereby preventing autophagosome-lysosome fusion and maturation of 
autophagic vacuoles, which results in the accumulation of autophagosomes (marked by 
LC3-II) in cells. Hence, one reliable method to determine if there are effects on autophagic 
flux is to expose cells to bafilomycin A1 and to measure the amount of LC3-II on western 
blots. Therefore, western blots of CHO-FL, CHO-Tau35 and CHO cell lysates, either 
untreated or exposed to bafilomycin (300 nM, 2 h), were probed with LC3 antibody (Figure 
4-9). In all three cell types, bafilomycin caused a substantial build-up of LC3-II, compared 
to untreated cells (P<0.01). Despite this increase, the amount of LC3-II in CHO-Tau35 cells 
remained significantly lower than that in CHO-FL and CHO cells after bafilomycin 
treatment (P<0.05 and P<0.001, respectively). In contrast, there was no significant 
difference in the amount of LC3-II present in CHO-FL and CHO cells treated with 
bafilomycin under these conditions. These findings further support the autophagic deficit 
in CHO-Tau35 cells because the amount of LC3-II-postive autophagosomes in these cells 
remained substantially lower upon induction of autophagic flux. 
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Figure 4-9 Reduced LC3-II in CHO-Tau35 cells upon induction of autophagic flux: Western 
blots of CHO-FL, CHO-Tau35 and untransfected CHO cell lysates probed with antibodies to 
LC3 and β-actin (loading control) in untreated and bafilomycin A1-treated (300 nM for 2 h) 
cells. Molecular weights (kDa) are shown on the left. The graph shows the quantitation of 
the western blots. Values represent mean ± SEM, n=6; two-way ANOVA, *P<0.05, 
**P<0.01, ***P<0.001. 
4.2.4 The effect of Tau35 expression on the size of CHO cells 
One of the defining functions of tau is to bind to microtubules, thereby promoting their 
stability and maintaining the structure of the cytoskeleton. In addition, tubulin acetylation 
is vital in modulating the function of microtubules (Perdiz et al., 2011). Acetylation of the 
Lys40 residue in α-tubulin is a key marker of polymer age and hence microtubule stability. 
Notably, deficits in tubulin acetylation at this site have been reported in a variety of 
neurodegenerative disorders, including Parkinson's disease and several tauopathies 
(Dubey et al., 2015; Zhang et al., 2015). 
 
The immunofluorescence images used to analyse LC3 puncta intensity and distribution 
were additionally used to calculate cell size of CHO-FL, CHO-Tau35 and CHO cells. Previous 
work in this laboratory showed that Tau35 in CHO cells has a reduced ability to bind to 
microtubules, as well as a marked reduction in acetylated tubulin (Guo et al., 2019). Such 
disruptions in tubulin acetylation and microtubule binding could also impact on the size 
and morphology of CHO cells as CHO-Tau35 cells appear to be more rounded than CHO-FL 
and CHO cells. Therefore, the area occupied by CHO-Tau35, CHO-FL and CHO cells was 
determined (Figure 4-10). The results showed that CHO-Tau35 cells occupy approximately 
35% less area compared to CHO cells (P<0.001), and they are approximately 25% smaller 
than CHO-FL cells (P<0.01). Additionally, CHO-FL cells exhibited a slight reduction of 
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approximately 16% in cell area compared to CHO cells (P<0.05). These results show that 
expression of both FL-tau and Tau35 has an impact on the size of CHO cells. 
 
 
Figure 4-10 Reduced cell size in CHO-Tau35 cells: Quantification of cell area in CHO-FL, 
CHO-Tau35 and CHO cells from immunofluorescence images of LC3. For each cell type, a 
total of 50 cells were counted. Values represent mean ± SEM one-way ANOVA, *P<0.05, 
**P<0.01, ***P<0.001. 
4.2.5 Exploring upstream targets of autophagy in CHO-Tau35 cells 
mTORC1 negatively regulates autophagy in mammals (Ravikumar et al., 2004b). 
Rapamycin and other mTOR kinase inhibitors have been widely used to induce autophagy, 
including under nutrient-rich conditions, in order to study the impact of mTORC1 inhibition 
on pathways such as autophagy. Reducing mTOR activity increases lifespan (Finkel, 2015; 
Weichhart, 2018) and, conversely, mTOR signaling is upregulated in AD brain (Bockaert 
and Marin, 2015; Sun et al., 2014). Specifically, phosphorylated mTOR and its downstream 
targets, including p70S6 kinase and ribosomal protein S6, have been reported to be 
increased in AD (Pei et al., 2008). Moreover, direct interaction between raptor (a subunit 
of mTORC1) and ULK1 can be detected under nutrient-rich conditions (chapter 1, Figure 
1-8). In addition, AMPK phosphorylation of raptor on two well-conserved serine residues 
inhibits mTORC1 and cell cycle arrest induced by energy stress (Gwinn et al., 2008). 
Notably, rapamycin-mediated induction of autophagy has also been shown to ameliorate 
Aβ and tau pathology in the brains of 3xTg-AD mice (Caccamo et al., 2010a). 
 
Therefore, the state of mTORC1 activation was investigated in the three CHO cell lines, 
with the aim of understanding the molecular mechanism that leads to the apparent deficit 
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in autophagy induced by Tau35 expression. mTORC1 activity was measured by probing 
western blots of CHO-FL, CHO-Tau35 and CHO cell lysates with antibodies to total and 
phosphorylated mTOR, S6 and raptor. Each CHO cell line was either untreated or exposed 
to rapamycin (1 μM, 6 h) to induce autophagy (Figure 4-11). The basal level of 
phosphorylated/total mTOR in CHO-Tau35 cells was significantly higher than that of CHO-
FL cells (Figure 4-10A, P<0.01), although this did not reach statistical significance when 
compared to mTOR activation in CHO cells (P=0.056). There was no difference between 
phosphorylated/total mTOR in CHO-FL and CHO cells. Rapamycin significantly reduced the 
amount of phosphorylated/total mTOR in all three CHO cell lines (P<0.01 in all cases).  
Notably, after rapamycin treatment, there were no significant differences in 
phosphorylated/total mTOR between CHO-FL, CHO-Tau35 and CHO cells (P>0.05). These 
results show that in comparison to the effects of FL-tau in CHO cells, Tau35 activates 
mTOR and this difference is repressed on induction of autophagy with rapamycin. 
 
To investigate the impact of mTORC1 on autophagy activation in CHO-Tau35 cells, western 
blots of untreated and rapamycin treated (1 μM for 6 h) CHO-FL, CHO-Tau35 and CHO cells 
were probed with LC3 antibody (Figure 4-11 B). As expected, rapamycin induced a 
statistically significant increase in LC3-II in CHO-FL cells (P<0.01), CHO-Tau35 cells (P<0.05) 
and CHO cells (P<0.001) compared to untreated cells. There was a marked reduction in 
LC3-II in CHO-Tau35 cells compared to CHO-FL and CHO cells (P<0.001). These results 
indicate that, in relation to autophagosome formation, CHO-Tau35 cells are less 




Figure 4-11 Activation of mTORC1 reduces autophagosome formation in CHO Tau35 
cells: Western blots of cell lysates prepared from CHO-FL, CHO-Tau35 and untransfected 
CHO cells, either untreated or rapamycin-treated (1 μM for 6 h), and probed with 
antibodies A phospho mTOR (ser2448) and total mTOR, B LC3-I, LC3-II and β-actin (loading 
control). Molecular weights (kDa) are shown on the left. The graphs show the quantitation 
of the western blots. Values represent mean ±SEM, n=6; two-way ANOVA, *P<0.05, 
**P<0.01, ***P<0.001. 
 
To confirm the observed activation of mTORC1 in CHO-Tau35 cells, phosphorylation of the 
mTORC1 substrate, S6 ribosomal protein (Ser240/244) and raptor (Ser792) were each 
assessed on western blots of the CHO cell lysates (Figure 4-12). The amount of 
phosphorylated/total S6 was dramatically increased in CHO-Tau35 cells compared to both 
CHO-FL and CHO cells, which exhibited little to no S6 phosphorylation (P<0.05). The 
amount of phosphorylated/total raptor was markedly decreased in CHO-Tau35 cells 
compared to CHO-FL (P<0.01) and CHO cells (P<0.05), indicating a lack of repression of 
mTORC1 by raptor in CHO-Tau35 cells. There was no significant difference in 
phosphorylated/total raptor at this site between CHO-FL and CHO cells. Taken together, 
these results show that multiple components of the mTORC1 complex are activated by the 




Figure 4-12 Confirmation of mTORC1 activation in CHO-Tau35 cells: Western blots of cell 
lysates prepared from CHO-FL, CHO-Tau35 and untransfected CHO cells probed with 
antibodies A phosphorylated (Ser240/244) and total S6, B phosphorylated (Ser792) and 
total raptor. Molecular weights (kDa) are shown on the left. The graphs show the 
quantitation of the western blots. Values represent mean ± SEM, n=6; one-way ANOVA, 
*P<0.05, **P<0.01. 
 
Trehalose is a non-toxic, naturally occurring disaccharide that induces autophagy and has 
been reported to aid degradation of mutant huntingtin and α-synuclein (Sarkar et al., 
2014). Trehalose activates autophagy through an mTOR-independent pathway, without 
stimulating ERK activation (Sarkar et al., 2007a). Administration of trehalose leads to 
degradation of mutant huntingtin in Neuro 2a cells exogenously expressing GFP-Htt 
(human huntingtin) (Q74), without affecting extracellular signal-regulated kinase (ERK) 
activity.  
 
To gain further insight into the autophagic dysfunction apparent in CHO-Tau35 cells, 
trehalose was used to assess the activation of autophagy by a mechanism independent of 
 138 
mTOR. CHO-FL, CHO-Tau35 and CHO cell lysates, either untreated or treated with 
trehalose (100 mM, 24 h), were probed on western blots with antibodies to LC3, and 
phosphorylated (active) and total ERK to assess the effect of this activator on 
autophagosome formation and ERK activity in CHO cells (Figure 4-13). The results show a 
significant increase in LC3-II in CHO-FL (P<0.001), CHO-Tau35 (P<0.01) and CHO cells 
following trehalose treatment. Figure 4-13 B shows a reduction in phosphorylated/total 
ERK in CHO-Tau35 cells compared to CHO-FL (P<0.001) and CHO cells (P<0.05). However, 
there was no difference in phosphorylated/total ERK between CHO-FL and CHO cells 
(P>0.05). Overall, these results indicate that CHO-Tau35 cells are more sensitive to 
trehalose treatment compared to CHO-FL and CHO cells, indicating that they have an 
increased ability to activate autophagy via an mTOR-independent route. Furthermore, the 
basal amount of activated ERK is markedly lower in these cells and an increase in ERK 




Figure 4-13 Increased autophagy activation in CHO-Tau35 cells upon activation of an 
mTOR-independent pathway: Western blots of cell lysates prepared from CHO-FL, CHO-
Tau35 and untransfected CHO cells probed with antibodies A LC3 I, LC3 II and β-actin 
(loading control) in untreated and 100 mM trehalose (Treh) treated for 24 h, B phospho 
ERK (dually phosphorylated active forms of ERK: ERK1 and ERK2) and total ERK in 
untreated cells. Molecular weights (kDa) are shown on the left. The graphs show the 
quantitation of the western blots. Values represent mean ± SEM, n=6 for panel A and n=3 
for panel B; one-way and two-way ANOVA, *P<0.05, **P<0.01, ***P<0.001. 
 
AMPK is activated by nutrient deprivation, thereby activating ULK1-dependent autophagy 
and apoptosis (Dite et al., 2017). However, AMPK may also trigger autophagy through an 
indirect mechanism by phosphorylating raptor at several sites, including Ser792, which 
inhibits mTORC1 (see Figure 4-11). A large body of evidence suggests that AMPK 
downregulation might participate in neurodegenerative diseases such as AD, Parkinson's 
disease, Huntington's disease and ALS (Herrero-Martin et al., 2009; Liang et al., 2007). 
 
Since AMPK plays a central role in a number of key cellular processes, AMPK activity was 
assessed in CHO-Tau35 cells by measuring the amount of phosphorylation at Thr172 
relative to total AMPK. Figure 4-14 shows that there was a statistically significant reduction 
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in phosphorylated/total AMPK in CHO-Tau35 cells compared to both CHO-FL (P<0.01) and 
CHO cells (P<0.05). There was no change in the amount of phosphorylated/total AMPK 
between CHO-FL and CHO cells (P>0.05). Overall, these results indicate that there is a 
reduction in the basal activity of AMPK in CHO-Tau35 cells which may be a further reason 
behind the autophagic deficit observed in these cells. 
 
 
Figure 4-14 Reduced AMPK activity in CHO-Tau35 cells: Western blot of cell lysates 
prepared from CHO-FL, CHO-Tau35 and untransfected CHO cells probed with antibodies to 
phosphorylated (Thr172) and total AMPK. Molecular weights (kDa) are shown on the left. 
The graph shows the quantitation of the western blots. Values represent mean ± SEM, 
n=3; one-way ANOVA, *P<0.05, **P<0.01. 
 
The activity of the ULK1 complex was investigated by measuring ULK1 phosphorylation on 
western blots of CHO-Tau35 cells. Data in Figure 4-15 A reveals a pronounced elevation in 
the total amount of ULK1 relative to GAPDH, in CHO-Tau35 cells compared to both CHO-FL 
(P<0.01) and CHO cells (P<0.05), while no difference was detected between CHO-FL and 
CHO cells (p>0.05). Figure 4-15 B (left graph) shows that there is no statistically significant 
difference in the amount of phosphorylated ULK1 at Ser555 between CHO-FL, CHO-Tau35 
and CHO cells (P>0.05). Figure 4-15 B (right graph) shows that there is no significant 
difference in the amount of phosphorylated ULK1 at this site, relative to the amount of 
total ULK1 between CHO-Tau35 and CHO cells, or between CHO-FL and CHO cells. 
However, there was a significant increase in the amount of phosphorylated ULK1 at Ser555 
in CHO-FL cells compared to CHO-Tau35 cells (P<0.05). Finally, Figure 4-15 C (left graph) 
shows similar results with phosphorylated ULK1 at Ser757, as there was no statistically 
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significant difference between CHO-FL, CHO-Tau35 and CHO cells (P>0.05). Moreover 
Figure 4-15 (right graph) shows that there is no statistically significant difference in the 
amount of phosphorylated ULK1 at Ser757 relative to total ULK1, between CHO-FL, CHO-
Tau35 and CHO cells. Taken together, these data indicate that there are no differences in 
the activity of the ULK1 complex between CHO-Tau35 and CHO cells as there are no 
differences in phosphorylation levels, even though there is an increase of total ULK1 in 
CHO-Tau35 cells. However, there was a significant increase in phosphorylated ULK1 at 
Ser55 in CHO-FL compared to CHO-Tau35 cells which is elusive of increased ULK1  









Figure 4-15 Changes in the activation of the ULK1 complex in CHO-Tau35 cells: Western 
blots of cell lysates of CHO-FL, CHO-Tau35 and untransfected CHO cells probed with 
antibodies A total ULK1 and GAPDH (loading control) B phospho ULK1 (Ser555) and GAPDH 
C phospho ULK1 (Ser757) and GAPDH. Molecular weights (kDa) are shown on the left. The 
graphs show the quantitation of the western blots. Values represent mean ± SEM, n=3; 
one-way ANOVA, *P<0.05, **P<0.01. 
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4.2.6 Investigating Tau35 expression on the autophagy substrate p62  
The p62 protein is a common component of inclusion bodies found in protein aggregation 
diseases affecting the brain. Bjorkoy and colleagues (2005; 2006) found that p62 forms 
two types of bodies in the cytoplasm of cells. One is a type of inclusion bodies, known as 
sequestosomes, which are membrane-free p62-containing protein aggregates (Bjorkoy et 
al., 2005; Bjorkoy et al., 2006). The other p62 bodies are membrane-confined 
autophagosomal and lysosomal structures. Moreover, p62 is also found in nuclear bodies. 
The polyubiquitin-binding ability of the ubiquitin-associated domain is needed to form 
inclusion bodies. These ubiquitin-containing p62 bodies are degraded by autophagy 
(Bjorkoy et al., 2005). 
 
The amount of p62 was assessed in CHO-FL, CHO-Tau35 and CHO cells using confocal 
immunofluorescence microscopy. The numbers of p62-positive puncta were counted in 
each cell type and normalised to the area of each cell (Figure 4-16 A, B). A significant 
increase was found in the number of p62 puncta in CHO-Tau35 cells compared to both 
CHO-FL and CHO cells (P<0.001), whereas there was no difference in the number of p62 
puncta between CHO-FL and CHO cells. Since a previous study showed a substantial 
reduction in p62 in areas of e P301S tau transgenic mouse brain in which the number of 
neurons containing tau inclusions was significantly reduced (Schaeffer et al., 2012a), the 
colocalisation of p62 with tau was determined. Figure 4-16 C shows that although there 
was a substantial amount of colocalisation of p62 in CHO-FL and CHO-Tau35 cells, there 
was no significant difference between the two cell lines.  
 
The pattern of p62 immunolabelling suggested a differential distribution of p62 puncta in 
the three CHO cell lines. Therefore, an analysis of p62 puncta distribution was performed 
by quantifying the number of p62-positive puncta at intervals of 3μm from the perimeter 
of the nucleus, as described for LC3, above (Figure 4-17). In untransfected CHO cells, p62 
puncta are evenly distributed throughout the perinuclear and more distal regions of the 
cell. Conversely, there appears to be a significant increase of 42% (Table 4-2) in the 
clustering of the puncta towards the perinuclear region of the cell (0-3 μm from the 
nucleus) in CHO-FL cells compared to CHO cells. This increased perinuclear distribution of 
p62 puncta is also seen in the CHO-Tau35 cells, in which there is an increase of 59% in the 
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clustering of the puncta around the perinuclear region (0-3 μm) compared to CHO cells. 
The puncta distribution intensity further out in the cells (at 12, 15 and 18 μm distances) 
remained significantly higher in the CHO-Tau35 cells compared to the CHO-FL and CHO 
cells. Conversely, there were no significant differences between CHO-FL and CHO cells at 
these distances. Results summarising the percentage increase in puncta distribution are 
shown in Table 4-2. These findings indicate that expression of either FL-tau or Tau35 both 




Figure 4-16 Increased p62 in CHO-Tau35 cells: A immunofluorescence of 4% PFA fixed 
CHO-FL, CHO-Tau35 and CHO cells co-stained with p62 antibody (green) and total tau 
antibody (red). Scale bar=10 µm. B Quantification of p62 puncta number normalised to cell 
area (μm2). C Quantification of the colocalisation of p62 puncta with tau. For the 
quantification, a total of 30 cells were analysed per condition. Values represent mean 
±SEM, n=3; one-way ANOVA or Student’s t-test, **P<0.01, ***P<0.001. 
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Figure 4-17 Trend of p62 puncta distribution: Data of distribution analysis carried on p62 
immunofluorescence images. For each cell type, a total of 50 cells were counted. Values 
represent mean ± SEM, two-way ANOVA, *P<0.05, **P<0.01, ***P<0.001. Black bars: FL, 
grey bars: Tau35, white bars: CHO. 
 
Table 4-2: Summary of the p62 puncta distribution in CHO-Tau35 and CHO-FL cells  
Distance from nucleus (µm) Percentage increase in 
puncta intensity between 
CHO-Tau35 and CHO cells 
Percentage increase in 
puncta intensity between 
CHO-FL and CHO cells 
0-3 59 42 
3-6 58 41 
6-9 45 10 
9-12 53 34 
12-15 44 4 
15-18 30 -18 
18+ 27 -40 
 
 146 
4.2.7 The effect of autophagy activation on tau phosphorylation 
To investigate whether the elevation in phosphorylated tau in CHO-Tau35 cells may be due 
to the observed deficit in autophagy, CHO-FL and CHO-Tau35 cells were treated with 
rapamycin (1 μM for 6 h) and phosphorylated/total tau was assessed on western blots 
probed with PHF1 and total tau antibodies compared to untreated cells. There was a 
significant increase in PHF1 immunoreactivity in CHO-Tau35 compared to CHO-FL cells 
(Figure 4-18 A, P<0.001) and this was not affected by rapamycin treatment for 6 h. These 
results indicate that under these conditions, rapamycin does not affect the clearance of 
tau phosphorylated at the PHF1 epitope (Ser396/Ser404). 
 
Since clearance of phosphorylated tau may be delayed following activation of autophagy, 
CHO-FL and CHO-Tau35 cells were exposed to 1 μM rapamycin for an extended period of 
15 h and tau phosphorylation was assessed on western blots probed with PHF1, Tau-1, and 
total tau antibodies (Figure 4-18 B). After 15 h rapamycin treatment, there was a 
significant reduction in the amount of PHF1 tau in CHO-FL cells (P<0.01), indicating that 
phosphorylated FL-tau may be degraded by autophagy. However, the amount of tau 
phosphorylated at the PHF1 epitope was significantly increased in CHO-Tau35 cells 
following 15 h rapamycin treatment (P<0.01), indicating a failure to remove 
phosphorylated Tau35. The amount of Tau-1 (dephosphorylated tau) was also measured in 
CHO-FL and CHO-Tau35 cells with and without 1 μM rapamycin treatment for 15 h (Figure 
4-18 B). The results reveal a significant decrease in the amount of Tau-1 in untreated CHO-
Tau35 cells compared to CHO-FL cells (p<0.01), again indicating that tau phosphorylation is 
induced by Tau35 expression. Rapamycin treatment resulted in a significant increase in 
Tau-1 in CHO-FL cells compared to their untreated counterparts (P<0.01), demonstrating 
that, similar to PHF-1, phosphorylation of FL-tau at the Tau-1 epitope is reduced by the 
induction of autophagy. In contrast, in CHO-Tau35 cells, although there was a modest 
reduction in Tau-1 immunoreactivity, suggesting increased tau phosphorylation, this was 
not significantly different from untreated CHO-Tau35 cells. These results show the 
differential effects of rapamycin-induced autophagy activation on FL-tau and Tau35, and 
suggest that when expressed in CHO cells, Tau35 may be more resistant to both 




Figure 4-18 Changes in tau phosphorylation following autophagy activation by 
rapamycin: Western blots of cell lysates prepared from CHO-FL and CHO-Tau35 cells 
probed with antibodies A PHF-1 (Ser396/404) and total tau (loading control) in untreated 
and 1 μM rapamycin (Rapa) treated for 6 h. B PHF-1 (Ser396/404), Tau-1 (Ser195, 198, 
199, and 202) and total tau in untreated and 1 μM rapamycin treated for 15 h. Molecular 
weights (kDa) are shown on the left of the blots. The graphs show the quantitation of the 
western blots. Values represent mean ± SEM, n=3; two-way ANOVA, *P<0.05, **P<0.01, 
***P<0.001. 
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4.2.8 Rescue of autophagy by inhibiting GSK3β 
GSK3 activity has been directly linked with impairments in the autophagy pathway and the 
development of tauopathies. For example, GSK3 inhibition reduces Aβ through the 
activation of the lysosomal/autophagy pathway, which increases the degradation of APP 
and its carboxy-terminal fragment (Parr et al., 2012b). 
 
To investigate the effect of GSK3 inhibition on autophagy activation, CHO-FL, CHO-Tau35 
and CHO cells were treated with the GSK3 inhibitor AR-A014418 (100 nM for 16 h). 
Western blots of treated and untreated cells were probed with antibodies against 
phosphorylated (Ser21/9, inactive) and total GSK3α/β (Figure 4-19 A). Under basal 
conditions, CHO-Tau35 cells showed a significant decrease in phosphorylated GSK3β 
compared to CHO-FL and CHO cells (P<0.05), indicating GSK3 activation, whereas there 
was no significant difference in phosphorylated/total GSK3β between CHO-FL and CHO 
cells. Following GSK3 inhibition with AR-A014418, there were significant increases in 
phosphorylated/total GSK3β in all of the three cell lines compared to their controls, 
indicating successful inhibition of GSK3β. In addition, there were no significant changes in 
phosphorylated GSK3β between CHO-FL, CHO-Tau35 and CHO cells following AR-A014418 
treatment. These results demonstrate that, unlike the situation in CHO-FL cells, GSK3β is 
more active in CHO-Tau35 cells, implicating this kinase as a candidate for the increased tau 
phosphorylation observed following Tau35 expression. Additionally, this could explain the 
deficit in basal autophagy observed in CHO-Tau35 cells.  
 
In parallel, western blots of untreated and AR-A014418-treated CHO-FL, CHO-Tau35 and 
CHO cells were probed with an antibody to LC3 to determine the effect of GSK3 on 
autophagy activation (Figure 4-19 B). Upon GSK3 inhibition, there were no significant 
changes in LC3-II between CHO-FL, CHO-Tau35 and CHO cells. Taken together, these 
results reveal that the inhibition of activated GSK3β rescues the initial deficit in autophagy 
seen in CHO-Tau35 cells. Notably, these results differ from the previous observations with 
HBSS and bafilomycin (Figure 4-8 and Figure 4-9, respectively), in which LC3-II remained 
significantly lower in CHO-Tau35 cells following activation of autophagy, indicating that 
those treatments were not able to rescue the basal autophagic deficits, while GSK3 




Figure 4-19 GSK3β inhibition rescues autophagy deficit in CHO-Tau35 cells: Western blots 
of cell lysates prepared from CHO-FL, CHO-Tau35 and untransfected CHO cells probed with 
antibodies A phosphorylated GSK3 (inactive GSK3α/β phosphorylated at Ser21/Ser9) and 
total GSK3 (loading control) in untreated and 100 nM AR-A014418 treated for 16 h. B LC3-
I, LC3-II and β-actin (loading control) in untreated and 100 nM AR-A014418 treated for 16 
h. Molecular weights (kDa) are shown on the left. The graphs show the quantitation of the 




4.3 Summary and discussion 
The overall aims of this chapter were to determine the effect of Tau35 expression on (1) 
cell viability and (2) early autophagy activation, autophagosome formation and 
maturation. To address these aims, experiments were carried out on CHO cells stably 
expressing Tau35 or FL-tau to distinguish the effects of FL-tau expression from those of 
Tau35. 
 
The main findings of this chapter include: 
• No differences in cell viability between CHO-FL, CHO-Tau35, and CHO cells. 
• Increased resistance to DTT in CHO-Tau35 cells compared to both CHO-FL and CHO 
cells. 
• Increased resistance to extended thapsigargin exposure in both CHO-FL and CHO-
Tau35 cells compared to CHO cells. 
• A reduction in the early autophagy marker beclin-1 in CHO-Tau35 cells compared 
to CHO-FL and CHO cells. No changes in Atg proteins in the three CHO cell lines. 
• Decreased LC3-II in CHO-Tau35 cells compared to CHO-FL and CHO cells under 
basal conditions, nutrient starvation and after induction of autophagic flux. 
Increased activity of mTORC1 in CHO-Tau35 cells. 
• Increased LC3-II in CHO-Tau35 cells compared to CHO-FL and CHO cells following 
autophagy induction via an mTOR-independent route. 
• Reduced ERK and AMPK activity in CHO-Tau35 cells compared to CHO-FL and CHO 
cells. No changes in phosphorylated ULK1, but an increased amount of total ULK1 
in CHO-Tau35 cells compared to CHO-FL and CHO cells. 
• Increased p62 in CHO-Tau35 cells compared to CHO-FL and CHO cells. No 
difference in p62/total tau colocalisation between CHO-FL and CHO-Tau35 cells. 
• Autophagy activation enhanced removal of phosphorylated tau in CHO-FL cells but 
not in CHO-Tau35 cells. 
• Inhibition of GSK3α/β rescues the autophagy deficit in CHO-Tau35 cells. 
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4.3.1 The effect of Tau35 expression on cell viability 
Neurodegeneration in the tauopathies is characterised by the accumulation of highly 
phosphorylated tau as) NFTs, and other tau-positive lesions, that are a key 
neuropathological hallmark of AD and related tauopathies (Nelson et al., 2012). Although 
the mechanisms that underlie neurodegeneration remain elusive, the ultimate outcome is 
neuronal loss. In AD for example, the build-up of toxic stimuli, such as β-amyloid, causes 
cell death through the up-regulation of apoptotic markers (Friedlander, 2003). However, 
multiple studies report that apoptosis accounts for only a small proportion of neurons lost 
in AD and other tauopathies. A study using HEK293 cells demonstrated that cells 
overexpressing tau exhibit marked resistance to apoptosis induced by various apoptotic 
stimuli, and correlated with an increase in tau phosphorylation and elevated GSK3 
activation (Li et al., 2007). Furthermore, in the same study, neuroblastoma cells 
harbouring highly phosphorylated tau showed an inverse staining pattern of PHF-1 to 
activated caspase-3, which is involved in the execution phase of apoptosis (Li et al., 2007). 
These findings may explain at least in part why CHO-Tau35 cells are able to bypass cell 
death, as these cells exhibit increasing amounts of phosphorylated tau as well as increased 
GSK3 activity. 
 
In order to further validate this finding, CHO-FL, CHO-Tau35 and CHO cells were treated 
with DTT and thapsigargin to induce the UPR and cell viability was assessed. After DTT 
treatment, there was a marked increase in cell viability and/or sensitivity to DTT in CHO-
Tau35 compared to CHO-FL and CHO cells. Due to the enhanced activation of the UPR in 
these cells, the increase in cell viability under these conditions is justified, as prolonged 
activation of PERK and increased CHOP can lead to the activation of potentially protective 
factors such as sXBP1, thereby promoting cell survival (Ron and Walter, 2007). On the 
other hand, cells behaved differently in response to thapsigargin treatment, where 6 hours 
of treatment at a concentration of 1 µM (which was sufficient to activate the UPR) led to 
no differences in cell viability between the three cell lines. However prolonged exposure to 
the drug led to a significant reduction in cell death in CHO-FL and CHO-Tau35 cells 
compared to CHO cells. The changes in response to both treatments can be explained by 
the differences in the mechanism of action between DTT and thapsigargin. While DTT 
disrupts protein disulfide bonding, thapsigargin inhibits the ER Ca2-dependent ATPase. 
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This may therefore imply that upon treatment with DTT, CHO-Tau35 cells are increasingly 
sensitive to DTT compared to CHO-FL and CHO cells. Conversely, prolonged treatment with 
thapsigargin renders CHO-Tau35 and CHO-FL more sensitive in comparison to CHO cells. 
4.3.2 Regulation of early autophagy and autophagosome formation/maturation 
The overt reduction in beclin-1 in CHO-Tau35 cells compared to CHO-FL and CHO cells is 
indicative of early autophagic dysfunction in these cells. These findings are corroborated 
by work carried out by Pickford et al. (2008), who showed that heterozygous deletion of 
the beclin-1 gene in mice decreased neuronal autophagy and caused a disruption in 
lysosomes, which led to a severe neurodegeneration phenotype. Furthermore, levels of 
beclin-1 were reportedly decreased in affected brain regions of patients with AD (Pickford 
et al., 2008b). 
 
Beclin-1 complexes with class III PI-3 kinases, notably Vps34 during autophagy. Additional 
regulatory proteins couple with Vps34 and beclin-1 to either promote autophagy, such as 
UVRAG, BIF-1, Atg14L and Ambra (Liang et al., 2008; Young et al., 2009), or to inhibit 
autophagy, such as Bcl-2 (Zhong et al., 2009). The interaction of beclin-1 with Bcl-2 
disrupts the interaction of beclin-1 with Vps34 (Patingre et al, 2005]. Thus, beclin-1 activity 
in autophagy is inhibited by interaction with Bcl-2 (and Bcl-XL) at the ER (Maiuri et al., 
2007). This interaction is disrupted by JNK1-mediated phosphorylation of Bcl-2 in response 
to starvation-induced signaling (Maiuri et al., 2007). Therefore, due to reduced beclin-1 in 
CHO-Tau35 cells, it is possible that less beclin-1 is able to interact with proteins such as 
Vps34, thereby hindering activation of autophagy (chapter 1, Figure 1-7). Concurrently, 
reduced beclin-1 could also result in a decreased interaction with Bcl-2, which could 
further explain why differences in cell viability were not observed upon Tau35 expression. 
However, more experimental work is required to understand if these are viable 
hypotheses.  
 
No changes in the amounts of Atg5, Atg7 and Atg13 were found in CHO-FL, CHO-Tau35 
and CHO cells. These three proteins have vital functions in the autophagy initiation process 
as outlined earlier in Chapter 1 (p55). However, Atg5-Atg12 conjugation is not always 
dependent on autophagy activation because, once the autophagosome is formed, these 
proteins together with Atg16L rapidly dissociate from the autophagosomal membrane and 
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their low abundance makes them difficult to detect, rendering them poor markers of 
autophagy (Barth et al., 2010). Atg7 facilitates the activation of Atg12 prior to its 
conjugation with Atg5. However, the lack of changes seen in Atg7 can be disregarded in 
this scenario by the fact that there are overt reductions in the basal levels of LC3 (which 
occurs downstream of Atg7 activation) in CHO-Tau35 cells.  
 
The decreased amount of LC3 observed is a robust marker of reduced autophagosome 
formation in CHO-Tau35 cells. This result is in contrast to the increase in LC3 detected in 
CHO-FL cells, indicating increased autophagosome formation in cells harbouring FL-tau. In 
other studies in this laboratory, CHO-Tau35 cells have been shown to have a reduced 
microtubule binding ability and a compromised cytoskeleton compared to CHO-FL cells 
(Guo et al., 2019). Since maximal autophagosome formation and efficient autophagosome 
motility require an intact microtubule network, it is plausible that these findings are inter-
related (Kochl et al., 2006). For instance, upon amino acid starvation, disassembling 
microtubules with high doses of nocodazole prevents autophagosome formation (Geeraert 
et al., 2010). This could explain why CHO-Tau35 cells are less sensitive to HBSS-mediated 
starvation compared to CHO-FL and CHO cells; due to the disruption in their microtubule 
network as well as reductions in acetylated tubulin. The prominent cytoskeletal changes 
previously detected in CHO-Tau35 cells could also explain the significant reduction in cell 
size that is also observed herein. Furthermore, the stimulation of autophagic flux with 
bafilomycin illustrated the marked reduction in LC3-II in CHO-Tau35 cells compared to 
CHO-FL and CHO cells. Overall, these findings indicate that CHO-Tau35 cells have a 
reduced capacity to produce autophagosomes and support the view that Tau35 expression 
induces a deficit in autophagy. 
 
The profound increases seen in markers of mTORC1 activity in CHO-Tau35 cells could 
contribute to the deficits observed in beclin-1 and LC3-II, as the mTORC1 complex acts as 
an inhibitor of autophagy. Enhanced mTORC1 activity could also account for the increase 
in phosphorylated tau noted in CHO-Tau35 cells, which is corroborated by previous 
findings showing that mTOR is able to regulate tau phosphorylation and degradation in 
3xTg-AD mice. This effect is ameliorated by rapamycin, which also attenuates age-
dependent cognitive decline in wild-type mice (Caccamo et al., 2010a). Treating P301S tau 
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transgenic mice with rapamycin also reduces tau phosphorylation at the AT180 and AT270 
epitopes, as well as the associated behavioural deficits (Caccamo et al., 2013a). The fact 
that CHO-Tau35 cells exhibit significantly reduced LC3-II following rapamycin treatment 
indicates that these cells are less responsive to autophagy activation. Consequently, this 
reduced sensitivity could explain why tau phosphorylation at the PHF-1 and Tau-1 epitopes 
is not reduced by extended rapamycin treatment, which contrasts with the effects of 
autophagy activation in CHO-FL cells.  
 
In addition to raptor being a component of the mTORC1 complex, it is also a substrate of 
AMPK. Phosphorylation of raptor by AMPK is required for suppression of mTORC1 activity 
induced by energetic stress (Howell et al., 2017). Moreover, raptor phosphorylation is 
necessary for the full engagement of an AMPK-mediated metabolic checkpoint (Gwinn et 
al., 2008). Therefore, the marked decrease in AMPK phosphorylation in CHO-Tau35 cells 
directly correlates with the observed reduction in raptor phosphorylation. AMPK 
additionally activates ULK1 by a coordinated cascade (Kim et al., 2011). In this chapter, the 
amounts of total ULK1 and ULK1 phosphorylated at Ser555 and Ser757 were measured in 
CHO-FL, CHO-Tau35 and CHO cells. No changes were detected at either of these two 
phosphorylation sites between CHO-Tau35 and CHO cells, however there was a modest 
increase in the amount of phosphorylated ULK1 at ser555 relative to total ULK1 in CHO-FL 
cells compared to CHO-Tau35 cells which indicates increased ULK1 activation in CHO-FL 
cells which may further contribute to the increased amounts of LC3 in these cells. 
Moreover, a substantial increase in the amount of total ULK1 in CHO-Tau35 cells compared 
to CHO-FL and CHO cells. Multiple other phosphorylation sites of the ULK1 complex are 
regulated by either mTORC1 or AMPK. For example, AMPK phosphorylates ULK1 at Ser317 
and Ser777. Therefore, the total increase in ULK1 in CHO-Tau35 cells could be due to 
changes in phosphorylation at these sites or other sites. However, further work screening 
numerous phosphorylation sites is required to identify changes in the complex that result 
in early autophagy impairments. 
 
The reduction in active ERK1/2 in CHO-Tau35 cells could also help to explain the decreased 
basal levels of LC3-II in these cells, because activation of ERK is reported to be a necessary 
step in the mTOR-independent route of autophagy activation (Wei et al., 2015). Notably 
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this reduction in active ERK1/2 rules out the likelihood of ERK1/2 activity being responsible 
for increased tau phosphorylation in CHO-Tau35 cells Phosphorylation (activation) of 
ERK1/2 plays an important role in the degradation of autophagy cargo, including p62 and 
mutant huntingtin protein aggregates (Wei et al., 2015). Therefore, the reduced ERK1/2 
activity could potentially contribute to the build-up of both phosphorylated tau and p62 in 
CHO-Tau35 cells. However, trehalose treatment of Neuro 2a and HeLa cells showed no 
effect on the expression or phosphorylation of ERK1/2 (Wei et al, 2015). Trehalose 
treatment led to a significant increase in the amount of LC3-II in CHO-Tau35 cells 
compared to CHO-FL and CHO cells, indicating enhanced sensitivity of CHO-Tau35 cells to 
trehalose. These findings are consistent with a study showing that trehalose 
administration reduces disease burden in the P301S mouse model of tauopathy (Schaeffer 
et al., 2012). Additionally, trehalose was able to both stimulate autophagy, as assessed by 
increased LC3-II formation, and reduce sarkosyl-insoluble, disease-associated tau in the 
brains of P301S tau transgenic mice (Schaeffer et al., 2012a). 
 
In addition to interacting with ERK, p62 also impinges on mTORC1 activity by interacting 
directly with raptor, thereby facilitating mTORC1 activation in response to the stimulation 
of pathway activation by amino acids (Sarkar, 2013). In NIH 3T3 cells lacking p62, 
autophagy is upregulated, which is similar to the upregulation of autophagy that 
accompanies decreased mTORC1 activity (Duran et al., 2011). Therefore, the increase in 
the number of p62 puncta observed in CHO-Tau35 cells further supports the view that 
Tau35 expression results in decreased basal autophagy and increased mTORC1 activity in 
this cell line. 
 
In HeLa cells, p62 puncta were mainly found in the cytoplasm, with much less staining in 
the nuclei. Moreover, it was noted that nuclear p62 had a more speckled appearance and 
a minority of cells (∼0.5%) displayed nuclear accumulation of p62 (Bjorkoy et al., 2005). 
This pattern of p62 staining has been observed in several other cell lines, including 
HEK293, MDCK II, HT1080, TERT fibroblasts, and NIH3T3 fibroblasts (Bjorkoy et al., 2005). 
These observations might explain the differences in the distribution of p62 puncta 
intensity in CHO-FL, CHO-Tau35 and CHO cells, as the more prominent perinuclear p62 
staining in the CHO-Tau35 cells compared to CHO-FL and CHO cells could indicate an 
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abnormality in p62 degradation in these cells. Furthermore, since p62 is degraded by 
autophagy, the perinuclear puncta in CHO-Tau35 cells may not be able to be degraded 
efficiently because autophagosomes may accumulate in the cytosol. In contrast, the 
distribution pattern of LC3 puncta exhibited a similar pattern in CHO-FL, CHO-Tau35 and 
CHO cells indicating that Tau35 did not induce any overt abnormality in the distribution of 
autophagosomes. 
 
Since increased colocalisation of p62 with tau inclusions has been shown in P301S tau 
transgenic mice (Schaeffer et al., 2012a), the colocalisation of p62 and tau was examined 
in the CHO cell lines. There was no change in the colocalisation of p62 and tau in CHO-
Tau35 cells when compared to CHO-FL cells. However, the study in P301S tau mice showed 
similar amounts of p62 in transgenic mice and wild-type controls, indicating that p62 
synthesis and basal autophagy were not affected by P301S tau expression in the transgenic 
mice. In contrast, the CHO cell models reported here exhibited significant differences in 
the amount of p62, suggesting that the increased p62 in CHO-Tau35 cells could potentially 
impact on its colocalisation with tau.  
 
Inhibition of GSK3 activity reduces tau phosphorylation, enhances binding of tau to 
microtubules, and promotes microtubule assembly (Hanger et al., 2009a). In a study using 
Tg601 mice (transgenic mice expressing wild-type human tau), the GSK3 inhibitor AR-
A014418 decreased p62 levels (Kambe et al, 2011). AR-A014418 also reduced the activity 
of GSK3β in CHO-Tau35 cells to a similar level as that observed in CHO-FL and CHO cells. 
Notably, GSK3 inhibition rescued the basal deficit in LC3-II that was observed in the CHO-
Tau35 cells, which differed from the results obtained following HBSS and bafilomycin 
treatments. 
 
Taken together, these results demonstrate that CHO-Tau35 cells exhibit a significant deficit 
in early autophagy as well as in markers of autophagosomes, that could not be rescued by 
amino acid starvation. It seems likely that these Tau35-induced changes may be mediated 
through increased activity of mTORC1 (possibly in combination with reduced activity of 
ERK and AMPK), activation of GSK3, and increased p62. Activation of autophagy with 
either trehalose or AR-A014418 rescued the basal reduction in LC3-II in CHO-Tau35 cells, 
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whereas rapamycin failed to do so. Overall, these findings indicate that CHO-Tau35 cells 
are more responsive to autophagy induction that does not directly target mTORC1 and 




Chapter 5 The effect of Tau35 expression on lysosomal biogenesis and 
functionality 
5.1 Introduction 
Autophagy is essential for neuronal survival and, in most disease states, is considered to 
be neuroprotective as it may be induced to alleviate cellular stress, such as nutrient 
deprivation and protein aggregation (Nixon and Yang, 2012). Initial studies suggested that 
the rate of autophagy in neurons is low (Nixon and Yang, 2012). However, more recent 
studies have indicated that neuronal autophagy is constitutively active and efficient in 
clearing autophagosomal cargoes (Boland et al., 2008a). In neurons, autophagic clearance 
depends on optimally functioning lysosomal proteolysis to maintain the retrograde 
delivery of autophagosomes to lysosomes in the cell body (Lee et al., 2010b). 
 
The increase in mTORC1 activation, and the deficits in early autophagy and 
autophagosome formation seen in CHO-Tau35 cells suggested the possibility of differences 
in late stages of autophagy involving the lysosome. Degradation of previously sequestered 
cargo (Chapter 4) only occurs once autophagosomes fuse with either endosomes or 
lysosomes (Wong and Cuervo, 2010). Lysosomal dysfunction triggers the development of 
characteristic features of the aged human brain including the accumulation of Aβ and 
NFTs. Moreover, a recent study in BE(2)-M17D neuroblastoma cells inducibly expressing 
human tau, showed that the autophagic-lysosomal, as well as endosomal systems play a 
role in tau clearance, whereas dysfunction of these systems results in the formation of 
insoluble tau aggregates in lysosomes (Hamano et al., 2008b). 
 
The production of lysosomes is closely regulated by TFEB through coordinated expression 
of autophagy and lysosomal target genes including lysosomal hydrolases, lysosome 
membrane proteins, and components of the V-ATPase complex that participate in 
lysosomal acidification (Settembre et al., 2011). Thus, TFEB positively regulates genes that 
are key to cellular degradative pathways. TFEB has been identified as a major player in 
coordinating autophagy through positively regulating autophagosome formation and 
autophagosome–lysosome fusion (Settembre et al., 2011). In addition, TFEB enhances 
protein clearance through lysosomal exocytosis, mediated by the lysosomal Ca2+ channel 
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MCOLN1 (Medina et al., 2011). Multiple mouse models of AD have demonstrated the 
beneficial effects mediated by TFEB, in relation to both Aβ and tau pathology (Parr et al., 
2012b; Xiao et al., 2014b; Xiao et al., 2015b). With respect to tau, enhancing the activity of 
the autophagy lysosomal pathway through exogenous TFEB expression in the brain, 
dramatically reduces tau pathology, neurodegeneration, and behavioural deficits in the 
rTg4510 mouse model of tauopathy (Polito et al., 2014). The proposed mechanism of 
action was through a TFEB–PTEN–Akt–mTOR–TFEB regulatory feedback loop, in which 
TFEB induces the autophagy lysosomal pathway through upregulation of PTEN and 
inhibition of Akt and mTOR, which further activates TFEB (Polito et al., 2014). 
 
Starvation activates autophagy and once this occurs, cellular lipids stored as triglycerides 
in lipid droplets are hydrolysed into fatty acids for energy (Lee et al., 2010b). Degradation 
of lipids and previously sequestered cargo, such as proteins and organelles is undertaken 
by lysosomes. The enzymatic degradation that occurs in lysosomes is highly dependent on 
them maintaining an acidic pH. Impaired lysosomal activity has been noted in hereditary 
lysosomal storage disorders, and recent studies have demonstrated a link between 
lysosomal dysfunction and neurodegenerative diseases such as AD and PD. (Boya, 2012). 
Abnormally elevated lysosomal pH and disruption of lysosomal proteolysis are major 
contributors to autophagy failure and its pathological consequences in AD (Nixon, 2013). 
 
The main class of lysosomal proteases are the cathepsins, which are essential for 
lysosomes to perform their degradative function effectively (Guo et al., 2017). Several 
different cathepsins exist (Chapter 1) and cathepsin D in particular, is associated with the 
development of neurodegeneration, including processing of APP, tau and apolipoprotein E 
(Fernandez-Montoya and Perez, 2015; Khurana et al., 2010). Studies in transgenic mice 
expressing human tau with three FTDP-17 missense mutations (TauVLW mice), showed 
increased cathepsin D and partial colocalization of cathepsin D with human mutant tau in 
the hippocampi of these mice (region where human mutant tau accumulates). Other work 
showed that cathepsin D is upregulated with age in a Drosophila model of AD and related 
tauopathies (expressing the human tau mutant R406W). Genetic analysis in this study 
showed that cathepsin D plays a neuroprotective role because genetic ablation of 
cathepsin D markedly potentiates tau-induced neurotoxicity, as well as in the nervous 
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tissue of transgenic Drosophila (Fernandez-Montoya and Perez, 2015; Khurana et al., 
2010). 
 
This chapter describes the influence of Tau35 expression on the biogenesis and function of 
lysosomes.  
5.2 Results 
5.2.1 Effect of Tau35 expression on lysosome biogenesis 
To begin to understand the effect of Tau35 expression on lysosome biogenesis, CHO-FL, 
CHO-Tau35 and CHO cells were labelled with an antibody recognising LAMP2 (a lysosomal 
membrane marker) to determine the lysosome load. 
  
There was a pronounced reduction in the number of LAMP2 puncta (lysosomes) per cell, 
standardised to cell area (μm2) in CHO-Tau35 cells compared to both CHO-FL and CHO cells 
(Figure 5-1 A and B, P<0.01 and P<0.05, respectively). There was no significant difference 
in the number of LAMP2 puncta between CHO-FL and CHO cells. Qualitative observations 
show an evident difference in the distribution of LAMP2 puncta between CHO-Tau35 cells, 
and CHO-FL and CHO cells. In CHO-FL and CHO cells, puncta appear to be evenly 
distributed across the cytoplasm, while in CHO-Tau35 cells, puncta are more apparent in 
the perinuclear region (Figure 5-1 A). The area of individual LAMP2 puncta was then 
quantified in each cell type (Figure 5-1 C). There were no significant differences between 
the size of the LAMP2 puncta in CHO-FL and CHO cells (P>0.05), or between CHO-Tau35 
and CHO cells, although in the latter case, the mean size appeared to be modestly reduced 
(P=0.065). There was a significant increase of 42% in the area of individual  LAMP2 puncta 
in CHO-FL cells compared to CHO-Tau35 (P<0.001). The circularity of the individual LAMP2 
puncta (corresponding to lysosomes) was measured and no significant differences were 
found between CH-FL, CHO-Tau35 and CHO cells (P>0.05) Figure 5-1 D), indicating that the 
morphology of lysosomes is not affected by expression of either Tau35 or FL-Tau. These 
results show that expression of Tau35 leads to a reduction in the number of lysosomes and 
that FL-tau increases the area of individual lysosomes. These findings suggest that these 
two forms of tau have differing effects on lysosomal degradation in CHO cells and that 
Tau35 might impair the biogenesis of lysosomes. 
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Figure 5-1 Reduction in the number of lysosomes and the area occupied by individual 
lysosomes in CHO-Tau35 cells: A Immunofluorescence of PFA-fixed CHO-FL, CHO-Tau35 
and CHO cells labelled with LAMP2 antibody (green) and Hoescht 33342 (blue), scale 
bar=10 µm. B Quantification of the number of LAMP2 puncta/cell/µm2. C Quantification of 
puncta area (µm2). D Quantification of puncta circularity (scale of 0-1 where 1 indicates a 
full circle). For the quantification, a total of 30 cells were analysed per condition. Values 




Due to the modest reduction in the number of LAMP2 puncta in CHO-Tau35 cells, the 
nuclear/cytoplasmic localisation of TFEB, which regulates lysosomal biogenesis was 
examined by immunofluorescence in the three cell lines. There was a statistically 
significant decrease of 26% in the nuclear localisation of TFEB in CHO-Tau35 cells 
compared to that in CHO cells (Figure 5-2 A and B, P<0.01). Furthermore, compared to 
CHO-FL cells, the CHO-Tau35 cells exhibited an 18%reduction in nuclear TFEB (P<0.05). 
There was no statistically significant difference in the number of CHO-FL and CHO cells 
harbouring nuclear TFEB (P>0.05). Taken together, these results indicate a substantial 
reduction in nuclear TFEB in CHO-Tau35 cells and hence the likelihood of an elevated 
amount of TFEB retained in the cytoplasm due to Tau35 expression compared to that in 
CHO-FL and CHO cells. This finding could contribute to the previously observed increase in 
mTORC1 activity (Chapter 4) as well as the reduced number of lysosomes (Figure 5-1) 





Figure 5-2 Reduced nuclear translocation of TFEB in CHO-Tau35 cells: A 
immunofluorescence of PFA-fixed CHO-FL, CHO-Tau35 and CHO cells expressing EGFP-
TFEB (green) and labelled with Hoescht 33342 (blue), scale bar=10 µm. B Quantification of 
the percentage of cells with nuclear TFEB. For the quantification, a total of 30 cells were 




Next, the amount of importin α7 was measured in different cell fractions of CHO-FL, CHO-
Tau35 and CHO cells to determine its subcellular localisation. There was no significant 
difference in the amounts of importin α7 relative to GAPDH, in the total cell lysates of 
CHO-FL, CHO-Tau35 and CHO cells (Figure 5-3 A, P>0.05). Similarly, there were no 
significant changes in importin α7 relative to GAPDH, in the cytoplasmic fractions of the 
three cell types (Figure 5-3 B, P>0.05). In contrast, there were marked decreases of 66% 
and 63%, respectively in the amount of importin α7 relative to histone H3, in the nuclear 
fraction of CHO-Tau35 cells compared to both CHO-FL and CHO cells (Figure 5-3 C, P<0.05). 
Notably, expression of FL-tau did not affect the amount of nuclear importin α7 compared 
to CHO cells (Figure 5-3 C, P>0.05). 
 
Taken together, these results illustrate that Tau35 selectively reduces the amount of 
importin α7 in the nucleus when expressed in CHO cells, which could explain the deficit in 















Figure 5-3 Reduced importin in the nuclear fraction of CHO-Tau35 cells: Western blots of 
CHO-FL, CHO-Tau35 and untransfected CHO cells. A Total cell lysates, B Cytosol, C Nuclei, 
probed with antibodies to importin α7, and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) or histone H3. Molecular weights (kDa) are shown on the left of the blots. The 
graphs show the quantitation of importin α7, relative to GAPDH or histone H3. Values 
represent mean ± SEM, n=3. One-way ANOVA. *P<0.05. 
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5.2.2 The effect of Tau35 expression on lysosome functionality 
The maintenance of a highly acidic (pH 4–5) environment, generated mainly by v-ATPase, 
is essential for normal functioning of lysosomes. Altered v-ATPase activity and lysosomal 
pH dysregulation have been implicated in cellular aging, longevity, and adult-onset 
neurodegenerative diseases, including PD and AD (Colacurcio and Nixon, 2016). Therefore, 
the acidity of lysosomes was measured in CHO-FL, CHO-Tau35 and CHO cells. LysoTracker 
probes are used to label acidic organelles in the cells, including lysosomes, late-stage 
endosomes and peroxisomes as they are highly selective for acidic organelles and are 
freely membrane permeant at a neutral pH (Chazotte, 2011). 
 
Qualitative observations from the raw data images of LysoTracker labelling in Figure 5-4 
illustrate that the distribution of LysoTracker puncta in CHO-FL and CHO cells is 
predominantly perinuclear. In contrast, the LysoTracker-labelled puncta in CHO-Tau35 
cells were less intense and appeared to be slightly more prominent at opposite poles of 
the CHO cells. Notably, the LysoTracker labelled puncta in CHO-FL cells appeared to be 
larger than those in CHO and CHO-Tau35 cells. These observations were confirmed in the 
quantitative analysis in which LysoTracker labelling revealed a 49% increase in the number 
of acidic structures in CHO-FL cells, compared to CHO-Tau35 and CHO cells (Figure 5-4, 
Figure 5-5, P<0.01). Although the number of Lysotracker-positive (acidic) puncta in CHO-
Tau35 cells appeared to be slightly reduced relative to CHO cells (37%), this difference was 
not statistically significant (Figure 5-5), indicating that Tau35 expression does not affect 
the number of acidic structures under basal conditions. Inhibition of V-ATPase with 
bafilomycin (200 nM for 2 h) significantly reduced the number of acidic structures in all 
three cell lines (P<0.01 for CHO-FL, and P<0.001 for CHO-Tau35 and CHO cells) (Figure 5-5), 
as expected. In CHO and CHO-Tau35 cells, bafilomycin treatment resulted in almost 
complete removal of LysoTracker-positive structures. In contrast, approximately 30% of 
the puncta remained in CHO-FL cells after bafilomycin treatment. Figure 5-5 C reveals that 
there were no significant differences between the areas of individual LysoTracker-positive 
puncta in CHO-FL and CHO cells (P>0.05), or between CHO-Tau35 and CHO cells. However, 
there was a significant increase in the area of individual LysoTracker puncta in CHO-FL cells 
compared to CHO-Tau35 cells (P<0.01). 
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In summary, these results demonstrate that under basal conditions, CHO-Tau35 cells 
exhibit a significant reduction in the number of acidic structures compared to CHO-FL cells, 
and show a slight but not significant reduction compared to that in CHO cells. This 
indicates a likely impairment in lysosome functionality induced by Tau35 expression in 
cells. The presence of an increased number of acidic puncta in CHO-FL cells following 
bafilomycin could suggest the presence of additional acidic structures in these cells, such 
as late-stage endosomes or peroxisomes, although this needs to be explored further. 
Furthermore, the reduction in the area of individual LysoTracker puncta in CHO-Tau35 cells 
compared to CHO-FL cells could indicate that full-length tau might have a propensity to 
cluster these acidic structures, and that this capacity is absent from Tau35. Overall, these 
findings demonstrate a reduction in the number of acidic structures induced by Tau35 
expression in CHO cells. Furthermore, qualitative observations demonstrate that the 
intracellular localisation of acidic structures is similar between CHO-FL and CHO cells, but 




Figure 5-4 Raw data and thresholded images of LysoTracker Deep Red stained cells: 
LysoTracker staining of PFA-fixed untreated CHO-FL, CHO-Tau35 and CHO cells. Panels on 
the left show the raw images before thresholding. Panels on the right show images after 





Figure 5-5 Reduced number of acidic structures in CHO-Tau35 cells: A LysoTracker 
staining of PFA-fixed CHO-FL, CHO-Tau35 and CHO cells, untreated and bafilomycin (Baf)-
treated (200 nM for 2 h). Scale bar=10 µm. B Quantification of LysoTracker 
puncta/cell/µm2. C Quantification of the area of LysoTracker (µm2). For the quantification, 
a total of 30 cells were analysed per condition. Values represent mean ± SEM, n=3 for each 
cell line; one-way ANOVA, **P<0.01, ***P<0.001. 
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To further explore the effect of Tau35 expression on lysosome functionality, cathepsin D 
and cathepsin L were assessed in CHO-FL, CHO-Tau35 and CHO cells using 
immunofluorescence. Cathepsin D deficiency is associated with the accumulation of Lewy 
bodies in PD, and with the appearance of amyloid plaques and NFT in AD. It is well 
established that this aspartic protease functions optimally at an acidic pH (Turk et al., 
1999). The role of cathepsin L is less well elucidated than that of cathepsin D in relation to 
neurodegeneration however, cathepsin L and B deficient mice reveal a degree of brain 
atrophy not previously seen in mice. Greatest activity is obtained close to pH 5-6 and 30-
40% of the enzyme remains activated at pH 7 (Turk et al, 1999). 
 
The number of cathepsin D puncta was quantified in each of the three cell lines. The 
results revealed a statistically significant decrease in the number of cathepsin D puncta in 
CHO-Tau35 cells compared to both CHO-FL and CHO cells (Figure 5-6A and B, P<0.001 for 
both). However, there were no differences in the number of cathepsin D puncta in CHO-FL 
and CHO cells (P>0.05), indicating that tau expression per se was not responsible for the 
reduction of puncta in Tau35-expressing cells. 
 
The mean colocalisation of LAMP2 and cathepsin D in the CHO cells exceeded 92% in all 
three cell lines, indicating an overall high degree of colocalisation of these two proteins, as 
expected from the primary association of cathepsin D with lysosomes (Figure 5-6 C). 
Comparison of the cells showed a small but significant reduction in the colocalisation of 
LAMP2 and cathepsin D puncta in CHO-Tau35 cells compared to CHO-FL and CHO cells 
(reductions of 3% and 4% in colocalisation, respectively) (P<0.05). There were no 
significant changes in LAMP2 and cathepsin D colocalisation in CHO-FL compared to CHO 
cells (P>0.05). The reduced colocalisation of cathepsin D and LAMP2 in Tau35-expressing 
cells may be related to the fact that lysosomal degradation capacity is impaired by 
expression of Tau35 as the location of this enzyme within lysosomes in pivotal for the 




Figure 5-6 Reduction in cathepsin D puncta and LAMP2/Cathepsin D colocalisation in 
CHO-Tau35 cells: A immunofluorescence of PFA-fixed CHO-FL, CHO-Tau35 and CHO cells 
labelled with LAMP2 (green) and cathepsin D (red) antibodies, and Hoescht 33342 (blue), 
scale bar=10 µm. B Quantification of number of cathepsin D puncta/cell/µm2, n=3 for each 
cell line. C Quantification of LAMP2/cathepsin D colocalisation, n=3 for each cell line. For 
the quantification, a total of 30 cells were analysed per condition. Values represent mean 
± SEM; one-way ANOVA, *P<0.05, ***P<0.001.  
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The amount of cathepsin L was determined in CHO-FL, CHO-Tau35 and CHO cells (Figure 
5-7 A and B). The results showed no differences in the number of cathepsin L puncta in any 
of the three cell lines (P>0.05). Notably, in contrast to the results obtained with cathepsin 
D, there was a significant increase in the colocalisation of LAMP2 and cathepsin L in CHO-
Tau35 cells compared to both CHO-FL (8%) and CHO cells (10%) (Figure 5-7, P<0.05 and 
P<0.01, respectively). There were no significant differences in LAMP2/cathepsin L 
colocalisation between CHO-FL and CHO cells (P>0.05). Unlike the observations made for 
LAMP2/cathepsin D colocalisation, the colocalisation of LAMP2/cathepsin L puncta was 
less in all three cell lines (67% in CHO-FL, 72% in CHO-Tau35 and 64% in CHO cells). This 
indicates that the overall colocalisation of lysosomes with cathepsin L is relatively reduced 
compared to cathepsin D in all the three cell lines. 
 
In summary, these results demonstrate a decrease in cathepsin D and a marked reduction 
in the degree of colocalisation of cathepsin D with lysosomes (LAMP2) caused by Tau35 
expression in CHO cells. Both changes could indicate a Tau35-induced impairment in 
lysosomal function. The increased colocalisation of cathepsin L with lysosomes in CHO-
Tau35 cells may be a further indicator of lysosomal dysfunction as this may correlate with 
an increased pH of the lysosomes as cathepsin L has been shown to be active at a pH of up 
to 6.5, which is substantially higher than the optimum pH activity of cathepsin D. The 
increase in cathepsin L colocalisation in CHO-Tau35 cells may also be an underlying reason 
behind the reduced cathepsin D in these cells as cathepsin L specifically degrades the 
single-chain isoform of cathepsin D (Streubel et al., 2018). Moreover the increased 
colocalisation of cathepsin L with lysosomes in CHO-Tau35 cells may be related to the 
function of this enzyme as it is responsible for degrading aggregating proteins like 
synuclein, so increased colocalisation with lysosomes might be enhanced by Tau35 




Figure 5-7 Figure 5 7 No change in Cathepsin L, but increased LAMP2/Cathepsin L 
colocalisation in CHO-Tau35 cells: A immunofluorescence of PFA-fixed CHO-FL, CHO-
Tau35 and CHO cells labelled with LAMP2 (green) and cathepsin L (red) antibodies, and 
Hoescht 33342 (blue), scale bar=10 µm. B Quantification of number of cathepsin L 
puncta/cell/µm2, n=3 for each cell line. C Quantification of LAMP2/cathepsin L 
colocalisation, n=3 for each cell line. For the quantification, a total of 30 cells were 
analysed per condition.  Values represent mean ± SEM; one-way ANOVA, *P<0.05, 
**P<0.01.  
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5.2.3 The impact of Tau35 expression on lipid clearance in CHO cells 
Lysosomes play an important role in lipid degradation and a wide range of different lipids 
including glycosphingolipids (GSLs), phospholipids and cholesterol, accumulate in cells as a 
consequence of lysosome dysfunction. Therefore, to further investigate lysosome 
fubction, CHO-FL, CHO-Tau35 and CHO cells were stained with BODIPY to fluorescently 
label intracellular neutral lipids, and the number of BODIPY-positive puncta were counted. 
The results of this analysis showed a marked, two-fold increase in the number of BODIPY 
puncta in CHO-Tau35 cells compared to CHO cells when normalised to cell area (Figure 5-8 
A and B, P<0.05). Although the number of BODIPY-positive lipid droplets in CHO-FL cells 
also appeared to be increased compared to CHO cells, this was not statistically significant. 
The area of individual BODIPY puncta was also significantly increased in CHO-Tau35 cells 
compared to that in CHO cells (Figure 5-8 C, P<0.01). Notably, the area of individual 
BODIPY puncta in CHO-FL cells was significantly increased compared to both CHO-Tau35 
and CHO cells (P<0.05 and P<0.001, respectively).  
 
Taken together, these findings demonstrate that expression of Tau35 in CHO cells leads to 
an increase both in the overall accumulation of neutral lipids and in the area occupied by 
individual lipid droplets compared to CHO cells. Expression of FL-tau did not affect the 
amount of neutral lipid puncta but their area was dramatically increased by FL-tau 
expression. This indicates that both FL-tau and Tau35 have an increased propensity to 
cause lipid clustering in CHO cells, although FL-tau has a greater propensity to result in the 




Figure 5-8 Increased lipid accumulation in CHO-Tau35 cells: A immunofluorescence of 
BODIPY stained followed by PFA-fixation of CHO-FL, CHO-Tau35 and CHO cells (green) and 
Hoescht 33342 (blue), scale bar=10 µm. B Quantification of the number of BODIPY 
puncta/cell/µm2. C Quantification of BODIPY puncta area (µm2). For the quantification, a 
total of 30 cells were analysed per condition. Values represent mean ± SEM, n=3 for each 
cell line; one-way ANOVA, *P<0.05, **P<0.01, ***P<0.001. 
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Since BODIPY labels a wide variety of intracellular lipid populations, CHO-FL, CHO-Tau35 
and CHO cells were subsequently immunolabelled with a specific lipid antibody to gain a 
more detailed understanding of which populations of lipids are altered by expression of 
Tau35 and FL-tau. Therefore, CHO-FL, CHO-Tau35 and CHO cells were immunolabelled 
with lysobisphosphatidic acid (LBPA), which is a lipid marker of late-stage endosomes. 
Visualising potential changes in LBPA is of interest because abnormalities in endosomes, 
and/or dysfunctional endosomal-lysosomal trafficking has been shown to play a pivotal 
role in neurodegenerative diseases such as AD. 
 
There was no change in the amount of LBPA puncta in CHO-Tau35 cells compared to CHO 
cells (Figure 5-9). In contrast, there was a statistically significant decrease in the number of 
LBPA puncta in CHO-FL cells compared to both CHO-Tau35 and CHO cells (P<0.001). The 
results also show no change in the area of individual LBPA puncta in CHO-Tau35 cells 
compared to CHO cells. However, the area of LBPA puncta in CHO-FL cells was significantly 
increased compared to both CHO-Tau35 and CHO cells (P<0.05 and P<0.01, respectively). 
 
Taken together these findings indicate that the number and size of LBPA puncta is 
equivalent in CHO-Tau35 and CHO cells, indicating that this marker of late-stage 
endosomes is not affected by Tau35 expression. In contrast, expression of FL-tau caused a 
significant reduction in the number of LBPA puncta, implying that tau expression either 
reduced the number of late-stage endosomes in CHO cells or led to the fusion of late-stage 
endosomes, which may explain the increase in LBPA area. The increased area of LBPA 
puncta in CHO-FL cells is consistent with the previous observations with BODIPY labelling 
in CHO-FL cells (Figure 5-8). This confirms the increased propensity for lipid clustering 





Figure 5-9 Lysophosphatidic acid in CHO-FL, CHO-Tau35 and CHO cells: A 
Immunofluorescence of PFA-fixed CHO-FL, CHO-Tau35 and CHO cells labelled with LBPA 
(green) antibody, and Hoescht 33342 (blue), scale bar=10 µm. B Quantification of the 
number of LBPA puncta/cell/µm2. C Quantification of the area of individual LBPA puncta 
(µm2). For the quantification, a total of 30 cells were analysed per condition. Values 




5.2.4 The effect of Tau35 expression on lysosome interaction with tau 
Next, the association of tau with lysosomes was assessed in CHO-FL and CHO-Tau35 cells 
by determining the degree of tau colocalisation with LAMP2 following PFA fixation. There 
is a significant increase in the colocalisation of tau and LAMP2 in CHO-Tau35 cells (64%) 
compared to CHO-FL cells (37%) (Figure 5-10, P<0.001). These results demonstrate that tau 
in CHO-Tau35 cells associates with lysosomes, which may in part, be due to the apparent 





Figure 5-10 Increased colocalisation of tau with LAMP2 in CHO-Tau35 cells: A 
Immunofluorescence of PFA-fixed CHO-FL, CHO-Tau35 and CHO cells labelled with LAMP2 
(green) and total tau (red) antibodies, and Hoescht 33342 (blue), scale bar=10 µm. B 
Quantification of LAMP2/total tau colocalisation. For the quantification, a total of 30 cells 
were analysed per condition. Values represent mean ± SEM, n=3 for each cell line; 
student’s t-test, ***P<0.001. 
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5.3 Summary and discussion 
 
The overall aim of this chapter was to determine the relative effects of expressing Tau35 
and FL-tau on lysosome biogenesis and lysosomal functionality in CHO cells. 
 
The main findings of this chapter include: 
• Reduced number of lysosomes in CHO-Tau35 cells compared to CHO-FL and CHO 
cells, and decreased area of individual lysosomes in CHO-Tau35 cells compared to 
CHO-FL cells. 
• Decreases in the nuclear translocation of TFEB and importin α7 (in the nuclear 
fraction) in CHO-Tau35 cells compared to CHO-FL and CHO cells. 
• Fewer acidic structures in CHO-Tau35 cells compared to CHO-FL and CHO cells. 
• Decrease in the number of cathepsin D puncta and cathepsin D/LAMP2 
colocalisation in CHO-Tau35 cells compared to CHO-FL and CHO cells. Conversely, 
there were no changes in the number of cathepsin L puncta in the three cell types. 
However, cathepsin L/LAMP2 colocalisation was increased in CHO-Tau35 cells 
compared to CHO-FL and CHO cells. 
• Increased number and area of individual BODIPY neutral lipid droplets in CHO-
Tau35 cells compared to CHO cells. CHO-FL cells exhibited an increase in the area 
of individual BODIPY droplets compared to both CHO-Tau35 and CHO cells. 
• Decrease in the number of LBPA puncta in CHO-FL cells compared to the other two 
cell types. LBPA puncta area was increased in CHO-FL cells compared to CHO cells, 
but similar to CHO-Tau35 cells. 
• There was an increase in LAMP2/total tau colocalisation in CHO-Tau35 cells 
compared to CHO-FL cells. 
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5.3.1 Effect of Tau35 on lysosome biogenesis 
Lysosomal biogenesis is tightly regulated by TFEB (Sardiello et al., 2009). The attenuated 
nuclear translocation of TFEB in CHO-Tau35 cells may contribute to the reduction in 
LAMP2 puncta, due to the inability of TFEB to facilitate the transcription of genes involved 
in lysosomal biogenesis. Increased retention of TFEB in the cytosol may be due to 
activation of mTOR signalling in CHO-Tau35 cells since, although phosphorylated mTOR 
was not significantly increased (P=0.055), phosphorylated ribosomal protein S6, a 
downstream target of mTOR, was increased, and raptor phosphorylation was reduced by 
Tau35 expression (Chapter 4). The findings reported here in CHO-Tau35 cells are 
supported by those of other groups investigating lysosomal abnormalities in 
neurodegenerative disease. For example, lysosomal deficiency is evident in a variety of in 
vitro and rodent models of PD and AD, such as CHO cells inducibly expressing the C-
terminal fragment of APP (APP-CTF) and APP/PS1 transgenic mice (Decressac et al., 2013; 
Dehay et al., 2010; Parr et al., 2012b; Xiao et al., 2015b). Furthermore, overexpressing 
TFEB or inducing nuclear translocation of TFEB improves PD symptoms and ameliorates α-
synuclein pathology in the in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse 
model of α-synuclein toxicity (Dehay et al., 2010). Therefore, the decreased amount of 
nuclear TFEB in CHO-Tau35 cells may further contribute to the toxic effects of Tau35. 
 
In AD, there is aberrant localisation of nuclear proteins involved in cell cycle activation 
including mislocalised cyclins and cyclin-dependent kinases, as well as components of 
mitogenic signal transduction pathways (McShea et al., 1997; Ogawa et al., 2003). For 
example, phosphorylated histone-3 has been reported to be mislocalised to the cytoplasm 
of AD neurons (Ogawa et al., 2003). The shuttling of a large number of nuclear proteins 
into the nucleus is mediated by importins (Macara, 2001). Shuttling of importin α1 
between the cytoplasm and the nucleus, and the subsequent importin α1-mediated 
cytoplasmic-nuclear transport, was demonstrated to be hindered in AD neurons compared 
to controls by immunohistochemistry (Lee et al., 2006). The overt decrease in importin α7 
observed in the nuclear fraction of CHO-Tau35 cells could therefore support the view that 
aberrant tau fragmentation could have a negative impact on nuclear-cytoplasmic 
trafficking. Furthermore, our finding may correlate with and potentially explain the 
increased cytoplasmic retention of TFEB apparent in CHO-Tau35 cells. However, it will be 
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important to examine additional components of the nuclear pore complex to validate this 
hypothesis and examine potential additional factors behind the cytoplasmic retention of 
TFEB in CHO-Tau35 cells.  
5.3.2 The effect of Tau35 on lysosome functionality 
A reduction in the number of acidic structures, including endosomes and lysosomes, 
labelled by LysoTracker in CHO-Tau35 cells compared to CHO-FL and CHO cells suggests 
compromised lysosomal functionality induced by Tau35 expression. The decline in the 
number of these acidic structures could be an underlying cause that would contribute to 
the autophagic abnormalities noted in CHO-Tau35 cells. Defective lysosomal function is 
now recognised as a primary factor in the pathogenesis of AD (Nixon and Yang, 2012; Zare-
Shahabadi et al., 2015), PD (Dehay et al., 2013), and FTLD (Gotzl et al., 2014). A study of 
PS1KO cells showed that defective lysosomal acidification is one of the main reasons for 
autophagic dysregulation under these conditions (Li et al., 2013; Wolfe et al., 2013). The 
results from that study revealed elevated lysosomal pH using ratiometric pH sensing dyes 
and decrease of LysoTracker signal, similar to the results obtained using LysoTracker in 
CHO-Tau35 cells. Moreover, lysosomal acidification defects were also demonstrated in the 
brains of PS1 hypomorphic and conditional PS1/2 knockout mice (Lee et al., 2010b). 
 
The apparent reduction in the number of cathepsin D puncta in CHO-Tau35 cells is a 
further indication of impaired lysosome function upon Tau35 expression. This is supported 
by previous findings showing that the complete loss of cathepsin D in mice results in the 
lysosomal neurodegenerative disorder, neuronal ceroid lipofuscinosis (Siintola et al., 2006; 
Steinfeld et al., 2006). Furthermore, cathepsin inhibition in mouse hippocampal slice and 
cell culture studies has previously been shown to affect tau proteolysis and solubility. 
Work by Khurana et al, using a Drosophila model of AD (UAS-tau1–421) , determined that 
removing cathepsin D substantially potentiated tau-induced neurotoxicity (Khurana et al., 
2010). Moreover, the presence of a neurotoxic C-terminally truncated tau fragment, that 
had previously been detected in AD brain is increased in the absence of cathepsin D in 
mice (Khurana et al., 2010). Therefore, the reduction in cathepsin D in CHO-Tau35 cells 
could potentially contribute to the elevation in the amount of phosphorylated tau 
observed in this cell model (Guo et al., 2019). 
 183 
 
The significant decrease in cathepsin D/LAMP2 colocalisation in CHO-Tau35 cells further 
reveals disruptions and abnormalities in the lysosomes. This observation is consistent with 
previous findings that report mislocalisation of cathepsin D in neurodegenerative disease. 
For example, cathepsin D immunoreactivity in AD brain is concentrated extracellularly 
within amyloid plaques, rather than being confined to lysosomes (Gowrishankar et al., 
2015). 
 
Although there were no changes detected in the numbers of cathepsin L puncta in CHO-FL, 
CHO-Tau35 and CHO cells, there was a significant increase in cathepsin L/LAMP2 
colocalisation in CHO-Tau35 cells compared to CHO-FL and CHO cells. As previously 
outlined, cathepsin L activity has a higher pH optimum than cathepsin D, and since there 
were less acidic structures observed in CHO-Tau35 cells, this may explain the increased 
ability of cathepsin L to associate with the lysosomes upon the expression of Tau35. The 
increase in cathepsin L/LAMP2 colocalisation could additionally explain the build-up of 
phosphorylated tau upon the expression of Tau35 as it cathepsin L has been shown to be 
involved in the cleavage of the mutant tau construct TauRDΔK280, generating a fragment 
which strongly promotes tau aggregation (Wang et al., 2009). 
 
The apparent elevation in both the number and size of BODIPY lipid droplets in CHO-Tau35 
cells is further evidence of lysosomal dysfunction caused by expression of Tau35 as lipids 
have been known to accumulate in a wide range of LSDs such as Niemann Pick type C 
(Walkley and Vanier, 2009).. Increased lipid accumulation in CHO-Tau35 cells could also be 
explained by the increased activity of GSK3β observed in these cells (Chapter 4), a 
phenomenon also observed in AD (Jazvinscak Jembrek et al., 2015).. It has been 
hypothesised that Aβ may increase tau phosphorylation by a mechanism dependent on 
GSK-3β. Consequently, there is often a correlation seen between the elevation of 
phosphorylated tau and the build-up of lipids (Jazvinscak Jembrek et al., 2015). 
 
The decreased number of LBPA puncta in CHO-FL cells suggests a reduction in late-stage 
endosomes in these cells. This reduction may be due to the elevated levels of Beclin 1 
previously detected in CHO-FL cells (Chapter 4). It was reported that a beclin-1-binding 
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autophagic tumour suppressor, UV radiation resistance-associated gene protein (UVRAG), 
interacts with the class C Vps complex of the endosomal fusion machinery. This interaction 
stimulates Rab7 GTPase activity and autophagosome maturation and fusion with late 
endosomes/lysosomes, thereby enhancing delivery and degradation of autophagic cargo. 
Furthermore, the UVRAG-class-C-Vps complex accelerates endosome–endosome fusion, 
resulting in rapid degradation of endocytic cargo (Liang et al., 2008). Therefore, the 
reduction in LBPA could potentially be due to enhanced degradation by the UVRAG 
complex. Furthermore, the findings in Chapter 4 show elevated LC3 in CHO-FL cells, 
indicating an increase in autophagosomes, which could further help to explain the 
observed decrease in LBPA in these cells. 
5.3.3 The link between lysosomes and tau 
The increased colocalisation of LAMP2 with total tau in CHO-tau35 cells relative to CHO-FL 
cells could provide a justification for the accumulation of phosphorylated tau caused by 
Tau35 expression. Monomeric tau is actively cleared through the proteasome (Brown et 
al., 2005), whereas the higher order tau oligomers and aggregates found in tauopathies, 
are preferentially degraded by the lysosome. In fact, proteasomal activity appears to be 
reduced in AD brain, and PHF-tau isolated from human AD brain was not degraded by the 
proteasome. In fact, aggregated tau was shown to inhibit the proteasome (Keck et al., 
2003; Rubinsztein, 2006). Therefore, upon Tau35 expression, highly phosphorylated tau 
would colocalise with lysosomes in an attempt to enhance tau degradation. However, due 
to the observed impairment in lysosome biogenesis, the reduced number of lysosomes 
present in CHO-Tau35 cells may lack the capacity to degrade the accumulating 
phosphorylated and aggregated tau. 
 
Taken together, the results from this chapter reveal that Tau35 expression in CHO cells 
causes a deficiency in lysosome biogenesis which may result from the reduction in nuclear 
translocation of TFEB, as well as a reduction in importin α7 and increased activity of 
mTORC1 (Chapter 4). In addition, reduced lysosome functionality is apparent due to Tau35 
expression in these cells through reduced numbers of acidic structures, cathepsin D, 
colocalisation of lysosomes with cathepsin D and enhanced lipid accumulation. Together, 
these cellular abnormalities and lack of effective lysosomal degradation, could contribute 
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Chapter 6 Discussion 
6.1 Summary of results 
The overall aims and objectives of this study were: 
• To assess changes in tau phosphorylation and UPR activation in different brain 
regions of aged Tau35 mice. 
• To investigate the effect of Tau35 expression on cell viability and autophagy 
activation using a Tau35 cell model. 
• To determine if Tau35 expression affects lysosome biogenesis and functionality in 
the cell model of Tau35.  
 
The primary findings of this thesis are summarised as follows: 
 
Tau35-expressing transgenic mouse brain exhibits region-dependent increases in tau 
phosphorylation and UPR activation 
In the Tau35 mouse model of tauopathy, expressing a C-terminal tau fragment associated 
with human tauopathy (Tau35), there were increases in tau phosphorylation that were 
brain region-dependent. The hippocampus was the most affected area in terms of tau 
phosphorylation, while the amygdala was the least affected. Furthermore, increased 
activation of the UPR was also brain region-dependent and this correlated with increased 
tau phosphorylation, with increased UPR activation observed in the hippocampus and no 
changes detected in the amygdala of Tau35 mice. 
 
Tau35 causes autophagic dysfunction without affecting viability of CHO cells 
To further elucidate the molecular mechanisms affected by Tau35 expression, a CHO cell 
model in which Tau35 is stably expressed was used to determine the effect of Tau35 
expression on cell viability and autophagic/lysosomal degradation. Tau35 did not induce 
cell death in CHO cells. Reductions in beclin-1 and LC3 indicate deficits in early 
autophagy/phagophore formation and a deficit in the number of autophagosomes, 
respectively. This induction of autophagic dysfunction by Tau35 is supported by the finding 
of increased p62 in CHO-Tau35 cells. Possible mechanisms underlying the deficits observed 
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in the autophagy pathway in CHO-Tau35 cells include increased activation of mTORC1 and 
decreased activity of AMPK. 
 
Lysosome biogenesis and functionality is impaired in CHO-Tau35 cells 
Reduced numbers of LAMP2 puncta were found in CHO-Tau35 cells, demonstrating that 
the there are fewer lysosomes in these cells. Increased cytoplasmic retention of TFEB and 
decreased importin α7 in CHO-Tau35 cells could be possible underlying reason for these 
Tau35-induced changes. Reductions in LysoTracker and cathepsin D labelling, as well as 
increased BODIPY staining in CHO-Tau35 cells support the view that Tau35 expression 
results in compromised lysosome functionality. 
 
A summary of all the changes in markers of autophagy and lysosomal degradation 
pathways is illustrated in Table 6-1. 
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Table 6-1 Summary of the changes in markers of autophagy and lysosomal degradation 
in CHO-FL and CHO-Tau35 cells 
Marker CHO-FL cells CHO-Tau35 cells 
Beclin-1 - Decreased 
Atg proteins (Atg5, Atg7 and Atg13) - - 
LC3 Increased Decreased 
Phospho mTOR (Ser2448) - - 
Phospho S6 - Increased 
Phospho raptor - Decreased 
Phospho ERK1/2 - Decreased 
Phospho AMPK (Thr172) - Decreased 
ULK1 - Increased 
Phospho ULK1 (Ser555 and Ser757) - - 
p62 - Increased 
LAMP2 (number) - Decreased 
Nuclear TFEB - Decreased 
LysoTracker (number) - Decreased 
Cathepsin D (number) - Decreased 
Cathepsin L (number) - - 
BODIPY (number) - Increased 
LBPA (number) Decreased - 
 
The table illustrates the changes in markers of autophagy and lysosomal degradation in 
CHO-FL and CHO-Tau35 cells in comparison with CHO cells. (-) indicates no change.  
  
 189 
6.2 Changes in Tau35 mouse and cell models 
In 2008, this laboratory identified a 35 kDa C-terminal tau fragment (Tau35), lacking the N-
terminus of tau but containing four microtubule-binding repeats (4R), that was readily 
detectable in PSP, CBD degeneration and 4R tau-related forms of FTLD, but was absent 
from healthy controls (Wray et al., 2008). Consequently, a Tau35-expressing mouse model 
was developed to study the effect of this fragment in vivo. Results showed that minimal 
expression of this tau fragment (<10%, relative to endogenous mouse tau) was sufficient 
to recapitulate key features of human tauopathies (Bondulich et al., 2016). Thus, Tau35 
mice exhibit progressive cognitive (associated with hippocampal-dependent learning) and 
motor deficits. Moreover, Tau35 mice exhibit Increased tau phosphorylation in the 
hippocampus, loss of synaptic protein, and reduced life span (Bondulich et al., 2016). 
Tau35 mice express a truncated species of WT human tau at a very low level making this 
model the first of its kind to date. No other mice expressing low amounts of WT human 
tau have been reported to exhibit tauopathy. These mice therefore represent a novel and 
highly relevant animal model of sporadic tauopathy. Furthermore, Tau35 accurately 
represents the spectrum of sporadic human tauopathies in the absence of significantly 
increased tau expression or the presence of any tau mutation. 
 
In this study N-terminal truncation of tau was shown to result in changes in tau 
phosphorylation in four different brain regions of 16-18 month old (aged) Tau35 mice. In a 
previous report, Bondulich et al (2016) reported increased tau phosphorylation at several 
different epitopes, but only in the hippocampus of mice aged up to 14 months (Bondulich 
et al., 2016). Therefore, the findings from the present study extend this work and 
demonstrate that Tau35 expression commences by affecting the hippocampus, but goes 
on to subsequently affect other brain regions as the mice age. This potentially indicates a 
spreading of tau pathology with increasing age, which parallels the findings in human 
tauopathy brain (Clavaguera et al., 2013; Iqbal et al., 2005). Overall, the results herein 
show that the hippocampus is the most affected brain region in Tau35 mice, followed by 
the brainstem and cerebellum, and frontal regions, with the amygdala being the least 
affected brain region. Notably, Zilka and colleagues found that the higher the expression 
level of truncated tau, the earlier the onset of tangle pathology and NFT formation (Zilka et 
al., 2006b). Therefore, considering the low-level expression of Tau35, it is not surprising 
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that increased tau phosphorylation is more prominent in older mice and spreads to brain 
regions other than the hippocampus once the mice age since this demonstrates the 
progression of disease. 
 
Tau35 mice exhibited increased activation of the UPR in the hippocampus compared to WT 
mice. This was apparent from the activation of PERK, a key component of one branch of 
the UPR, as well as increased CHOP, a pro-apoptotic executioner of the UPR, and also IRE1 
activation in the hippocampus of Tau35 mice. In contrast, activation of the PERK branch of 
the UPR was not apparent in the amygdala. Thus, these findings demonstrate that UPR 
activation is brain region-dependent in Tau35 mice and that this occurs in conjunction with 
tau phosphorylation. A large body of evidence has demonstrated a correlation between 
activation of the UPR and the development of several tauopathies, including AD and FTLD-
tau (Höglinger et al., 2011; Pereira et al., 2014). Recent reports show that disrupted tau 
phosphorylation upon UPR activation was found in P301L tau transgenic mice (Radford et 
al., 2015). Moreover, increases in BiP are present in temporal cortex and hippocampus in 
AD compared with nondemented controls (Hoozemans et al., 2009). However, the 
mechanisms underlying this disruption in tau phosphorylation have not been well 
elucidated. One proposed mechanism in relation to the UPR and AD is that UPR activation 
precedes the widespread occurrence of neurofibrillary degeneration, as the protein 
expression levels of BiP are increased at an early stage of AD pathology in the temporal 
cortex (Hoozemans et al., 2009). The results from the present study therefore, show that 
abnormal truncation of tau abolishes its physiological function, as well as exerting a toxic 
effect via activation of branches of the UPR pathway. 
 
A growing link between the UPR and autophagy has been substantiated. For example, the 
PERK–eIF2α pathway is essential for autophagy induction after unfolded or misfolded 
proteins accumulate in the ER lumen (B’chir et al., 2013). Specifically, ATF4 and CHOP were 
shown to transcriptionally regulate more than a dozen Atg genes (B’chir et al., 2013). In 
addition, it is notable that IRE1 is also implicated in the activation of autophagy (Ogata et 
al., 2006). Tumour necrosis factor (TNF) receptor-associated factor 2 (TRAF2)-dependent 
activation of IRE1 and JNK leads to Bcl-2 phosphorylation, enabling the dissociation of 
beclin-1 leading to the activation of the PI3K complex (Deegan et al., 2013). 
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 Alongside this murine model of tauopathy, a CHO cell model of Tau35 was developed to 
identify key molecular mechanisms that may be responsible for phenotypic changes in the 
mice. Initial studies on this cell line revealed that Tau35 has a reduced ability to bind to 
and stabilise microtubules and has reduced acetylated tubulin and increased activity of 
GSK3β (Guo et al., 2019). Due to the crosstalk that occurs between the UPR and autophagy 
pathways, the effect of Tau35 expression on the autophagy and lysosomal degradation 
pathway was investigated in order to examine the underlying mechanistic changes of 
these pathways in  CHO-Tau35 cells.  
 
An overt reduction in the amount of beclin-1 was apparent in CHO-Tau35 cells compared 
to CHO-FL and CHO cells, demonstrating an early impairment in the autophagy pathway. 
Several recent studies have implicated decreases in beclin-1 in the pathogenesis of AD 
(Jaeger et al., 2010; Lucin et al., 2013). Specifically, neuronal expression of beclin-1 
gradually reduces during ageing but this rate of decline is faster in AD-affected brains 
(Jaeger et al., 2010; Pickford et al., 2008a). One consequence of the depletion of beclin-1 is 
an increase in cleaved (active) capsase-3 which may subsequently lead to apoptosis (Rohn 
et al., 2011). However, no differences were found in cell death between CHO-FL, CHO-
Tau35 and CHO cells. Therefore, in CHO-Tau35 cells, the observed decrease in beclin-1 
may occur through an alternative route. It is likely that the decrease in beclin-1 is a result 
of a reduction in activated AMPK in CHO-Tau35 cells, as AMPK mediates its pro-autophagic 
effects through beclin-1 (Zhang et al., 2016). As a consequence, these observed deficits in 
CHO-Tau35 cells lead to reduced formation of autophagosomes, as indicated by a 
reduction in LC3-II. This autophagy deficit was not rescued when autophagic flux was 
induced with bafilomycin A1, indicating that CHO-Tau35 cells are less efficient than 
untransfected CHO cells in forming autophagosomes. 
 
There now appears to be a growing link between autophagic function and the tauopathies. 
Phosphorylated tau accumulation is increased in brain-specific Atg7 knockout mice 
compared to WT control mice (Inoue et al., 2012), indicating that phosphorylated tau is a 
substrate of autophagy. Consistently, phosphorylated tau colocalises with LC3 and p62 in 
post-mortem human brain from AD, PSP, and CBD, likely because both LC3 and p62 
become engulfed into autophagosomes but are not degraded by autolysosomes (Piras et 
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al., 2016b). The build-up of phosphorylated tau in CHO-Tau35 cells could therefore 
partially be accounted for by the deficits observed in the autophagy pathway. Although 
increased colocalisation between p62 and tau was not evident in CHO-Tau35 cells, there 
was a significant increase in the number of p62 puncta, which supports the concept of 
defective autophagy induced by Tau35. There was additionally a marked increase in the 
colocalisation of LAMP2 puncta with tau in CHO-Tau35 cells compared to both CHO-FL and 
CHO cells. This finding supports the observation of increasingly phosphorylated tau (as 
seen in CHO-Tau35 cells) is a substrate of autophagy. 
 
Increased mTORC1 activity was apparent in the CHO-Tau35 cell model as illustrated by 
increased phosphorylated ribosomal S6 protein, decreased phosphorylated raptor, 
although the increase in mTOR was not found to be significant (P=0.056). Enhanced mTOR 
signaling has been implicated in AD pathogenesis. Evidence from post-mortem human AD 
brains indicates that the levels of phospho-mTOR and its downstream target p70S6K, are 
increased compared to age-matched control cases, suggesting higher mTOR activity in AD 
brains (An et al., 2003; Pei and Hugon, 2008). Additional studies show that mTOR is 
implicated in tau-mediated pathogenesis in AD and related tauopathies as the mTORC1 
complex induces tau expression and promotes its GSK3β-dependent phosphorylation 
(Caccamo et al., 2013b). Therefore, it is likely that the increased activity of GSK3β noted in 
CHO-Tau35 cells and the resulting increase in tau phosphorylation, are both a 
consequence of increased mTORC1 activity. Inhibition of GSK3β activity using the specific 
inhibitor AR-A014418, ameliorated the decline in LC3-II in CHO-Tau35 cells, implicating 
both mTORC1 and GSK3β in the impairment in autophagy. On the other hand, inhibition of 
mTORC1 using rapamycin was not able to restore the deficits in LC3-II or to reverse the 
increased tau phosphorylation in CHO-Tau35 cells. Although rapamycin is considered to be 
the canonical inhibitor of mTOR, some functions that regulate cap-dependent translation 
and autophagy are resistant to inhibition by rapamycin. This may explain why rapamycin 
treatment was not able to rescue the autophagy deficit observed in CHO-Tau35 cells. 
 
There is also significant interplay between mTORC1 and TFEB. TFEB is considered as being 
the master regulator of autophagy as it influences the expression of genes encoding 
proteins of the autophagy-lysosome pathway. Furthermore, the nuclear abundance of this 
 193 
transcription factor can be altered to match cellular demand for lysosome biogenesis and 
autophagosome-lysosome function (Roczniak-Ferguson et al., 2012a). The cytoplasmic 
retention of TFEB in CHO-Tau35 cells is a possible underlying reason for the reduced 
number of lysosomes and impairment in early autophagy activation. The beneficial effect 
of TFEB has been demonstrated in multiple models of AD including N2a cells stably 
expressing APP carrying the Swedish mutation, and APP/PS1 mice (Parr et al., 2012a; Xiao 
et al., 2014a; Xiao et al., 2015a). With respect to tau, enhancing the autophagy pathway 
through exogenous TFEB expression in the brain dramatically reduces tau pathology, 
neurodegeneration, and behavioural deficits in the rTg4510 mouse model (Martini-Stoica 
et al., 2016b). Moreover, activation of TFEB by fisetin, a naturally occurring flavonol, 
increases degradation of phosphorylated tau in neurons (Polito et al., 2014). The levels of 
TFEB expression and phosphorylation status have not yet been established in CHO-Tau35 
cells so future work is required to gain further insight of the effect of Tau35 on TFEB. 
 
The decreased number of acidic structures in CHO-Tau35 cells is an indication of 
impairment in lysosome functionality. Alterations in the pH of lysosomes have been 
observed in tauopathies (Gomez-Suaga et al., 2011; Lim et al., 2001). Presenilin 1 
mutations in AD have been shown to result in failure of V-ATPase V0a1 subunit maturation 
and assembly of the V-ATPase complex, which is necessary for lysosomal acidification and 
protease activity (Lee et al., 2015; Lee et al., 2010a). Future work on understanding the 
reason behind the decrease in acidic structures in CHO-Tau35 cells is required.  
 
A vast array of evidence indicates that disruption of the proteolytic clearance of 
autophagic vesicles by lysosomes is the principal basis for the neuronal accumulation of 
autophagic vesicles in AD brain. Even when autophagy is strongly induced in primary 
cortical neurons by rapamycin, autophagosomes can rapidly mature to autolysosomes 
without a major build-up of autophagic vacuoles (Boland et al., 2008b). In contrast, the 
autophagic vacuoles that accumulate in AD brain are autolysosomes and autophagosomes 
that have been reported to be filled with undigested or partially digested substrates 
(Nixon et al., 2005b). A similar pattern of autophagic vacuole accumulation and neuritic 
dystrophy is observed when lysosomal degradation is inhibited by deleting one or more 
cathepsins (Koike et al., 2000; Koike et al., 2005), by using cysteine protease inhibitors, or 
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general lysosomal enzyme inhibitors in vivo (Boland et al., 2008b; Ivy et al., 1989; Ivy et al., 
1984). The reduction in cathepsin D puncta and the colocalisation of cathepsin D with 
LAMP2 in CHO-Tau35 cells is a further indication of impaired lysosome functionality and 
this may contribute further to the build-up of phosphorylated tau and lipids in these cells. 
 
AD has long been recognised pathologically by the presence of long-lived protein 
aggregates such as amyloid plaques and neurofibrillary tangles, that accumulate as the 
disease progresses. Oxidatively modified proteins, lipids, and DNA additionally accumulate 
in AD brain (Kamat et al., 2008). As highlighted here, work from this study provides several 
lines of evidence that indicate a substantial reduction in lysosomal functionality in CHO-
Tau35 cells. The accumulation of neutral lipids, further reinforces this finding, illustrating 
the decline in the degradative capacity of lysosomes. Lipid accumulation was initially 
identified as being a primary consequence of LSDs, such as Niemann Pick type C disease, in 
which increased tau phosphorylation is also apparent. (Lieberman et al., 2012; Menzies et 
al., 2015). Accumulation of lipids ultimately leads to defective lysosomal and non-
lysosomal proteins, resulting in the build-up of autophagic and endosomal substrates. 
Interestingly, on the other hand, the late endosomal lipid marker LBPA was not increased 
in CHO-Tau35 cells which may indicate normal function of this pathway. However, future 
work is required to examine the effect of Tau35 expression on the late endocytic pathway. 
 
Overall, the findings from this study provide a detailed understanding of some of the 
molecular mechanisms of protein degradation that are adversely affected by Tau35 
expression. These findings are summarised in Figure 6-1. 
 195 
 
Figure 6-1 Schematic representation of the effects of Tau35 expression in cells: The 
diagram shows potential mechanisms by which Tau35 could be involved in the 
development of neurodegenerative disease. Tau35 expression leads to increased 
activation of the UPR, mTORC1, GSK3β, and inhibits AMPK. These changes lead to reduced 
activation of the autophagy and lysosomal degradation system, leading to lipid 
accumulation and neurodegeneration. Increased mTORC1 activation also leads to the 
cytoplasmic retention of TFEB, which reduces autophagy activation and lysosome 
biogenesis yielding the same outcome. Increased GSK3β activity causes an accumulation of 
phosphorylated tau also leading to neurodegeneration. Red crosses indicate inhibition. 
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6.3 Therapeutic perspectives of this study 
Currently there is no cure for the human tauopathies. A great deal of research has been 
devoted to the identification of therapeutic treatments for AD and other tauopathies. The 
primary therapeutic approaches that have been considered include increasing microtubule 
stabilisation, inhibiting tau phosphorylation, enhancing clearance of misfolded tau or NFTs, 
inhibiting propagation of tau pathology, tau immunotherapy, and attenuating 
inflammatory pathways (Yoshiyama et al., 2012). Although the evidence for tau-based 
treatments for AD shows promise, they have not yet been successful. Therefore, 
alternative treatment strategies that are safe and effective are pivotal for combating these 
disorders. 
 
In recent years modulating components of the UPR pathway as potential treatment for 
neurodegenerative disease has received a great deal of attention (C Stefani et al., 2012; 
Ma and Klann, 2014; Salminen et al., 2009; Scheper and Hoozemans, 2013). Of the three 
UPR branches, the PERK and IRE1 branches have been extensively described as being 
involved in AD, PD, HD and ALS (Ferreiro and Pereira, 2012a). On the other hand, given 
that upstream signals of the UPR may be amplified during the activation process of the 
UPR, a subtle inhibition of factors involved in the initiation stage of UPR (targets that are 
more upstream in the pathway) is believed to be able to induce significant therapeutic 
effects. Hence, inhibition of PERK and IRE1 have been proposed as a potential therapeutic 
strategy for neurodegenerative disease (Maly and Papa, 2014). 
 
The inhibition of PERK has been attempted via different avenues to reverse the effects of 
neurodegeneration. The first of these approaches was through the direct knockout of the 
PERK gene (Ma and Klann, 2014). Deletion of the PERK gene restores the defect in the 
translation of synaptic proteins and rescues the neurodegenerative phenotype, such as 
neuronal cell death, and memory impairments in PERK knockout mice (Ma et al., 2013b; 
Moreno et al., 2012). Furthermore, inhibition of PERK activity has also been targeted by 
small molecules. Treatment with GSK2606414, an ATP-competitive small molecule 
inhibitor of PERK, rescued neurodegeneration, similar to genetic interference with the 
PERK pathway (Moreno et al., 2012). These findings provide a promising proof-of-concept 
for the effectiveness of PERK inhibition as a feasible therapeutic intervention in disorders 
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in which the PERK branch of the UPR is activated. However, although such approaches 
ameliorated neurodegeneration, they also resulted in some severe side effects. For 
example, homozygous PERK−/− mice displayed severe phenotypic abnormalities, similar to 
those of people affected by Wolcott–Rallison syndrome, including hepatic and renal 
dysfunction caused by mutations in the gene encoding PERK (Delépine et al., 2000). Severe 
abnormalities in the function of the endocrine and exocrine pancreas leading to systemic 
problems and early mortality were also evident following the knockdown of PERK (Harding 
et al., 2001; Zhang et al., 2012). Treatment with GSK2606414 also led to severe pancreatic 
abnormalities (Moreno et al., 2013). Considering increased PERK activation was apparent 
in the hippocampus of 16-18 month old Tau35 mice, this suggests that inhibiting PERK may 
be a compelling method to reverse the effects of Tau35 in human tauopathies, but only if 
the detrimental side effects can be avoided. 
 
Targeting of IRE1 and XBP1 have also been attempted to reduce UPR activation. Given the 
dual functions of IRE1 as both an RNase and a protein kinase, three types of inhibitors 
have been developed. Type I kinase inhibitors that inhibit autophosphorylation of IRE1, but 
have no effect on RNase activity, have yet to show any promise (Wang and Mandelkow, 
2012b). Type II inhibitors inhibit both kinase and RNase activities and therefore block all 
signaling through IRE1 (Ghosh et al., 2014). Type III inhibitors function by inhibiting RNase 
activity of IRE1 (Cross et al., 2012; Sanches et al., 2014), and these inhibitors could exert 
protective effects through blocking the generation of activated XBP1. With regards to 
XBP1, a study of a transgenic model of HD, showed that deletion of XBP1 was protective 
and accompanied by increased autophagic clearance of the huntingtin aggregates (Vidal et 
al., 2012). Overall these findings suggest a potential therapeutic strategy through the use 
of type III IRE1 inhibitors and lowering XBP1 expression in order to reverse over-activation 
of the UPR 
 
Autophagy upregulation has been shown to have a neuroprotective and anti-ageing role in 
animal models. Its upregulation as a putative treatment of neurodegeneration, could 
potentially improve symptoms of neurodegeneration, as it promotes cell survival, 
improves mitochondrial function and resistance to oxidative stress. Several autophagy-
inducing drugs have been shown to decrease the accumulation of protein aggregates and 
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improve neurodegenerative pathologies. In AD mouse models, long-term rapamycin 
treatment reduces Aβ42 and rescues cognitive deficits (Boland et al., 2008b; Caccamo et 
al., 2010b). Furthermore, rapamycin reduces the accumulation of huntingtin and cell death 
in HD cell models (Ravikumar et al., 2004a; Sarkar et al., 2009), as well as decreasing 
aberrant protein aggregation in two models of ALS (Wang et al., 2012). The induction of 
autolysosome formation appears to be a feasible therapeutic strategy for the tauopathies. 
Indeed, inducing autolysosome formation through rapamycin or temsirolimus, an 
analogue of rapamycin, has proven to be effective and alleviated tau phosphorylation in 
neurons and reversed the progression of tau pathology in P301S tau transgenic mice (Jiang 
et al., 2014; Ozcelik et al., 2013). In CHO-Tau35 cells, rapamycin treatment successfully 
inhibited activation of mTOR, but failed to rescue the autophagy deficit in these cells. 
Moreover, phosphorylated tau was not cleared in CHO-Tau35 cells following rapamycin, 
possibly due to some mTOR-resistant properties of rapamycin (Thoreen and Sabatini, 
2009). Therefore, attempting to reverse the autophagic deficit in CHO-Tau35 cells using 
rapamycin is not a suitable treatment. Treatment with torin 1 may be a better approach to 
increase autophagic activity through inhibition of mTOR, as this drug does not have the 
mTOR-resistant properties of rapamycin (Thoreen and Sabatini, 2009).  
 
Tackling deficits in autophagy by targeting mTOR-independent mechanisms has shown 
promise as a desirable proof of concept. GTM-1, a novel mTOR-independent autophagy 
inducer, has been shown to ameliorate Aβ pathology in mice (Chu et al., 2013). In addition, 
trehalose, an mTOR-independent activator of autophagy, has been shown to reduce Aβ 
accumulation (Rodríguez-Navarro et al., 2010) and facilitate the clearance of mutant α-
synuclein in vitro  (Rodríguez-Navarro et al., 2010). In vivo, trehalose has been shown to 
rescue dopaminergic activity in PD mouse models, to delay pathology in HD mouse models 
(Hebron et al., 2013; Vidoni et al., 2018), and to prolong lifespan in ALS mice (Castillo et al., 
2013). Trehalose has also been shown to reduce tau aggregates and improve neuronal 
survival in several mouse models of the tauopathies (Congdon et al., 2012; Schaeffer et al., 
2012b). Trehalose treatment proved to be effective in CHO-Tau35 cells and rescued the 
deficits observed in LC3-II. Therefore, the results herein demonstrate that activating 
autophagy via an mTOR-independent route may be a promising approach to counteract 
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the reduction of autophagy caused by Tau35 expression, and hence may be of use in 
human tauopathies. 
 
A drug that has shown great promise for PD treatment is resveratrol. This drug induces 
autophagy through the AMPK pathway, and has neuroprotective effects in a rodent model 
of PD (6-OHDA-induced PD rat) (Jin et al., 2008). The mechanism of action of resveratrol 
has been proposed to involve the rescue of ATG4-mediated autophagosome formation 
(Vidoni et al., 2018). The anti-diabetic drug metformin and berberine have additionally 
been shown to modulate autophagy activity through AMPK-dependent mechanisms, 
although their exact mechanisms of action remain poorly understood. Metformin 
improves neurodegeneration in AD and HD models (the R6/2 line with ∼150 glutamine 
repeats) (Ma et al., 2007; Song, 2016) and berberine has been shown to induce beneficial 
effects in the AD P301S transgenic mouse model (Haghani et al., 2015; Jiang et al., 2015). 
 
Direct intracerebral delivery of beclin-1 has also been attempted in PD models in order to 
enhance the production of autophagosomes. One study resulted in a rescue of 
neurodegenerative phenotypes observed in a transgenic mouse of PD overexpressing α 
synuclein. (Spencer et al., 2009). Such findings show potential promise in the use of beclin-
1 mimetics or other autophagy inducers for the treatment of neurodegenerative disease. 
Another therapeutic approach to enhance autophagy activation has been attempted 
through targeting cathepsins. In this avenue, the use of cystatin B inhibitors is promising, 
since it ameliorates cognitive decline in AD mouse models (Sun et al., 2008). The proposed 
mechanism of these inhibitors is to promote lysosomal activity by activating cathepsins, 
thereby leading to the effective clearance of autophagosomes. 
 
Lithium treatment has also shown some promise for the treatment of neurodegenerative 
disease (Feng et al., 2008). Lithium suppresses tau phosphorylation in mice via GSK3β 
inhibition and reduces cell death (Zhang et al., 2011). Moreover, lithium also decreases the 
levels of inositol 3-phosphates (IP3), which inhibit autophagy (Sade et al., 2016). In this 
study inhibition of GSK3β activity in CHO-Tau35 cells rescued the decreased activity of 
autophagy. Inhibiting GSK3β activity has additionally been shown to promote α-tubulin 
acetylation (Nakakura et al., 2015), which has been noted as a consequence of Tau35 
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expression in Tau35 mice (Bondulich et al., 2016) and in CHO-Tau35 cells (Guo et al., 
2019). 
 
While all of these proposed potential treatment strategies may prevent 
neurodegeneration, it is important to note that autophagy-enhancing agents may also be 
detrimental due to over activation of these pathways. Hence, treatment with autophagy-
modifying agents will likely require careful consideration of the degree to which these 
mechanisms are activated/inhibited. Therefore, the dose and times of treatment must be 
carefully monitored to achieve the optimal balance of autophagy activation. 
6.4 Concluding remarks 
In conclusion, in this study, a mouse and cell model expressing a disease-associated and N-
terminally truncated tau fragment (Tau35) were used. Several important and disease-
relevant pathological changes had been previously detected due to expression of Tau35 in 
mice. The findings from this study provide important insight into some of the underlying 
molecular mechanisms that lead to tau-mediated neurodegeneration as a consequence of 
tau truncation. Both the animal and cell models used in this study could serve as useful 
tools to further elucidate the detrimental effects of Tau35, and could aid in the 
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